JP2009256323A - Pyrazolopyrimidine derivative - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new compound inhibiting HSP90 action, especially a new compound inhibiting the function of HSP90 as a chaperone protein and having antitumor activity. <P>SOLUTION: Provided are a pyrazolopyrimidine compound inhibiting ATPase activity of HSP90, having antitumor activity, having various substituents and represented by formula (1), an HSP90 inhibitor containing a compound represented by formula (1), a drug containing a compound represented by formula (1), an anticancer agent containing a compound represented by formula (1), a pharmaceutical composition containing a compound represented by formula (1), a method for the treatment of cancer using a compound represented by formula (1), etc. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

The present invention relates to heat shock protein 90 (heat shock protein 90).
, HSP90) and tricyclic compounds derived from pyrazolopyrimidines.

HSP90 is the major intracellular chaperone protein. A chaperone protein binds to various proteins and folds of the bound proteins (foldin).
It is a protein that assists g). Protein groups that require HSP90 for folding are collectively referred to as HSP90 client proteins (HSP90 client pr).
otein).

In addition to HSP90, the folding mechanism of client proteins by HSP90 includes cochaperones, partner proteins (partn)
er protein and immunophilin are involved, and these are considered to cooperate to assist the folding of the HSP90 client protein (Non-patent Document 1). It has not been elucidated. HSP90 client protein is considered to form a complex with HSP90, co-chaperone, etc., and then undergo a conformational change to become a mature type.
When it is not normally folded by SP90 or the like, it is considered that it is ubiquitinated and degraded by the proteasome (Non-patent Documents 1 to 4).

In recent years, HSP90 inhibitors have been used as candidates for therapeutic agents for various diseases (for example, neurodegenerative diseases such as cancer and Alzheimer's disease, cardiovascular diseases, infectious diseases, autoimmune diseases or diseases associated with cell damage due to apoptosis). It is expected (Non-Patent Document 2).

In particular, since many cancer-related proteins including anticancer drug molecular targets are HSP90 client proteins, HSP90 inhibitors are expected as candidates for anticancer drugs. For example, H
A plurality of proteins involved in cancer development and enhancement such as er2, Raf, Akt, and telomerase are known as HSP90 client proteins (Non-patent Document 1). These cancer-related proteins use HSP90 as a chaperone protein,
Each of them is considered to change from an immature type to a mature type protein and to act on canceration of cells. HSP90 is a protein that is present not only in cancer cells but also in normal cells. Compared to normal cells, HSP90 has higher affinity with client proteins and also has ATPase activity necessary for its chaperone activity in cancer cells. It has been reported that it is activated (Non-Patent Documents 1 to 3). Therefore, it is considered that HSP90 inhibitors can simultaneously inactivate a plurality of cancer-related proteins specifically in cancer cells, and are expected as candidates for anticancer agents having a strong and broad antitumor spectrum.

As HSP90 inhibitors, geldanamycin, herbimycin, 17-allylaminogeldanamycin (17-all)
ylaminogeldanamicin, 17-AAG) and the like are known (Non-patent Documents 1 to 4). These compounds inhibit the function of HSP90 as a chaperone protein by binding to the ATP binding pocket on the N-terminal side of HSP90 and inhibiting the binding of HSP90 and ATP. In addition to the above, various compounds have been reported as compounds that inhibit HSP90 (Patent Document 1, Non-Patent Document 5 and Non-Patent Document 6).
).

International Publication No. 2005/28434 Pamphlet

Medicinal Research Reviews (2006) Vol. 26, no. 3, 310-338 TRENDS in Molecular Medicine (2004) Vol. 10, no. 6, 283-290 British Journal of Pharmacology (2005) 146, 769-780 TRENDS in Biochemical Sciences (2006) Mar, 31 (3), 164-172 Journal of Medicinal Chemistry (2005) Vol. 48, no. 13, 4212-4215 Journal of Medicinal Chemistry (2006) Vol. 49, no. 1, 381-390

As described above, although an HSP90 inhibitor is expected to be used as a medicine, particularly as an anticancer agent, an effective compound has not yet been obtained. Therefore, development of a novel compound that inhibits the action of HSP90, in particular, a novel compound that inhibits the function of HSP90 as a chaperone protein and has antitumor activity is demanded.

As a result of intensive studies to solve the above problems, the present inventors have found that ATPas of HSP90.
As a novel compound that inhibits e activity and has antitumor activity, a tricyclic compound derived from pyrazolopyrimidine represented by the formula (1) was found, and the present invention was completed.

That is, the present invention provides the following:
[1] Formula (1)

[In Formula (1),
R ¹ is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms,
Represents an ethylene group or a propenylene group,
R ² represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent,
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
here,
The same or different substituents are
Each independently a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkenyl group having 1 to 8 carbon atoms, C1-C8 alkynyl group which may have a substituent, C1-C8 alkoxy group which may have a substituent, C1-C8 which may have a substituent An alkoxycarbonyl group, an optionally substituted alkanoyloxy group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, a substituted group An alkylsulfonyloxy group having 1 to 8 carbon atoms which may have a group, an amino group which may have a substituent, a cyano group, an aryl group which may have a substituent, and a substituent. Heterocyclic groups, oxo groups and = NOR 31 ^(wherein, R ³¹ is. Represents a hydrogen atom or a substituent having 1 to 8 carbon atoms which may have alkyl group) represents a substituent selected from the group consisting of,
In addition, when there are a plurality of the same or different substituents, any two of the same or different substituents have a substituent together with the carbon atom to which they are substituted. A saturated or unsaturated condensed or spiro 3-membered to 8-membered ring may be formed. ]
Or a salt or a solvate thereof.

[2] The compound according to [1], a salt thereof or a salt thereof, wherein R ^{1 in} formula (1) is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms. Solvate.

[3] R ² is a heterocyclic group which may have a substituent of Formula (1), [1] or [2
Or a salt or a solvate thereof.

[4] ^{R 2} is pyridyl group which may have a substituent of Formula (1), [1] to [3]
Or a salt thereof or a solvate thereof.

[5] The ring A in the formula (1) is a 6-membered or 7-membered ring (wherein the constituent atoms of the ring of the ring A are carbon atoms other than the 6-position sulfur atom) [1] To [4], a salt thereof, or a solvate thereof.

[6] R ^{3 in the} formula (1) is a hydrogen atom or 1 to 4 identical or different substituents substituted on the ring A,
here,
The same or different substituents are
Each independently a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkynyl group having 1 to 8 carbon atoms, and a substituent. An optionally substituted alkoxy group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, and an optionally substituted carbon A substituent selected from the group consisting of an alkylsulfonyloxy group of formulas 1-8, an optionally substituted amino group, a cyano group, an optionally substituted heterocyclic group and an oxo group; Yes,
In addition, when there are a plurality of the same or different substituents, any two of the same or different substituents have a substituent together with the carbon atom to which they are substituted. May form a saturated or unsaturated condensed or spiro 3-membered to 8-membered ring,
[1] A compound, a salt thereof, or a solvate thereof according to any one of [5].

  [7] Formula (1) is the following formula (1a)

(In the formula ^(1a), R 1, ^{R 2} and ^{R 3} are each the same meaning as ^R 1, ^{R 2} and ^{R 3} in [1].) A compound according to [1], a salt thereof Or a solvate thereof.

  [8] Formula (1) is replaced by the following formula (1b)

(In the formula ^(1b), R 1, ^{R 2} and ^{R 3} are each the same meaning as ^R 1, ^{R 2} and ^{R 3} in [1].) A compound according to [1], a salt thereof Or a solvate thereof.

  [9] Formula (1) is converted into the following formula (1c)

(In the formula ^(1c), R 1, ^{R 2} and ^{R 3} are each the same meaning as ^R 1, ^{R 2} and ^{R 3} in [1].) A compound according to [1], a salt thereof Or a solvate thereof.

  [10] Formula (1) is the following formula (1d)

(In the formula ^(1d), R 1, ^{R 2} and ^{R 3} are each the same meaning as ^R 1, ^{R 2} and ^{R 3} in [1].) A compound according to [1], a salt thereof Or a solvate thereof.

  [11] Formula (2)

[In Formula (2),
R ¹ is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms,
Represents an ethylene group or a propenylene group,
R ² represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent,
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
here,
The same or different substituents are
Each independently a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkenyl group having 1 to 8 carbon atoms, C1-C8 alkynyl group which may have a substituent, C1-C8 alkoxy group which may have a substituent, C1-C8 which may have a substituent An alkoxycarbonyl group, an optionally substituted alkanoyloxy group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, a substituted group An alkylsulfonyloxy group having 1 to 8 carbon atoms which may have a group, an amino group which may have a substituent, a cyano group, an aryl group which may have a substituent, and a substituent. Heterocyclic groups, oxo groups and = NOR 31 ^(wherein, R ³¹ is. Represents a hydrogen atom or a substituent having 1 to 8 carbon atoms which may have alkyl group) represents a substituent selected from the group consisting of,
In addition, when there are a plurality of the same or different substituents, any two of the same or different substituents have a substituent together with the carbon atom to which they are substituted. May form a saturated or unsaturated condensed or spiro 3-membered to 8-membered ring,
R ⁴ represents an amino group having a protecting group. ]
Or a salt or a solvate thereof.

  [12] Formula (3)

[In Formula (3),
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
here,
The same or different substituents are
Each independently a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkenyl group having 1 to 8 carbon atoms, C1-C8 alkynyl group which may have a substituent, C1-C8 alkoxy group which may have a substituent, C1-C8 which may have a substituent An alkoxycarbonyl group, an optionally substituted alkanoyloxy group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, a substituted group An alkylsulfonyloxy group having 1 to 8 carbon atoms which may have a group, an amino group which may have a substituent, a cyano group, an aryl group which may have a substituent, and a substituent. Heterocyclic groups, oxo groups and = NOR ³¹ (wherein, R ³¹ is. Represents a hydrogen atom or a substituent having 1 to 8 carbon atoms which may have alkyl group) represents a substituent selected from the group consisting of,
In addition, when there are a plurality of the same or different substituents, any two of the same or different substituents have a substituent together with the carbon atom to which they are substituted. A saturated or unsaturated condensed or spiro 3-membered to 8-membered ring may be formed. ]
Or a salt or a solvate thereof.

[13] An HSP90 inhibitor comprising the compound according to any one of [1] to [10], a salt thereof, or a solvate thereof.

[14] An ATPase activity inhibitor of HSP90 containing the compound according to any one of [1] to [10], a salt thereof, or a solvate thereof.

[15] A binding inhibitor of HSP90 and ATP, comprising the compound according to any one of [1] to [10], a salt thereof, or a solvate thereof.

[16] A medicament comprising the compound, salt or solvate thereof according to any one of [1] to [10] as an active ingredient.

[17] An anticancer agent comprising the compound according to any one of [1] to [10], a salt thereof, or a solvate thereof as an active ingredient.

[18] A pharmaceutical composition comprising the compound according to any one of [1] to [10], a salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

[19] A method for treating cancer, comprising administering the compound, salt or solvate thereof according to any one of [1] to [10].

[20] Use of the compound according to any one of [1] to [12], a salt thereof, or a solvate thereof for the manufacture of a medicament.

According to the present invention, a novel compound that inhibits the action of HSP90, HSP90 containing the compound
Therapeutic agents for diseases caused by the action of the drug, methods for treating diseases caused by the action of HSP90 using the compound, and the like are provided. In particular, the present invention provides a novel compound that inhibits the function of HSP90 as a chaperone protein and has antitumor activity, an anticancer agent containing the compound, a method for treating cancer using the compound, and the like.

In the present invention, “heat shock protein 90”, “heat shock proto”
“ein 90” or “HSP90” refers to any or all of the HSP90 family, unless otherwise specified. Examples of the HSP90 family include HSP90α and HSP90.
SP90β, 94 kDa glucose-regulated protein (GR
P94) and Hsp75 / tumor necrosis factor receive
Tor associated protein 1 (TRAP1).

In the present invention, the “HSP90 inhibitor” refers to a compound or composition that partially or completely inhibits the action of HSP90, for example, a compound or composition that partially or completely inhibits the expression of HSP90, or Examples thereof include compounds or compositions that partially or completely inhibit the function of HSP90 as a chaperone protein.

Here, “the function of HSP90 as a chaperone protein” means that HSP90 assists the folding of the client protein to lead the client protein into a functioning form, or the function of HSP90 to stabilize the client protein, etc. .

Therefore, as an HSP90 inhibitor, specifically, for example, a compound that inhibits the expression of HSP90, a compound that inhibits the binding of HSP90 and a client protein, a compound that inhibits the binding of HSP90 to a cochaperone or immunophilins, and HSP90 A compound that inhibits the binding of ATP, a compound that inhibits the ATPase activity of HSP90, or a compound that inhibits the conformational change of HSP90. The HSP90 inhibitor can be used as a therapeutic agent for diseases caused by the action of HSP90.

In the present invention, “diseases caused by the action of HSP90” include, for example, neurodegenerative diseases such as cancer, Alzheimer's disease, cardiovascular diseases, infectious diseases, autoimmune diseases or diseases associated with cell damage due to apoptosis. It is done.

  Below, each substituent in Formula (1)-(3) of this invention is demonstrated.

First, R ^{1 will be} described.

R ¹ represents a methylene group, an ethylene group or a propenylene group which may be substituted by one or two alkyl groups having 1 to 8 carbon atoms.

“Methylene group, ethylene group or propenylene group optionally substituted by one or two alkyl groups having 1 to 8 carbon atoms” means linear, branched or cyclic alkyl having 1 to 8 carbon atoms. A methylene group, an ethylene group or a propenylene group which may be substituted by one or two groups. Examples of the alkyl group having 1 to 8 carbon atoms include a methyl group, an ethyl group, a propyl group,
Examples include isopropyl group, cyclopropyl group, cyclobutyl group, cyclopentyl, cyclohexylethyl group and the like.

Next, R ^{2 will be} described.

R ² represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent.

The aryl group in the “aryl group optionally having substituent (s)” refers to a substituent derived from a monocyclic or complex aromatic hydrocarbon compound. The aryl group may be bonded at any position. Examples of the aryl group include a phenyl group, a naphthyl group, and a fluorenyl group. These aryl groups are groups each consisting of an optionally substituted alkyl group having 1 to 8 carbon atoms and the following substituent groups c), d), f) to j) and l) to q). 1 or the same or different 2 to 5 substituents selected from the above may be substituted.

Here, the carbon number 1 to 1 in the “optionally substituted alkyl group having 1 to 8 carbon atoms”.
The 8 alkyl group means a linear, branched or cyclic alkyl group having 1 to 8 carbon atoms. Examples of the alkyl group having 1 to 8 carbon atoms include a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl, and a cyclohexylethyl group. These alkyl groups having 1 to 8 carbon atoms are the substituent groups c) to j) described later.
And 1) or 2 or 3 substituents of the same or different types selected from 1) to q) may be substituted. As long as these substituents can be substituted, they may be substituted on the same carbon atom in the alkyl group having 1 to 8 carbon atoms, or may be substituted on different carbon atoms.

The heterocyclic group in “optionally substituted heterocyclic group” means a saturated or unsaturated monocyclic ring containing one or more oxygen atoms, nitrogen atoms or sulfur atoms as constituent atoms of the ring structure Alternatively, it refers to a substituent derived from a condensed heterocyclic compound. The heterocyclic group may be bonded at any position. Examples of the saturated heterocyclic group include azetidine, pyrrolidine, imidazolidine, triazolidine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, thiazolidine, piperidine, piperazine, tetrahydropyran, dioxane, tetrahydrothiopyran, morpholine, thiomorpholine, homomorpholine or homopiperazine The group derived from is mentioned. Examples of the unsaturated heterocyclic group include pyrrole, pyrazole,
Imidazole, triazole, tetrazole, thiophene, furan, thiazole, oxazole, isothiazole, isoxazole, pyridine, dihydropyridine, pyridazine,
Examples thereof include groups derived from pyrimidine, pyrazine, quinoline, isoquinoline, indole, 1,3-dioxaindane, benzothiazole, benzodioxole, benzodioxan or thiazolopyridine. These heterocyclic groups may have a substituent group having 1 carbon atom.
1 to 8 alkyl groups and the same or different 2 to 5 substituents selected from the group consisting of c), d), f) to j) and l) to q) of the substituent groups described later It may be substituted with a group. Here, "the C1-C8 alkyl group which may have a substituent" is defined similarly to the above.

Next, R ^{3 will be} described.

R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A (wherein the same or different substituents are each independently a halogen atom, hydroxy group, carboxy Group, an alkyl group having 1 to 8 carbon atoms which may have a substituent, an alkenyl group having 1 to 8 carbon atoms which may have a substituent, and 1 carbon atom which may have a substituent An alkynyl group having 8 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms which may have a substituent, an alkoxycarbonyl group having 1 to 8 carbon atoms which may have a substituent, and a substituent; 1 to 1 carbon atoms
8 alkanoyloxy group, carbamoyl group which may have a substituent, carbamoyloxy group which may have a substituent, alkylsulfonyloxy group having 1 to 8 carbon atoms which may have a substituent , An amino group which may have a substituent, a cyano group, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, an oxo group and ═NOR ³¹ (
Here, R ³¹ represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms which may have a substituent. And when there are a plurality of the same or different substituents, any two of the same or different substituents are the carbons to which they are substituted. A saturated or unsaturated condensed or spiro type 3-membered to 8-membered ring which may have a substituent may be formed together with the atom).

When R ³ represents 2 to 4 identical or different substituents, these substituents may be substituted on the same carbon atom in ring A as long as they can be substituted, or on different carbon atoms. May be substituted.

The “optionally substituted alkyl group having 1 to 8 carbon atoms” is defined similarly to the definition in R ² above.

The alkenyl group having 1 to 8 carbon atoms in the “optionally substituted alkenyl group having 1 to 8 carbon atoms” refers to a linear, branched or cyclic alkenyl group having 1 to 8 carbon atoms. . Examples of the alkenyl group having 1 to 8 carbon atoms include vinyl group, allyl group, 1-propenyl group, 3-
Examples thereof include a methyl-2-pentenyl group, 1-butenyl group, cyclopentenyl group, and cyclohexenylethyl group. These alkenyl groups having 1 to 8 carbon atoms are one or the same or different two or three substituents selected from c) to j) and l) to q) of the substituent group described later. May be substituted. These substituents have 1 carbon as long as they can be substituted.
It may be substituted with the same carbon atom in -8 alkenyl groups, or may be substituted with different carbon atoms.

The “C1-C8 alkynyl group” in the “optionally substituted alkynyl group having 1-8 carbon atoms” refers to a straight-chain or branched alkynyl group having 1-8 carbon atoms. Carbon number 1-8
As the alkynyl group, for example, ethynyl group, 1-propynyl group, 2-propynyl group,
Examples thereof include a 1-butynyl group, a 3-butynyl group, and a 4-pentynyl group. These alkynyl groups having 1 to 8 carbon atoms are one or two or three of the same or different substituents selected from c) to j) and l) to q) of the substituent group described later. May be substituted.
As long as these substituents can be substituted, they may be substituted on the same carbon atom in the alkynyl group having 1 to 8 carbon atoms, or may be substituted on different carbon atoms.

The “C1-C8 alkoxy group” in the “optionally substituted alkoxy group having 1 to 8 carbon atoms” refers to an alkoxy group containing the above-mentioned alkyl group having 1 to 8 carbon atoms in its structure.
Examples of the alkoxy group having 1 to 8 carbon atoms include methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, isobutyloxy group, cyclopropylmethyloxy group, and cyclopentylmethyloxy group. These alkoxy groups having 1 to 8 carbon atoms are one or the same or different two or three substituents selected from c) to j) and l) to q) of the substituent group described later. May be substituted. These substituents are
As long as it can be substituted, it may be substituted with the same carbon atom in the alkoxy group having 1 to 8 carbon atoms, or may be substituted with a different carbon atom.

The “C1-C8 alkoxycarbonyl group” in the “optionally substituted C1-C8 alkoxycarbonyl group” means an alkoxycarbonyl group containing the above-mentioned C1-C8 alkoxy group in its structure Say. Examples of the alkoxycarbonyl group having 1 to 8 carbon atoms include methoxycarbonyl group, ethoxycarbonyl group, n-propyloxycarbonyl group, isopropyloxycarbonyl group, isobutyloxycarbonyl group, cyclopropylmethyloxycarbonyl group, and cyclopentylmethyloxycarbonyl. Groups and the like. These alkoxycarbonyl groups having 1 to 8 carbon atoms are one or the same or different two or three substituents selected from c) to j) and l) to q) of the substituent group described later. May be substituted. As long as these substituents can be substituted, they may be substituted on the same carbon atom in the alkoxycarbonyl group having 1 to 8 carbon atoms, or may be substituted on different carbon atoms.

1 carbon atom in the “optionally substituted alkanoyloxy group having 1 to 8 carbon atoms”
The -8 alkanoyloxy group means an alkanoyloxy group having an alkanoyl group having 1 to 8 carbon atoms in its structure. The “C 1-8 alkanoyl group” refers to a straight chain, branched chain or cyclic alkanoyl group having 1 to 8 carbon atoms, such as a formyl group, acetyl group, n-propionyl group, n-butyryl group. , Isobutyryl group, cyclopropanecarbonyl group, cyclohexanecarbonyl group and the like. Accordingly, examples of the alkanoyloxy group having 1 to 8 carbon atoms include formyloxy group, acetyloxy group, n-propionyloxy group, n-butyryloxy group, isobutyryloxy group, cyclopropanecarbonyloxy group, and cyclohexanecarbonyloxy group. Groups and the like. These alkanoyloxy groups having 1 to 8 carbon atoms are one or the same or different two or three substituents selected from c) to j) and l) to q) of the substituent group described later. May be substituted. These substituents may be substituted on the same carbon atom in the alkanoyloxy group or may be substituted on different carbon atoms as long as they can be substituted.

The “optionally substituted carbamoyl group” means, in addition to the carbamoyl group, a carbamoyl group having a substituent or a 4-membered to 7-membered saturated nitrogen-containing heterocyclic carbonyl optionally having a substituent. Refers to the group.

Here, the carbamoyl group having a substituent includes an alkyl group having 1 to 8 carbon atoms which may have a substituent defined as described above, and a substituent defined as described above. An optionally substituted alkenyl group having 1 to 8 carbon atoms, an optionally substituted alkynyl group having 1 to 8 carbon atoms, and a substituent defined as defined for R ² above. One selected from the group consisting of an aryl group optionally having a substituent and a heterocyclic group optionally having a substituent defined in the same manner as defined for R ² above, or two of the same or different A carbamoyl group substituted with a substituent.

Examples of the 4- to 7-membered saturated nitrogen-containing heterocyclic carbonyl group include an azetidinocarbonyl group, a pyrrolidinocarbonyl group, a morpholinocarbonyl group, and a piperazinocarbonyl group. The 4- to 7-membered saturated nitrogen-containing heterocyclic carbonyl group includes an alkyl group which may have a substituent defined in the same manner as described above, and c) to j) and l) to a substituent group described later. One or two or three substituents or atoms selected from q) may be substituted. These substituents may be substituted on the same carbon atom in the saturated nitrogen-containing heterocyclic carbonyl group or may be substituted on different carbon atoms as long as they can be substituted. In addition, when the saturated nitrogen-containing heterocyclic carbonyl group contains a nitrogen atom as its constituent atom in addition to the nitrogen atom bonded to the carbonyl group such as a piperazinocarbonyl group, nitrogen other than the nitrogen atom bonded to the carbonyl group The atom includes a) and b) of the substituent group described later.
, J), k), n), p) and q) may be substituted.

The “carbamoyloxy group optionally having substituent (s)” refers to a carbamoyloxy group containing in its structure an optionally substituted carbamoyl group as defined above.
Examples of the carbamoyloxy group include carbamoyloxy group, methylcarbamoyloxy group, ethylcarbamoyloxy group, cyclopropylmethylcarbamoyloxy group, N
, N-dimethylcarbamoyloxy, N-ethyl-N-methylcarbamoyloxy, pyrrolidinocarboxy group, morpholinocarboxy group or 4-methylpiperazinocarboxy group.

“Alkylsulfonyloxy group optionally having substituent (s)” is an alkylsulfonyloxy group having in its structure an optionally substituted alkyl group having 1 to 8 carbon atoms as defined above. Say. Examples of the optionally substituted alkylsulfonyloxy group having 1 to 8 carbon atoms include an optionally substituted methanesulfonyloxy group and an optionally substituted ethanesulfonyloxy group. Group, an isopropylsulfonyloxy group which may have a substituent, a cyclopropanesulfonyloxy group which may have a substituent, a cyclopentanesulfonyloxy group which may have a substituent or a substituent. And cyclopentylmethanesulfonyloxy group which may be used.

The “amino group optionally having a substituent” refers to an amino group substituted with one or two of the same or different substituents in addition to the amino group. The substituent of the amino group is an alkyl group having 1 to 8 carbon atoms which may have a substituent as defined above, and the carbon number which may have a substituent as defined above. An alkenyl group having 1 to 8 carbon atoms, an alkynyl group having 1 to 8 carbon atoms which may have a substituent as defined above, and a carbon number which may have a substituent as defined above An alkoxycarbonyl group having 1 to 8 carbon atoms, an alkanoyl group having 1 to 8 carbon atoms which may have a substituent as defined above, and a carbamoyl group which may have a substituent as defined above A group, an aryl group which may have a substituent defined in the same manner as the definition in R ² above, a heterocyclic group which may have a substituent defined in the same manner as the definition in R ² above, a substituent Arylcarbonyl group which may have a group, Optionally having a heterocyclic carbonyl group, an optionally substituted alkylsulfonyl group having 1 to 8 carbon atoms, an optionally substituted arylsulfonyl group, and optionally having a substituent. Selected from the group consisting of heterocyclic sulfonyl groups.

Here, the “arylcarbonyl group optionally having substituent (s)” means an arylcarbonyl group containing in its structure an aryl group optionally having substituent (s) defined in the same manner as defined for R ² above. Say. Examples of the arylcarbonyl group which may have a substituent include a phenylcarbonyl group which may have a substituent, a naphthylcarbonyl group which may have a substituent, or a substituent. And a suitable fluorenylcarbonyl group.

The “optionally substituted heterocyclic carbonyl group” means a heterocyclic carbonyl group containing in its structure an optionally substituted heterocyclic group as defined in R ² above. Say. Examples of the heterocyclic carbonyl group which may have a substituent include a furoyl group which may have a substituent, a tetrahydrofuroyl group which may have a substituent, and a substituent. A tetrahydropyrancarbonyl group which may have a substituent, a pyrrolidinecarbonyl group which may have a substituent, a pipecolinoyl group which may have a substituent, a morpholinecarbonyl group which may have a substituent, and a substituent. It may have a piperazine carbonyl group which may be substituted, a picolinoyl group which may have a substituent, a nicotinoyl group which may have a substituent, an imidazole carbonyl group which may have a substituent or a substituent. And an optional thiazolecarbonyl group.

The “optionally substituted alkylsulfonyl group having 1 to 8 carbon atoms” refers to an alkyl group having 1 to 8 carbon atoms that may have a substituent similar to the above definition in its structure. An alkylsulfonyl group is included. Examples of the optionally substituted alkylsulfonyl group having 1 to 8 carbon atoms include a methanesulfonyl group which may have a substituent, an ethanesulfonyl group which may have a substituent, and a substituted group. An isopropylsulfonyl group which may have a group, a cyclopropanesulfonyl group which may have a substituent, a cyclopentanesulfonyl group which may have a substituent or a cyclopentyl which may have a substituent And a methanesulfonyl group.

The “arylsulfonyl group optionally having substituent (s)” refers to an arylsulfonyl group having in its structure an aryl group optionally having substituent (s) defined in the same manner as defined for R ² above. Examples of the arylsulfonyl group which may have a substituent include a phenylsulfonyl group which may have a substituent, a naphthylsulfonyl group which may have a substituent, or a substituent. And a good fluorenylsulfonyl group.

The “optionally substituted heterocyclic sulfonyl group” means a heterocyclic sulfonyl group containing in its structure an optionally substituted heterocyclic group as defined in R ² above. Say. Examples of the optionally substituted heterocyclic sulfonyl group include a tetrahydropyransulfonyl group which may have a substituent, a thiophenesulfonyl group which may have a substituent, and a substituent. Optionally substituted furansulfonyl group, optionally substituted isoxazolesulfonyl group, optionally substituted thiazolesulfonyl group, optionally substituted imidazolesulfonyl group, substituted Examples thereof include a pyrazolesulfonyl group which may have a group or a pyridinesulfonyl group which may have a substituent.

The “aryl group optionally having substituent (s)” is defined in the same manner as defined for R ² above.

The “heterocyclic group optionally having substituent (s)” is defined in the same manner as defined for R ² above.

“When there are a plurality of the same or different substituents, any two substituents of the same or different substituents, together with the carbon atom to which they are substituted, have a substituent. Saturated or unsaturated condensed or spiro 3-membered to 8-membered rings may be formed. "Means that ring A in formula (1) may have a substituent. It means that a good 3- to 8-membered ring is bonded in a condensed type or a spiro type. The 3- to 8-membered ring may be a saturated ring or an unsaturated ring, and may contain a nitrogen atom, an oxygen atom, or a sulfur atom in addition to a carbon atom as a ring-constituting atom. . The 3-membered to 8-membered ring may be substituted with one or the same or different two or three substituents selected from a) to q) of the above substituent group. As long as these substituents can be substituted, these substituents may be substituted on the same carbon atom in a 3- to 8-membered ring, or may be substituted on different carbon atoms.

The “optionally substituted alkyl group having 1 to 8 carbon atoms” in R ³¹ is the above R ^3.
Defined in the same way as in

Next, R ^{4 will be} described.

R ⁴ represents an amino group having a protecting group.

The protecting group of the “amino group having a protecting group” is not particularly limited as long as it is a protecting group used in a normal organic chemical reaction. Examples of the amino group having a protecting group include an alkanoylamino group having 1 to 6 carbon atoms, a tert-butoxycarbonylamino group, a di (tert-butoxycarbonyl) amino group, a benzyloxycarbonylamino group, and di (benzyloxy). Carbonyl) amino group, p-methoxybenzylamino group, di (p-methoxybenzyl) amino group, 2,4-dimethoxybenzylamino group, di (2,4-dimethoxybenzyl) amino group or N- (tert-butoxycarbonyl) ) -N- (2,4-dimethoxybenzyl) amino group and the like.

  Next, the ring A will be described.

  Ring A represents a 5- to 8-membered ring. Ring A is represented by formula (1):

It is a 5- to 8-membered heterocyclic ring containing one sulfur atom as a ring-constituting atom in the 6-position of the compound of formula (1). The constituent atoms of the ring of ring A are composed of carbon atoms other than the above sulfur atoms. Also,
Ring A may have a double bond in the ring A.

[Substituent group]
a) An alkyl group having 1 to 8 carbon atoms “an alkyl group having 1 to 8 carbon atoms” refers to a linear, branched or cyclic alkyl group having 1 to 8 carbon atoms. Examples of the alkyl group having 1 to 8 carbon atoms include a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexylethyl group.

b) a C1-C8 halogenated alkyl group "a C1-C8 halogenated alkyl group" is 1 or the same or different 2-4
A group in which one halogen atom is substituted with an alkyl group as defined in a) above. The halogen atoms may be substituted with the same carbon atom or may be substituted with different carbon atoms.

c) Halogen atom d) Hydroxy group e) Oxo group f) Cyano group g) Carboxy group h) C1-C8 alkoxy group "C1-C8 alkoxy group" is defined in a) above An alkoxy group containing an alkyl group having 1 to 8 carbon atoms in its structure.

i) A halogenated alkoxy group having 1 to 8 carbon atoms “a halogenated alkoxy group having 1 to 8 carbon atoms” means an alkoxy having a halogenated alkyl group having 1 to 8 carbon atoms defined in the above b) in its structure. Refers to the group.

j) A C1-C8 alkoxycarbonyl group "C1-C8 alkoxycarbonyl group" means the alkoxycarbonyl group which contains the C1-C8 alkoxy group defined in said h) in the structure.

k) An alkanoyl group having 1 to 8 carbon atoms "an alkanoyl group having 1 to 8 carbon atoms" refers to a linear, branched or cyclic alkanoyl group having 1 to 8 carbon atoms. Examples of the alkanoyl group having 1 to 8 carbon atoms include formyl group, acetyl group, n-propionyl group, n-butyryl group, isobutyryl group, cyclopropylcarbonyl group, and cyclohexylacetyl group.

l) An alkanoyloxy group having 1 to 8 carbon atoms "an alkanoyloxy group having 1 to 8 carbon atoms" refers to an alkanoyloxy group having in its structure an alkanoyl group having 1 to 8 carbon atoms as defined in k) above. . Examples of the alkanoyloxy group having 1 to 8 carbon atoms include formyloxy group, acetyloxy group, n-propionyloxy group, n-butyryloxy group, isobutyryloxy group, cyclopropylcarbonyloxy group or cyclohexylacetyloxy group. Can be mentioned.

m) an amino group which may be substituted with one or the same or different two alkyl groups having 1 to 8 carbon atoms, “substituted with one or the same or different two alkyl groups having 1 to 8 carbon atoms; The term “amino group that may be used” refers to an unsubstituted amino group or an amino group substituted with one or two alkyl groups having 1 to 8 carbon atoms as defined in a) above.

n) a carbamoyl group which may be substituted by one or the same or different two or one alkyl group having 1 to 8 carbon atoms, “substituted by one or the same or different two alkyl groups having 1 to 8 carbon atoms A carbamoyl group which may be formed is an unsubstituted carbamoyl group or a carbon number of 1 as defined in a) above
Refers to a carbamoyl group substituted with 1 or 2 alkyl groups of ~ 8.

o) An alkanoylamino group having 1 to 8 carbon atoms "an alkanoylamino group having 1 to 8 carbon atoms" refers to an alkanoylamino group having in its structure an alkanoyl group having 1 to 8 carbon atoms defined in k) above. .

p) A phenyl group which may be substituted with one or the same or different two or three substituents selected from the substituent group consisting of a) to d) and f) to o) above.

q) Saturated or unsaturated, which may be substituted with one or the same or different two or three substituents selected from the substituent group consisting of a) to d) and f) to o) above 4
~ 7-membered monocyclic heterocyclic group.
Examples of saturated 4- to 7-membered monocyclic heterocyclic groups include azetidine, pyrrolidine, imidazolidine, triazolidine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, thiazolidine, piperidine, piperazine, tetrahydropyran, dioxane, tetrahydrothiopyran, morpholine , A group derived from thiomorpholine, homomorpholine or homopiperazine. Examples of the unsaturated 4- to 7-membered monocyclic heterocyclic group include pyrrole, pyrazole, imidazole, triazole, tetrazole, thiophene, furan, thiazole, oxazole, isothiazole, isoxazole, pyridine, dihydropyridine, pyridazine, pyrimidine, And groups derived from quinoline, isoquinoline, indole, 1,3-dioxaindane, benzothiazole or thiazolopyridine.

In one embodiment of the present invention, R ¹ is preferably a methylene group which may have one or two alkyl groups having 1 to 8 carbon atoms, and more preferably an unsubstituted methylene group.

R ² is preferably a heterocyclic group which may have a substituent. As the heterocyclic group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a benzothiazole group or a thiazolopyridyl group is preferable. Examples of the substituent that can be substituted on the heterocyclic group include a halogen atom,
An alkyl group, a halogenated alkyl group, an alkoxy group or a halogenated alkoxy group is preferred.

R ³ is a hydrogen atom or 1 to 4 same or different substituents substituted on ring A (wherein the same or different substituents are each independently a hydroxy group, carboxy group, substituted An optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkynyl group having 1 to 8 carbon atoms, and an optionally substituted group having 1 to 8 carbon atoms. It has an alkoxy group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, an optionally substituted amino group, a cyano group, and a substituent. Or a substituent selected from the group consisting of a heterocyclic group and an oxo group, or when there are a plurality of the same or different substituents, any two substituents of the same or different substituents are The carbon atom they are substituting with And a saturated or unsaturated condensed or spiro type 3-membered to 8-membered ring which may have a substituent is preferable. 4 identical or different substituents (wherein the same or different substituents each independently have an optionally substituted alkyl group having 1 to 8 carbon atoms and a substituent). More preferably selected from the group consisting of an optionally substituted alkynyl group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group and an optionally substituted amino group. The number of the same or different substituents is preferably 1 or 2.

R ⁴ is preferably a di (tert-butoxycarbonyl) amino group or a di (p-methoxybenzyl) amino group, and more preferably a di (tert-butoxycarbonyl) amino group.

Ring A is preferably a 6-membered or 7-membered ring. Specifically, as ring A, the following formulas (1a) to (1d):

Or

(In the formulas (1a) to (1d), R ¹ , R ² and R ³ are respectively R ¹ and R in the formula (1).
² and ^{R 3} as synonymous. The corresponding partial structure in the compound represented by any one of (1) is preferred.

The compound represented by the formula (1) of the present invention may have stereoisomers or optical isomers derived from asymmetric carbon atoms. These stereoisomers, optical isomers, and mixtures thereof Any of these are included in the present invention.

The compound represented by the formula (1) of the present invention is a novel tricyclic compound derived from pyrazolopyrimidine. The compound represented by the formula (1) of the present invention inhibits the ATPase activity of HSP90 and is useful as an HSP90 inhibitor. Furthermore, the compound represented by the formula (1) of the present invention exhibits antitumor activity against various tumor cells and is useful as an anticancer agent by inhibiting HSP90. In addition, the compound represented by the formula (1) of the present invention has a highly reactive substituent (for example,
It does not have a halogen atom (such as a chlorine atom), and is excellent in that there is little concern that the activity will decrease due to a reaction with a molecule in the living body (for example, a reaction with the SH group of glutathione in the living body). .

  In another embodiment of the invention, the formula (2)

(In Formula (2), R ¹ , R ² , R ³ and Ring A are respectively R ¹ , R ² , R in Formula (1).
³ and ring A are synonymous. R ⁴ represents an amino group having a protecting group. ) Is important as a production intermediate of the compound represented by the formula (1).

  In another embodiment of the invention, the formula (3)

(In formula (3), R ³ and Ring A are respectively the same meanings as R ³ and Ring A in the formula (1).) The compound represented by the compounds of formula (1) It is important as a production intermediate.

The tricyclic pyrazolopyrimidine derivative of the present invention may be in a free form or may be in the form of a salt or a solvate.

The salt of the compound represented by the general formula (1) of the present invention is not particularly limited as long as it is a medically acceptable salt, and examples thereof include acid addition salts and carboxy group salts. Examples of acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, phosphate, acetate, methanesulfonate, benzene Examples thereof include organic acid salts such as sulfonate, toluenesulfonate, citrate, maleate, fumarate, and lactate. Examples of the carboxyl group salt include alkali metal salts such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, ammonium salt, triethylamine salt, N-methylglucamine salt, Tris
Either an inorganic salt such as (hydroxylmethyl) aminomethane salt or an organic salt may be used.

The solvate is not particularly limited as long as it is medically acceptable, and specific examples include hydrates and alcohol solvates.

Next, the typical manufacturing method of the compound represented by Formula (1) is demonstrated. In addition, each reaction may use an appropriate protecting group, if necessary, and may use a desired conversion in a normal organic chemical reaction. The type of protecting group and the conversion order of each substituent are as follows. There is no particular limitation.

(I) Main Step Compound (1) can be produced, for example, according to the following scheme 1.

[In each formula, R ¹ , R ² , R ³ , R ⁴ and ring A are defined as above.
LG ¹ , LG ² and LG ³ represent leaving groups. ]
Examples of the leaving groups LG ¹ , LG ² and LG ³ include a halogen atom, a toluenesulfonyloxy group, a methanesulfonyloxy group and a trifluoromethanesulfonyloxy group. LG ¹ is preferably a chloro group. LG ² is preferably a bromo group, a toluenesulfonyloxy group or a methanesulfonyloxy group. LG ³ is preferably a chloro group, a bromo group or an iodo group.

As described in Scheme 1, the hydroxyl group of compound (6) can be converted to, for example, thionyl chloride, thionyl bromide, toluenesulfonyl chloride, methanesulfonyl chloride, or trifluoromethanesulfonyl chloride in the presence of a base based on common knowledge in organic chemistry. The compound (5) can be obtained by converting to a leaving group LG ² such as a halogen atom, a toluenesulfonyloxy group, a methanesulfonyloxy group, or a trifluoromethanesulfonyloxy group.

Compound (4) can be obtained by reacting compound (5) with sodium hydrogen sulfide in N, N-dimethylformamide and then treating with base. Or compound (5)
Can also be reacted with potassium thioacetate in N, N-dimethylformamide to obtain compound (4). Examples of the base include potassium carbonate and potassium hydrogen carbonate, and potassium carbonate is preferable. The reaction temperature may be −10 ° C. to 70 ° C., and −1
0 degreeC-30 degreeC is preferable.

When the R ¹ -R ² group is a protecting group such as a 4-methoxybenzyl group, the compound (4) is subjected to acid treatment or hydrogenolysis, and then the amino group (R ⁴ ) having a protecting group. It can convert into a compound (3) by processing on deprotection reaction conditions suitable for a protecting group.
Representative examples of deprotection reaction conditions suitable for the protecting group are described below. For example, when the amino group substituted with a protecting group is an alkanoylamino group or an aroylamino group, it can be converted to an amino group by hydrolysis using an aqueous solution such as sodium hydroxide, potassium hydroxide or ammonia. . When the amino group substituted with a protecting group is a tert-butoxycarbonylamino group or a di-tert-butoxycarbonylamino group, it can be converted to an amino group by treatment with an acid such as hydrochloric acid or trifluoroacetic acid. .

Compound (3) is treated with LG ³ -R ¹ -R ^{2 in} the presence of a base in a solvent,
It can lead to compound (1). As the solvent, N, N-dimethylformamide, N-
Examples include methyl pyrrolidone, tetrahydrofuran or dimethyl sulfoxide. Examples of the base include sodium hydride, sodium ethoxide, potassium tert-butoxide, potassium hydroxide, potassium carbonate, cesium carbonate and the like. Reaction temperature is 0 ° C
What is necessary is just ~ 100 degreeC. The reaction time may be 1 hour to 48 hours.

On the other hand, when the —R ¹ —R ² group of the compound (4) is not a protective group, the compound (1) is obtained by treating the amino group (R ⁴ ) having a protective group under the above deprotection reaction conditions. be able to.

(II) the substituents R ³ on Ring A of the A ring on compounds conversion step obtained in the above Scheme 1 substituent R ³ (1) or (4), organic chemistry as illustrated in Scheme 2 below Can be converted to other substituents based on the general knowledge of

[In each formula, R ¹ , R ² , R ⁴ and ring A are defined as above. R ⁷ R
⁸ NCO represents a carbamoyl group which may have a substituent (here, the carbamoyl group which may have a substituent is defined in the same manner as defined in R ³ above). R ⁹ is
An alkyl group having 1 to 8 carbon atoms which may have a substituent (wherein the alkyl group having 1 to 8 carbon atoms which may have a substituent is the same as defined in R ³ above) Defined).
]
As shown in Scheme 2, for example, carboxylic acid derivative (1-1b) can be obtained by hydrolyzing cyano derivative (4-1a) in which R ³ of compound (4) is a cyano group under acidic conditions. it can. At that time, an amino group having a protecting group (R ⁴ ) by hydrolysis under acidic conditions.
) Is deprotected and converted to an amino group.

The carboxylic acid derivative (1-1b) is converted into an amide derivative (1-
1c). A method generally used as a peptide synthesis method may be applied to the condensation reaction with an amine. Examples of the peptide synthesis method include an azide method, an acid chloride method, a DCC (dicyclohexylcarbodiimide) method, an active ester method, a carbonyldiimidazole method, a method using a water-soluble carbodiimide or a method using diethylcyanophosphate. Can do. These methods are described in M.M. Bondansky
Y. S. Klausner and M.M. A. “Peptide Syn” by Ondetti
thesis ”(A Wiley-interscience publication
, New York, 1976), G.M. R. “Synthetic P” by Pettit
eptides "(Elsevier Scientific Publication
Company, New York, 1976) or edited by The Chemical Society of Japan, 4th edition, Experimental Chemistry Course Vol. 22, Organic Synthesis IV (Maruzen Co., Ltd., 1992), etc. As a solvent used in this condensation reaction, N, N-dimethylformamide, N-methylpyrrolidone,
Examples thereof include pyridine, chloroform, methylene chloride, tetrahydrofuran, dioxane, acetonitrile and the like, or a mixed solvent thereof. The reaction temperature should just be -20 degreeC-50 degreeC, and -10 degreeC-30 degreeC is preferable. As the amine, a commercially available compound may be used, or an amine produced by the method described in the literature, the method described in Examples or a method according to those methods may be used.

The carboxylic acid derivative (1-1b) can be converted to the ester derivative (1-1d) by a condensation reaction with various alcohols (R ⁹ —OH) or a substitution reaction with various alkyl halides. As a condensation reaction between the carboxylic acid derivative (1-1b) and various alcohols, a condensation reaction or Mitsunobu reaction in the presence of an acid catalyst such as hydrochloric acid or sulfuric acid may be used. In the substitution reaction with various alkyl halides, the carboxyl group may be alkylated using a suitable base in a solvent.

Further, for example, when R ³ in the compound (4) is a hydroxyl group, as shown in Scheme 3, the hydroxyl group is converted into an alkoxy group, a carbamoyloxy group, an alkanoyloxy group, or an oxo group, By treating with appropriate deprotection reaction conditions suitable for the protecting group,
The corresponding compound (1-1f), compound (1-1g), compound (1-1h) or compound (1-1i) can be obtained, respectively.

[In each formula, R ¹ , R ² , R ⁴ , R ⁹ , R ⁷ R ⁸ NCO and ring A are defined as above. R ¹⁰ represents a hydrogen atom or an optionally substituted alkyl group having 1 to 8 carbon atoms (here, the optionally substituted alkyl group having 1 to 8 carbon atoms is Defined in the same manner as in R ³ above). ]
For the conversion of a hydroxyl group to an alkoxy group (conversion from the compound (4-1e) to the compound (4-1f)), a method generally used as a method for synthesizing ethers may be applied. For example, the alcohol derivative (4-1e) may be treated with an alkyl halide in a solvent in the presence of a base. Examples of the solvent include N, N-dimethylformamide, N-methylpyrrolidone, diethyl ether, tetrahydrofuran or toluene. Examples of the base include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium tert-butoxide, potassium tert-butoxide, pyridine, DBU or diisopropylethylamine, and sodium hydride is preferable. The reaction temperature is -8.
What is necessary is just 0 degreeC-150 degreeC, and 0 degreeC-100 degreeC is preferable. The reaction time may be 15 minutes to 72 hours. Those methods are described in the Chemical Society of Japan, 4th edition, Experimental Chemistry Course, Volume 20, Organic Synthesis I.
I (Maruzen Co., Ltd., 1992).

Conversion of hydroxyl group to carbamoyloxy group (compound (4-1e) to compound (4-1g)
For the conversion to (a), a method generally used as a carbamoylation reaction may be applied. For example, a method of treating an alcohol derivative (4-1e) with an isocyanate derivative in a solvent,
Alternatively, a method of adding an amine after treating the alcohol derivative (4-1e) with 1,1′-carbonyldiimidazole or phosgene in a solvent can be mentioned.

Conversion of hydroxyl group to alkanoyloxy group (compound (4-1e) to compound (4-1h)
For the conversion to (a), a method generally used as an alkanoylation reaction may be applied. Examples thereof include an azide method, an acid chloride method, a DCC (dicyclohexylcarbodiimide) method, an active ester method, a carbonyldiimidazole method, a method using a water-soluble carbodiimide, and a method using diethylcyanophosphate.

As a method for converting a hydroxyl group to an oxo group (conversion from the compound (4-1e) to the compound (4-1i)), Mukaiyama oxidation, Swern oxidation or a modification thereof may be replaced with oxalyl chloride.
An oxidation reaction using CC, trifluoroacetic anhydride, acetic anhydride, or sulfur trioxide pyridine complex can be mentioned. These methods are described in the Chemical Society of Japan, “4th edition, Experimental Chemistry Course Vol. 23, Organic Synthesis V (Maruzen Co., Ltd., 1992)”.

Compounds (4-1f), (4-1g), (4-1h) and (4) produced by the above method
-1i) is treated under the deprotection reaction conditions suitable for the protecting group of the amino group (R ⁴ ) having a protecting group, whereby compounds (1-1f), (1-1g), (1-1h) (1-1i) can be converted.

Further, when R ³ in compound (4) is an oxo group, as shown in Scheme 4, for example, reductive amination reaction with various amines using ketone derivative (4-1i) as a raw material The amine derivative (4-1j) can be converted into the amine derivative (4-1j) by treatment with an appropriate deprotection reaction condition suitable for the protecting group.

[In each formula, R ¹ , R ² , R ⁴ and ring A are defined as above. R ^7a
R ^8a N represents an amino group which may have a substituent (here, the amino group which may have a substituent is defined in the same manner as defined in R ³ above). ]
Examples of the reducing agent used for the reductive amination reaction include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, and the like. Such a method is described in “Chemical Society of Japan, 4th edition, Experimental Chemistry Course Vol. 20, Organic Synthesis II (Maruzen Co., Ltd.,
1992).

In addition, a compound in which both R ^7a and R ^8a of the amine derivative (4-1j) are a hydrogen atom is an oxime derivative (4-1k) that can be obtained by a condensation reaction between a ketone derivative (4-1i) and hydroxylamine. ) Can also be obtained.

Further, when R ^7a and / or R ^8a of the amine derivative (4-1j) is a hydrogen atom, further chemical modification is possible as described in Scheme 5. For example, an amine derivative (4-1ja) to a compound having an alkoxycarbonylamino group (4
-1l), a compound having a carbamoylamino group (4-1m), a compound having an alkanoylamino group (4-1n), a compound having an alkylsulfonylamino group, an arylsulfonylamino group or a heterocyclic sulfonylamino group (4-1o) ) And then converting the R ⁴ to an amino group by treatment under appropriate deprotection reaction conditions suitable for the protecting group, respectively,
Corresponding compound (1-1l), compound (1-1m), compound (1-1n) or compound (
1-1o) can be obtained.

[In each formula, R ¹ , R ² , R ⁴ and ring A are defined as above. R ^8a
May have a hydrogen atom, an alkyl group having 1 to 8 carbon atoms which may have a substituent, an alkenyl group having 1 to 8 carbon atoms which may have a substituent, or a substituent. An alkynyl group having 1 to 8 carbon atoms, an aryl group which may have a substituent, or a heterocyclic group which may have a substituent is shown. R ⁹ represents an alkyl group having 1 to 8 carbon atoms which may have a substituent. R ¹¹ and R ¹² are each independently a hydrogen atom, an optionally substituted alkyl group having 1 to 8 carbon atoms, or an optionally substituted alkenyl group having 1 to 8 carbon atoms. , An alkynyl group having 1 to 8 carbon atoms which may have a substituent, an aryl group which may have a substituent, or a heterocyclic group which may have a substituent; R ¹³ represents a hydrogen atom, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted aryl group, or an optionally substituted heterocyclic group. (Wherein the alkyl group having 1 to 8 carbon atoms which may have a substituent in R ^8a , R ⁹ , R ¹¹ , R ¹² and R ¹³ is defined in the same manner as defined in R ³ above. 1 carbon atom which may have a substituent in R ^8a , R ¹¹ and R ¹²
Alkenyl groups 8 are as defined for the R ^3. The alkynyl group having 1 to 8 carbon atoms which may have a substituent in R ^8a , R ¹¹ and R ¹² is defined in the same manner as defined in R ³ above. The aryl group which may have a substituent in R ^8a , R ¹¹ , R ¹² and R ¹³ is defined in the same manner as defined in R ³ above. R ^8a , R
¹¹ , R ¹² and the heterocyclic group which may have a substituent in R ¹³ are defined in the same manner as in R ³ above). ]
As a method for converting an amino group to an alkoxycarbonylamino group (from an amine derivative (4-1ja) to a compound having an alkoxycarbonylamino group (4-1l)), for example, an amine derivative (4-1jb) is a base. Examples thereof include a method of condensing with a carbonate derivative such as alkoxycarbonyl chloride under the conditions. Such a method is described in, for example, “4th edition, Experimental Chemistry Course Volume 20, Organic Synthesis II (Maruzen Co., Ltd., 1992)” edited by the Chemical Society of Japan.

Examples of the method for converting an amino group into a carbamoylamino group (from an amine derivative (4-1ja) to a compound having a carbamoylamino group (4-1m)) include, for example, cyanic acid of an amine derivative (4-1ja) or Addition reaction to isocyanate, or amine derivative (4-1ja) or amine to be introduced (R ¹¹ —NH—R ¹² ) is first reacted with 1,1′-carbonyldiimidazole or phosgene in a solvent. Examples of the method include adding a remaining amine after the treatment.

Examples of the method for converting an amino group into an amide (from an amine derivative (4-1ja) to an amide (4-1n)) include condensation reactions of an amine derivative (4-1ja) with various carboxylic acids. be able to. For the condensation reaction, a method generally used as the peptide reaction described above may be applied.

Conversion of an amino group into an alkylsulfonylamino group, an arylsulfonylamino group or a heterocyclic sulfonylamino group (a compound having an alkylsulfonylamino group, an arylsulfonylamino group or a heterocyclic sulfonylamino group from an amine derivative (4-1ja) (4 −
As a method for conversion to 1o), there can be mentioned a condensation reaction of an amine derivative (4-1ja) with various alkylsulfonyl chlorides, arylsulfonyl chlorides or heterocyclic sulfonyl chlorides under basic conditions.

Furthermore, as shown in Scheme 6, when the substituent on ring A of compound (4) is a hydroxyl group, a compound containing a double bond in ring A can be produced.

[In each formula, R ¹ , R ² and R ⁴ are respectively defined in the same manner as described above. ]
As described in Scheme 6, for example, the alcohol (4c-1e) is treated with methanesulfonyl chloride in the presence of a base in a solvent to give methanesulfonate (4c-1p).
)Obtainable. As the solvent, dichloromethane, chloroform, dichloroethane, tetrahydrofuran and the like are preferable, and these dehydrated solvents are more preferable. The base is preferably a tertiary amine such as triethylamine or diisopropylethylamine.
As reaction temperature, -10-30 degreeC is preferable. By treating methanesulfonate (4c-1p) with a base in a solvent, (4d-1q) containing a double bond in ring A can be obtained. As a solvent for this reaction, N, N-dimethylformamide, N-methylpyrrolidone, toluene, dichloromethane, chloroform, dichloroethane, tetrahydrofuran or the like is preferable. As the base, potassium carbonate, sodium tert-butoxide, potassium tert-butoxide, pyridine, DBU, diisopropylethylamine and the like are preferable. The reaction temperature may be adjusted to an appropriate temperature according to the base to be used. For example, when potassium carbonate is used as the base, 50 to 80 ° C. is preferable. The compound (4d-1q) is treated with an appropriate deprotection reaction condition suitable for the protecting group of the amino group (R ⁴ ) substituted with a protecting group to give a derivative (1d-1q) containing a double bond in ring A ).

Moreover, also when the substituent on the ring A of a compound (4) is a halogen atom, the compound which contains a double bond in the ring A by a base treatment similarly can be manufactured.

Further, when ring A is a 7-membered ring and R ³ is an oxo group, for example, as shown in Scheme 7, it can be converted to other substituents based on ordinary knowledge of organic chemistry.

[Wherein R ¹ , R ² , R ⁴ , R ^7a R ^8a N and R ⁹ are defined in the same manner as described above.
R ^3a and R ^3b mean any one of the plurality of substituents of R ³ , and R ¹⁴ is a vinyl group which may have a substituent or an aryl group which may have a substituent. Means. ]
By treating the ketone derivative (4c-1i) in a solvent in the presence of 0.5 to 1.5-fold molar equivalents of a halogenoalkane and a base with respect to the ketone derivative, a mono-substituted alkyl (R ^3
a = H, 4c-1r) and by treatment in the presence of 2 to 3 molar equivalents of a halogenoalkane and a base relative to the ketone derivative, it can be converted into a disubstituted alkyl (4c-1r), In particular, it can be converted to a spirocycloalkane derivative (4c-1r) by treatment in the presence of a dihaloethane such as dibromoethane and a base. In addition, N-
By treatment in the presence of a base such as fluorobenzenesulfonimide and the like, it can be converted into a mono- and difluoro form (4c-1r). As the solvent, tetrahydrofuran, N, N
-Dimethylformamide, N-methylpyrrolidone, dimethylsulfoxide and the like can be mentioned, and dimethylsulfoxide and N, N-dimethylformamide are more preferable. Bases include sodium hydride, sodium tert-butoxide, potassium tert-
Examples include butoxide, potassium carbonate, sodium carbonate and the like, and potassium carbonate and sodium hydride are preferable. The reaction temperature may be adjusted to an appropriate temperature according to the base used. For example, in the case of potassium carbonate, 0 ° C to 80 ° C is preferable, 20 ° C to 40 ° C is more preferable, and in the case of sodium hydride, -78. ° C to 80 ° C is preferable, and -10 ° C to 40 ° C is more preferable. The ketone derivative (4c-1r) can be treated in the same manner as in Scheme 4 and Scheme 5 to synthesize various derivatives.

In addition, the β-ketoaldehyde equivalent (4c-1s) can be obtained by heating the ketone derivative (4c-1i) in a solvent such as N, N-dimethylformamide dimethylacetal and toluene or benzene. It has been reported that β-ketoaldehyde equivalents such as (4c-1s) can be converted to pyridone derivatives, pyrimidine derivatives, pyrazole derivatives, oxazole derivatives, etc. (Conversion method of β-ketoaldehyde equivalents to pyridone derivatives) For example, Bioorganic & Medicinal Chemistry (2
003) Vol. 11, no. 22, 4749-4759. A method of converting a β-ketoaldehyde equivalent to a pyrimidine derivative is described in Journal of Medicin.
al Chemistry (1978) Vol. 21, no. 7, 623-628. A method for converting a β-ketoaldehyde equivalent to a pyrazole derivative is described in Journal
of Heterocyclic Chemistry (1982) Vol. 19, N
o. 6, 1355-1361. A method of converting a β-ketoaldehyde equivalent to an oxazole derivative is described in Journal of Heterocyclic Chemis.
try (1983), Vol. 20, no. Refer to 3, 645-648, etc.
). For example, (4c-1s) can be converted to an oxazole derivative (4d-1t) by treating with hydroxylamine hydrochloride. Alternatively, (4c-1s) can be converted to a pyrazole derivative (4d-1u) by treatment with hydrazine.

Moreover, it can convert into a triflate body (4-1v) by processing a ketone derivative (4c-1i) in the presence of trifluoromethanesulfonic anhydride and a base. Examples of the solvent include methylene chloride, acetonitrile, tetrahydrofuran, N, N-dimethylformamide and the like, and methylene chloride is preferable. Examples of the base include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium tert-
Examples include butoxide, potassium tert-butoxide, pyridine, triethylamine, DBU, diisopropylethylamine, and the like, and triethylamine is preferable. The reaction temperature may be −80 ° C. to 150 ° C., preferably −10 ° C. to 40 ° C. Subsequently, the vinyl and aryl derivative (4d-2v) can be produced from the triflate (4d-1v) by a coupling reaction with an organic boronic acid derivative in the presence of a metal catalyst and a base. In this coupling reaction, an appropriate additive may be used to accelerate the reaction. The organic boronic acid derivative can be commercially available or can be produced by a known method. References for the method for producing the organic boronic acid derivative and the coupling reaction include “Chemical Reviews, 1995,
95, 2457-2483 ".

The amount of the organic boronic acid derivative used is preferably in the range of 1 to 2 molar equivalents of the triflate (4d-1v). As the metal catalyst, a palladium catalyst is preferable. For example, [1,1 ′
-Bis (diphenylphosphino) ferrocene] dichloropalladium (II) / dichloromethane complex (1: 1) or dichlorobis (triphenylphosphine) palladium (II)
And tetrakis (triphenylphosphine) palladium (0).
As a usage-amount of a metal catalyst, the range of 0.01-0.2 times molar equivalent is preferable with respect to a triflate body (4d-1v). Examples of the base include inorganic bases such as tripotassium phosphate, potassium carbonate, sodium carbonate, and cesium carbonate, and tripotassium phosphate and sodium carbonate are preferable. As a usage-amount of a base, the range of 1-100 times molar equivalent is preferable with respect to a triflate body (4d-1v). Examples of the additive include organic phosphorus compounds such as 1,1′-bis (diphenylphosphino) ferrocene (dppf) and triphenylphosphine. The amount of the additive used may be triflate (4d-1v). For 0.05 ~
A range of 0.2 molar equivalent is preferred.

The solvent for the coupling reaction is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent. For example, ether solvents such as 1,4-dioxane and 1,2-dimethoxyethane, N, Amide solvents such as N-dimethylformamide and N-methyl-2-pyrrolidone, hydrocarbon solvents such as toluene and benzene, alcohol solvents such as methanol and ethanol, polar solvents such as acetonitrile and water, etc. are preferred. You may use a solvent as a 2 or more types of mixed solvent. The reaction temperature ranges from 10 ° C. to the boiling point of the solvent,
The range of room temperature to 100 ° C is preferred. The reaction time is usually about 1 to 50 hours.

Moreover, it can convert into an ester body (4d-1w) by reacting in alcohol as a solvent in carbon monoxide atmosphere on the said reaction conditions, without using an organic boronic acid derivative. As the alcohol, methanol and ethanol are preferable.

The carboxylic acid derivative (4d-2w) can be produced by hydrolyzing the compound (4d-1w) that is an ester derivative. The hydrolysis reaction is preferably a known alkaline hydrolysis, and as a reference, there is an experimental chemistry course (4th edition, Vol. 22, edited by The Chemical Society of Japan, Maruzen Co., Ltd.) “Organic Synthesis IV: Acid / Amino Acid / Peptide, P6 to P11 "and the like. The amide derivative (4d-3w) can be produced in the same manner as in Scheme 2.
The alcohol derivative (4d-3x) can be produced by reducing the carboxylic acid derivative (4d-2w). The reduction reaction is preferably a known reduction reaction, and as a reference, there is an experimental chemistry course (third edition, Vol. 14, edited by The Chemical Society of Japan, Maruzen Co., Ltd.) “Reaction and Synthesis of Organic Compounds [1], P477- P478 "and the like.

The acetic acid ester derivative (4d-1y) can be produced from the ketone derivative (4c-1i) by a carbon increase reaction represented by the Wittig reaction. The carbon increase reaction is preferably a known reaction,
Experimental Chemistry Course (4th Edition, Vol. 22, edited by The Chemical Society of Japan, Maruzen Co., Ltd.) “Organic Synthesis I: Hydrocarbon / Halogen Compounds, P57 to P69” and the like can be mentioned. The hydrolysis reaction from the acetate derivative (4d-1y) to the acetate derivative (4d-2y) can be produced in the same manner as described above. The acetic acid amide derivative (4d-3y) can be produced in the same manner as in Scheme 2.

The amine derivative (4d-3z) can be produced by a rearrangement reaction of the carboxylic acid derivative (4d-2y). As the rearrangement reaction, a known rearrangement reaction is preferable.
4th edition, Vol. 22. (Chemical Society of Japan, Maruzen Co., Ltd.) “Organic Synthesis II: Alcohol / Amine, P302 to P308”. The amine derivative (4d-4z) is
It can be modified by the same method as shown in Scheme 5.

The ethanol derivative (4d-2a) can be produced by reducing the acetate derivative (4d-1y). The reduction reaction is preferably a known reduction reaction, and as a reference, an experimental chemistry course (third edition, Vol. 14, edited by The Chemical Society of Japan, Maruzen Co., Ltd.) “Reaction and Synthesis of Organic Compounds [1], P474- P477 "and the like. Ethylamine derivatives (4
d-2b) can be produced by a substitution reaction. The substitution reaction is preferably a known reaction, such as “Chemical Synthesis II: Alcohol / Amine Compounds, P284-P290”, etc. it can.
Compounds (4c-1r), (4d-1t), (4d-1u), (4d-2v), (4d-3
w), (4d-3x), (4d-3y), (4d-4z) and (4d-2b) are treated with appropriate deprotection reaction conditions suitable for the protecting group to give the corresponding amine derivative (1c -1
r), (1d-1t), (1d-1u), (1d-1v), (1d-1w), (1d-1
x), (1d-1y), (1d-1z) and (1d-2a), respectively.

(III) Production Process of Raw Material Compound (6) shown in Scheme 1 is a document relating to the production of various 1H-pyrazolo [3,4-d] pyrimidine derivatives (for example, Synthesis, Vol. 10, pages 645-647,
1975; Tetrahedron, 48, 8089-8100, 1992; W
O2005 / 28434; or WO 98/4399, etc.) and the like, and the like, for example, can be produced according to the method described below based on ordinary knowledge of organic chemistry.

Compound (6) which is a synthesis raw material of a compound in which ring A in general formula (1) is a 7-membered ring or an 8-membered ring
a) can be prepared, for example, according to Scheme 8.

[In each formula, R ¹ , R ² and R ⁴ are respectively defined in the same manner as described above. ]
Compound (10) can be obtained by treating aldehyde derivative (11) with 3-butenylmagnesium bromide in a solvent. Examples of the solvent used in this reaction include toluene, benzene, diethyl ether, tetrahydrofuran and the like, and tetrahydrofuran is preferable. The reaction temperature should just be -78 degreeC-50 degreeC, and -20 degreeC-30 degreeC is preferable.

Compound (10) can be converted to ketone derivative (9) by treatment under appropriate oxidation reaction conditions. In this case, the oxidation reaction may be Mukaiyama oxidation, Swern oxidation, an oxidation reaction using DCC, trifluoroacetic anhydride, acetic anhydride or sulfur trioxide pyridine complex instead of oxalyl chloride, or an oxidation using manganese dioxide. Reaction.

The ketone derivative (9) can be converted to the compound (8) by treatment with R ² —R ¹ —NHNH ₂ in a solvent. Examples of the solvent used in this reaction include alcohol, methylene chloride, tetrahydrofuran, dioxane and the like, or a mixed solvent thereof. The reaction temperature should just be -20 degreeC-50 degreeC, and -10 degreeC-30 degreeC is preferable. R ² -R ¹ -N
When these salts are used instead of HNH ₂ , an equivalent or excess amount of base may be used. Examples of the base include triethylamine.

The 6-position amino group of compound (8) is protected with an appropriate protecting group and converted to compound (7).
, 2-diol reaction can be performed to obtain the diol derivative (6a). Alkene diolation includes potassium permanganate in the presence of alkali, addition of water in the presence of mercury salt (Kucherov-Denges method), catalytic amount of osmium tetroxide and amine oxide as co-oxidant. Osmium oxidation reaction using or dihydroxylation reaction using iodine (Prevoat method or Woodward method) and the like.

In the diol derivative (6a), the primary hydroxyl group is protected with a bulky protecting group such as a tert-butyldiphenylsilyl group, and then the secondary hydroxyl group is removed with a leaving group LG ² (for example, p-toluenesulfonyloxy group or methanesulfonyl). The compound (5) can be converted into an oxy group or the like to give a compound (5) described in Scheme 1, and then subjected to a ring-closing reaction to lead to a compound (4) in which ring A is a 7-membered ring.

In addition, the diol derivative (6a) has a primary hydroxyl group selectively leaving group LG ² (for example,
Compound (4) in which ring A is an 8-membered ring by converting to p-toluenesulfonyloxy group or methanesulfonyloxy group, etc. to give compound (5) described in Scheme 1 and then subjecting to a ring-closing reaction Can lead to.

In the reaction for producing (10) from compound (11) described in scheme 8, 3-butenylmagnesium bromide is replaced with 4-pentenylmagnesium bromide, and a similar reaction is performed, whereby the ring in compound (1) is obtained. The following diol derivative (6b), which is a raw material for a compound in which A is an 8-membered ring, can be obtained.

[Wherein R ¹ , R ² and R ⁴ are respectively defined in the same manner as described above. ]
In the diol derivative (6b), the primary hydroxyl group is protected with a bulky protecting group such as a tert-butyldiphenylsilyl group, and then the secondary hydroxyl group is removed with a leaving group LG ² (for example, p-toluenesulfonyloxy group or methanesulfonyl). The compound (5) can be converted into an oxy group or the like to give a compound (5) described in Scheme 1, and then subjected to a ring-closing reaction, whereby the compound (4) in which ring A is an 8-membered ring can be led.

A compound in which the ring A in the general formula (1) is a 6-membered ring or a 7-membered ring can be produced, for example, from the diol derivative (6c). The diol derivative (6c) can be produced according to Scheme 9.

[In each formula, R ¹ , R ² and R ⁴ are respectively defined in the same manner as described above. ]
The compound (17) can be obtained by treating the aldehyde derivative (11) with allyl bromide and indium powder in a solvent. Alkene derivative (17) can also be obtained by Grignard reaction using aldehyde derivative (11) and allylmagnesium bromide. The triol derivative (16) can be obtained by subjecting the alkene derivative (17) to the aforementioned 1,2-diolation reaction. The triol derivative (16) can be converted to the acetal derivative (15) by treatment with 2,2-dimethoxypropane and a catalytic amount of acid in a solvent, or by treatment with an acid catalyst in acetone. As an acid catalyst, p
-Toluenesulfonic acid. The acetal derivative (15) is converted into the compound (10) by the same three-step treatment as the conversion from the compound (10) to the compound (7) in scheme 8 described above.
14) and the compound (13) can be led to the acetal derivative (12). The diol derivative (6c) can be obtained by treating the acetal derivative (12) with a catalytic amount of acid in alcohol.

In the diol derivative (6c), the ring A is a 7-membered ring or 8 from the above diol derivative (6a).
In the same manner as in the method of converting to the compound (4) which is a member ring, the ring A can be led to the compound (4) which is a 6-membered ring or a 7-membered ring.

Further, the alcohol derivative (6d) can be obtained by further converting the diol derivative (6c) according to the method described in Scheme 10. Alcohol derivative (6d)
Can be used as starting compound (6) when ring A of compound (1) in scheme 1 is a 6-membered ring.

[In each formula, R ¹ , R ² , R ³ and R ⁴ are respectively defined in the same manner as described above. ]
The aldehyde derivative (18) can be obtained by subjecting the diol derivative (6c) to an oxidation reaction using sodium periodate. The alcohol derivative (6d) can be obtained by reacting the aldehyde derivative (18) with various nucleophiles in a solvent. As the nucleophile, trimethylsilyl cyanide, various Grignard reagents, organolithium reagents or organozinc reagents can be used. By this reaction, the substituent R ³ is a cyano group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkenyl group having 1 to 8 carbon atoms, and a substituent. To obtain an alcohol derivative (6d) which is an alkynyl group having 1 to 8 carbon atoms, an aryl group which may have a substituent, or a heterocyclic group which may have a substituent. be able to.

Diol derivative (6a) or diol derivative (6b) instead of diol derivative (6c)
), The alcohol derivative (6e) or the alcohol derivative (6f) can be obtained by carrying out the reaction described in Scheme 9 in the same manner. The alcohol derivative (6e) can be used as the starting compound (6) when the ring A of the compound (1) in Scheme 1 is a 7-membered ring. The alcohol derivative (6f) can be used as a starting compound (6) when the ring A of the compound (1) in Scheme 1 is an 8-membered ring.

[In each formula, R ¹ , R ² , R ³ and R ⁴ are respectively defined in the same manner as described above. ]
The ATPase activity of HSP90 can be examined using an ATPase assay commonly used by those skilled in the art. For example, the ATPase activity of HSP90 can be detected using recombinant HSP90 protein and ATP in the presence or absence of a test compound, as described in Test Example 2 below. Alternatively, the ATPase assay can be performed, for example, by Analytical Biochemistry 327, 176-183 (20
04) or the method described in Nature 425, 407-410 (2003).

Inhibition of HSP90 expression can be examined using Northern blotting, Western blotting, ELISA or the like commonly used by those skilled in the art. For example, mRNA recovered from cells cultured in the presence or absence of the test compound, Northern blotting was performed, and mRNA recovered from cells cultured in the presence of the test compound compared to the absence of the test compound If the amount of HSP90 mRNA is reduced, the test compound is HS
Identifies compounds that inhibit P90 expression. Alternatively, for example, Cancer. R
es. 65, 6401-6408 (2005), Western blotting may be performed to examine the amount of HSP90 protein.

Inhibition of the binding of HSP90 to the client protein can be examined using, for example, immunoprecipitation and Western blotting commonly used by those skilled in the art. Immunoprecipitation and Western blotting are described, for example, in J. Org. Biol. Chem. 277, 10346
The method described in -10353 (2002) may be implemented.

Compounds that inhibit the binding of HSP90 to cochaperones and immunophilins can be examined, for example, using immunoprecipitation and Western blotting commonly used by those skilled in the art. For example, the method described in Nature 425, 407-410 (2003) may be performed to examine the binding of HSP90 to cochaperone or immunophilins in the presence or absence of the test compound.

Inhibition of the binding between HSP90 and ATP can be examined, for example, by using a binding test between labeled ATP and HSP90. For example, J. et al. Biol. Chem. 272, 18608
The method described in -18613 (1997) may be performed to examine the binding of HSP90 and labeled ATP in the presence or absence of a test compound.

Inhibition of HSP90 conformational change can be achieved, for example, by bis-ANS (1,1′-
bis (4-anilino-5-naphthalene sulfonic aci
conformational assay using d)
ay). Conformational assays are described, for example, in J. Org. M
ed. Chem. 47, 3865-3873 (2004).

The compounds of the present invention can be used, for example, for the treatment of various cancers such as lung cancer, digestive organ cancer, ovarian cancer, uterine cancer, breast cancer, liver cancer, head and neck cancer, blood cancer, renal cancer or testicular tumor.

The pharmaceutical composition containing the compound of the present invention can be administered as various injections such as intravenous injection, intramuscular injection and subcutaneous injection, or by various methods such as oral administration and transdermal administration. Among these administration methods, intravenous administration and oral administration by an aqueous preparation are preferable.
An aqueous preparation can be prepared by forming an acid adduct with a pharmacologically acceptable acid or by forming an alkali metal salt such as sodium. In the case of oral administration, it may be in the free form or in the salt form.

As a preparation method of the preparation, an appropriate preparation can be selected according to the administration method, and the preparation can be prepared by various commonly used preparation methods. Among the dosage forms of the antitumor agent of the present invention, examples of the oral agent include tablets, powders, granules, capsules, solutions, syrups, elixirs, and oily or aqueous suspensions. In the case of injections, stabilizers, preservatives or solubilizers can be used in the preparation. A solution that may contain these adjuvants and the like may be stored in a container and then prepared as a solid preparation by lyophilization or the like. Moreover, the single dose may be stored in one container, and the multiple doses may be stored in one container.

Examples of the solid preparation include tablets, capsules, granules, pills, troches, and powders. These solid preparations may contain a pharmaceutically acceptable additive together with the compound of the present invention. Examples of additives include fillers, extenders, binders, disintegrants,
Solubilizers, wetting agents or lubricants can be mentioned, and these can be selected and mixed as necessary to prepare a preparation.

Examples of the liquid preparation include solutions, elixirs, syrups, suspensions, and emulsions. These liquid preparations may contain a pharmaceutically acceptable additive together with the compound of the present invention. Examples of the additive include a suspending agent or an emulsifier, and these can be selected and mixed as necessary to prepare a formulation.

The compounds of the present invention can be used for the treatment of cancer in mammals, particularly humans. The dose and administration interval can be appropriately selected according to the judgment of the doctor according to the location of the disease, the height, weight, sex, or medical history of the patient. When a compound of the present invention is administered to a human, the dosage range is from about 0.01 mg / kg body weight to 100 mg / kg body weight, preferably about 0.05 mg / k per day.
g body weight to 50 mg / kg body weight, more preferably 0.1 mg / kg body weight to 10 mg / kg
It is weight. When administered to humans, it is preferably administered once a day, or divided into 2 to 4 times, and repeated at appropriate intervals. In addition, the daily amount may exceed the above amount depending on the judgment of the doctor.

The present invention will be specifically described with reference to the following examples. However, the present invention is not limited to these examples, and is not construed as being limited in any way. In addition, in this specification, reagents, solvents and starting materials not particularly described are readily available from commercial sources.

(Example 1)
Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraaza Acenaphthylene-4-yl} imide dicarbonate


1) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) -3-buten-1-ol

To a mixture of 2-amino-4,6-dichloropyrimidine-5-carbaldehyde (63.83 g) and N, N-dimethylformamide (500 mL) was added indium powder (45
. After adding 81 g), sodium iodide (99.66 g) was added at an internal temperature of 10 ° C. with cooling in an ice bath. Allyl bromide (67.5 mL) was added to the obtained mixture over 20 minutes, and after confirming a decrease in the internal temperature once increased, the ice bath was removed and the mixture was stirred for 2 hours. The reaction mixture was concentrated to about 200 mL under reduced pressure, and then ethyl acetate (1.5 L) and saturated aqueous sodium hydrogen carbonate (1 L) were added to the residue and stirred. The mixture was filtered through Celite, and the filtrate was separated. The organic layer was washed with water and then saturated brine in this order. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was reduced to about 150 under reduced pressure.
Concentrated to about mL. Hexane was added to the obtained residue and stirred, and then the solid was collected by filtration to give the title compound (57.24 g, 74%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.46 (1H, d), 2.66 (1H, ddd), 2
. 82 (1H, ddd), 5.13 (1H, d), 5.16 (1H, d), 5.27 (1
H, dd), 5.33 (2H, br.s), 5.75-5.85 (1H, m).

2) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) -2- (2,2-dimethyl- [1,3] dioxolan-4-yl) ethane-1-ol

1- (2-Amino-4,6-dichloropyrimidin-5-yl) -3-butene-1-
A mixture of all (57.24 g), N-methylmorpholine-N-oxide (147.6 g), tetrahydrofuran (500 mL), acetone (500 mL), water (500 mL) and osmium tetroxide (62 mg) at room temperature for 2 days Stir. After confirming the disappearance of the raw materials, a saturated aqueous sodium thiosulfate solution (1 L) was added, and the reaction mixture was concentrated to about 1.5 L under reduced pressure. The residue was saturated with sodium chloride and extracted with tetrahydrofuran.
The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure to distill off the solvent. N, N-dimethylformamide (500 mL), 2,2-dimethoxypropane (210 mL) and p-toluenesulfonic acid monohydrate (18.61 g) were added to the resulting residue,
Stir at room temperature for 14 hours. After adding saturated sodium bicarbonate water (1 L) and water (1 L) to the reaction mixture,
Extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated to about 100 mL under reduced pressure, and hexane was added to the residue and stirred, and the precipitated crystals were collected by filtration to give the title compound (53.88 g, 77%) as a solid.

3) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) -2- (2,2-dimethyl- [1,3] dioxolan-4-yl) ethane-1-one

While cooling with an ice bath, the above 1- (2-amino-4,6-dichloropyrimidin-5-yl) -2-
(2,2-Dimethyl- [1,3] dioxolan-4-yl) ethane-1-ol (2.3
2 g) and dimethyl sulfoxide (30 mL) are added to triethylamine (5.
25 mL) and sulfur trioxide pyridine complex (2.45 g) were added, and the ice bath was removed and the mixture was stirred for 2 hours. The reaction mixture was added dropwise to 0.5N aqueous hydrochloric acid (300 mL), and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, and then dried over anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure and the solvent was distilled off to obtain a crude product of the title compound (2.08 g, 90%) as a solid. The obtained compound was used in the next reaction without purification.
ESI-MS m / z: 270 (M + H) ⁺ .

4) [(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -hydrazine hydrochloride

Under cooling in an ice bath, hydrazine monohydrate (360 ml) and methanol (3.3 L) were mixed with 2- (chloromethyl) -4-methoxy-3,5-dimethylpyridine (125.95 g).
) And stirred for 30 minutes, the ice bath was removed, and the mixture was heated and stirred at 60 ° C. for 2.5 hours. After cooling to room temperature, water (1.5 L) was added to the reaction mixture, and about 3.5 L of solvent was distilled off under reduced pressure. 2N Aqueous sodium hydroxide solution (1 L) and sodium chloride (300 g) were added to the resulting concentrated residue, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (1.5 L), 4N hydrochloric acid dioxane solution (550 ml) was added under ice bath cooling, and the mixture was stirred at -2 ° C for 13 hr. The precipitated solid was collected by filtration, washed with dichloromethane, isopropyl ether and dichloromethane in this order, and dried to give the title compound (112.6 g, 68%).
¹ H-NMR (DMSO-d ₆ ) δ: 2.32 (3H, s), 2.38 (3H, s), 3
. 98 (2H, s), 4.41 (2H, s), 8.57 (1H, s).

5) 4-Chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-amine

While cooling in an ice bath, 1- (2-amino-4,6-dichloropyrimidin-5-yl) of 3) above
-2- (2,2-dimethyl- [1,3] dioxolan-4-yl) ethane-1-one (1
. 68 g), 4) [(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]
-To a mixture of hydrazine hydrochloride (2.87 g) and anhydrous dichloromethane (60 mL) was added a solution of triethylamine (3.44 mL) in anhydrous dichloromethane over 20 minutes. After removing the ice bath and stirring for 2 hours, chloroform and water were added to the reaction mixture for liquid separation. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (ethyl acetate-chloroform) to obtain the title compound (1.79 g, 75%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.35 (3H, s), 1.41 (3H, s), 2.2
2 (3H, s), 2.29 (3H, s), 3.10 (1H, dd), 3.44 (1H, d
d), 3.71-3.74 (1H, m), 3.74 (3H, s), 4.02 (1H, dd)
), 4.55-4.60 (1H, m), 5.21 (2H, br.s), 5.47 (2H,
s), 8.15 (1H, s).
ESI-MS m / z: 433 (M + H) ^<+> .

6) Di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3,5-dimethylpyridine- 2-
Yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

6-di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (1.29 g) and dehydrated tetrahydrofuran (50 mL)
-Dimethylaminopyridine (36 mg) and di-tert-butyl dicarbonate (3.9)
0 g) was added, followed by stirring at room temperature for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (1.63 g, 86%) as an oil. Obtained.
¹ H-NMR (CDCl ₃ ) δ: 1.35 (3H, s), 1.38 (3H, s), 1.4
2 (18H, s), 2.20 (3H, s), 2.26 (3H, s), 3.27 (1H, d
d), 3.53 (1H, dd), 3.74 (3H, s), 3.76 (1H, dd), 4.
04 (1H, dd), 4.57-4.64 (1H, m), 5.65 (1H, dd), 8.
07 (1H, s).
ESI-MS m / z: 633 (M + H) ^<+> .

7) Di-tert-butyl {4-chloro-3- (2,3-dihydroxypropyl) -1
-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

6-di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (12.52 g) in methanol (250 mL) was added p-toluenesulfonic acid monohydrate (3 .76 g) was added and stirred at room temperature for 7 hours. The reaction mixture was poured into saturated brine and extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (ethyl acetate-methanol) to give the title compound (9.64 g, 8
2%) was obtained as an amorphous material.
¹ H-NMR (CDCl ₃ ) δ: 1.42 (18H, s), 2.20 (3H, s), 2.
29 (3H, s), 2.77-2.80 (1H, m), 3.31-3.33 (2H, m)
3.51-3.54 (1H, m), 3.64-3.67 (1H, m), 3.74 (3H
, S) 3.76-3.79 (1H, m) 4.24-4.30 (1H, m) 5.66 (2H
, S), 8.03 (1H, s).
ESI-MS m / z: 593 (M + H) ⁺ .
8) Di-tert-butyl {4-chloro-3- (2-hydroxyethyl) -1-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4
-D] pyrimidin-6-yl} imide dicarbonate

Under cooling in an ice bath, the above 6-di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3, 5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (154 mg), tetrahydrofuran (1 mL), methanol (
To a mixture consisting of 1 mL) and water (1 mL), sodium periodate (278 mg) was added, and the ice bath was removed and stirred for 1 hour. Saturated aqueous sodium hydrogen carbonate (40 mL) and ethyl acetate (40 mL) were added to the reaction mixture to separate the layers. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Methanol (4 mL) was added to the resulting residue, and sodium borohydride (25 mg) was added in small portions while cooling with an ice bath, followed by stirring for 1 hour. The reaction mixture was diluted with ethyl acetate, and washed successively with 0.1N aqueous hydrochloric acid solution and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the solvent was evaporated to give a crude product of the title compound (129 mg, 88%) as an oil. The obtained compound was used in the next reaction without purification.
¹ H-NMR (CDCl ₃ ) δ: 1.43 (18H, s), 2.21 (3H, s), 2.
28 (3H, s), 3.36 (2H, t), 3.75 (3H, s), 4.07 (2H, t
), 5.66 (2H, s), 8.07 (1H, s).
ESI-MS m / z: 563 (M + H) ^<+> .
9) 2- {6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
, 4-d] pyrimidin-3-yl} ethyl 4-methylbenzenesulfonate

Under cooling in an ice bath, the above 6-di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3, To a mixture of 5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (64 mg) and dehydrated dichloromethane (1 mL) was added triethylamine (0.048 mL). ), P-toluenesulfonyl chloride (43 mg)
And 4-dimethylaminopyridine (0.7 mg) was added, the ice bath was removed, and the mixture was stirred for 12 hours. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (7
4 mg, 91%) was obtained as an amorphous material.
ESI-MS m / z: 717 (M + H) ^<+> .
10) Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate

Under cooling in an ice bath, the above 6-di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1-[(4-methoxy-3, 5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (74 mg), N, N-dimethylformamide (1 mL) and potassium thioacetate (19 mg) ) Was stirred for 2 hours, then the ice bath was removed and 1.5% was removed.
Stir for hours. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure and the solvent was evaporated to obtain a crude product of the title compound (59 mg) as an oil. The obtained compound was used in the next reaction without purification.
ESI-MS m / z: 543 (M + H) ⁺ .
(Example 2)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4- Amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6 from step 10) of Example 1 under ice bath cooling -Thia-1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate (59
mg) and dichloromethane (2 mL) to a mixture of trifluoroacetic acid (0.5 mL)
Then, the ice bath was removed and the mixture was stirred for 2 hours. After the reaction solution was concentrated under reduced pressure, the obtained residue was dissolved in ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine in this order.
The organic layer was dried over anhydrous magnesium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-methanol) to give the title compound (26 mg, 85%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.28 (3H, s), 3.1
2 (2H, t), 3.43 (2H, t), 3.74 (3H, s), 5.22 (2H, br
. s), 5.44 (2H, s), 8.21 (1H, s).
ESI-MS m / z: 343 (M + H) ^<+> .
(Example 3)
Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3 5-tetraazaacenaphthylene-4-yl} imide dicarbonate

1) Di-tert-butyl {4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -3- (2-oxoethyl) -1H-pyrazolo [3,4 d
] Pyrimidin-6-yl} imide dicarbonate

With cooling in an ice bath, di-tert-butyl {4-chloro-3-yl represented by Step 7) of Example 1
(2,3-dihydroxypropyl) -1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (1.34 g), tetrahydrofuran (15 mL), methanol (15 mL)
) And water (15 mL), sodium periodate (1.95 g) was added in small portions and the ice bath was removed and stirred for 1 hour. To the reaction mixture ethyl acetate (40 mL)
And filtered. The filtrate was separated, and the organic layer was washed with water and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure and the solvent was distilled off to obtain a crude product of the title compound (1.32 g, 104%) as an amorphous substance. .
The obtained compound was directly used in the next reaction without purification.
¹ H-NMR (CDCl ₃ ) δ: 1.44 (18H, s), 2.22 (3H, s), 2.
28 (3H, s), 3.75 (3H, s), 4.21 (1H, d), 5.70 (2H, s)
), 8.12 (1H, s), 9.90 (1H, t).
2) Di-tert-butyl {4-chloro-3- (2-cyano-2-hydroxyethyl)
-1-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

Under cooling in an ice bath, the di-tert-butyl {4-chloro-1-[(4-methoxy-3,
5-Dimethylpyridin-2-yl) methyl] -3- (2-oxoethyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (796 mg) and dichloromethane (10 mL) Trimethylsilylcyanide (0.219 mL)
And triethylamine (0.198 mL) were added, and the ice bath was removed and the mixture was stirred for 16 hours. Chloroform (80 mL) and 0.5 N aqueous hydrochloric acid solution (100 mL) were added to the reaction mixture, followed by liquid separation. The organic layer was dried over anhydrous magnesium sulfate and filtered, and then the filtrate was concentrated under reduced pressure.
The obtained residue was dissolved in acetonitrile (20 mL), 1N hydrochloric acid aqueous solution (10 mL)
And stirred at room temperature for 30 minutes. Saturated aqueous sodium bicarbonate (80 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate,
The filtrate was concentrated under reduced pressure, and the solvent was distilled off to give a crude product of the title compound (788).
mg, 94%). The obtained compound was directly used in the next reaction without purification.
ESI-MS m / z: 588 (M + H) ^<+> .
3) 2- {6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
, 4-d] pyrimidin-3-yl} -1-cyanoethyl 4-methylbenzenesulfonate

Crude di-tert-butyl {4-chloro-3- (2-cyano-2-hydroxyethyl) -1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-
To a mixture of pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (788 mg) and dehydrated dichloromethane (12 mL), p-toluenesulfonyl chloride (
511 mg), then triethylamine (0.56 mL) was added dropwise, then 4
-Dimethylaminopyridine (16 mg) was added and stirred at room temperature for 3 hours. The reaction mixture was diluted with chloroform and washed with water. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (450 mg, 45%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.45 (18H, s), 2.21 (3H, s), 2.
28 (3H, s), 2.44 (3H, s), 3.68-3.80 (5H, m), 5.51
(1H, dd), 5.60 (2H, d), 5.65 (1H, d), 7.28 (2H, d)
, 7.67 (2H, d), 8.09 (1H, s).
ESI-MS m / z: 742 (M + H) ⁺ .
4) Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2, 3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate

While cooling with an ice bath, the above 2- {6- [bis (tert-butoxycarbonyl) amino] -4-
Chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H
-A mixture of pyrazolo [3,4-d] pyrimidin-3-yl} -1-cyanoethyl 4-methylbenzenesulfonate (450 mg) and dehydrated N, N-dimethylformamide (8 mL) was added to sodium hydrogen sulfide monohydrate. After adding the Japanese product (58 mg), the ice bath was removed and the mixture was stirred for 1 hour. After potassium carbonate (84 mg) was added to the reaction mixture, the mixture was further stirred for 30 minutes. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (277 mg, 81%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.45 (18H, s), 2.22 (3H, s), 2.
28 (3H, s), 3.55 (1H, dd), 3.64 (1H, dd), 3.74 (3H
, S), 4.58 (1H, dd), 5.66 (2H, s), 8.16 (1H, s).
ESI-MS m / z: 568 (M + H) ⁺ .
Example 4
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-
Carbonitrile

Di-tert-butyl {7-cyano-2-[(4-methoxy- of step 4) of Example 3
3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-
1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate (30 m
g) and dichloromethane (1 mL) to a mixture of trifluoroacetic acid (0.25 mL)
Then, the ice bath was removed and the mixture was stirred for 1 hour. After confirming disappearance of the starting materials, the reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate was added to the residue, and the precipitated solid was collected by filtration and washed with water.
The obtained solid was dried to give the title compound (13.8 mg, 71%).
¹ H-NMR (DMSO-d ₆ ) δ: 2.18 (3H, s), 2.22 (3H, s), 3
. 35 (2H, dd), 3.47 (1H, dd), 3.72 (3H, s), 5.34 (1
H, t), 5.37 (2H, s), 7.16 (2H, s), 8.09 (1H, s).
ESI-MS m / z: 368 (M + H) ^<+> .
(Example 5)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7-methyl-
7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-
Amine 1) Di-tert-butyl {4-chloro-3- (2-hydroxypropyl) -1-[(
4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
4-d] pyrimidin-6-yl} imide dicarbonate

Di-tert-butyl of Step 1) of Example 3 under cooling with dry ice-acetone bath {4
-Chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -3
To a mixture of-(2-oxoethyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (120 mg) and dehydrated tetrahydrofuran (1 mL) was added 3N diethyl ether solution of methylmagnesium bromide (0 .15 mL) was added dropwise and stirred for 1 hour. A saturated aqueous ammonium chloride solution (1 mL) was added dropwise to the reaction mixture, and then the dry ice-acetone bath was removed. Ethyl acetate (30 mL) and water (30 mL) were added to the reaction mixture and the layers were separated, and the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel thin layer chromatography (ethyl acetate-hexane) to give the title compound (52 mg, 42%) as an oil.
ESI-MS m / z: 577 (M + H) ^<+> .
2) 2- {6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
, 4-d] pyrimidin-3-yl} -1-methylethyl 4-methylbenzenesulfonate

Di-tert-butyl {4-chloro-3- (2-hydroxypropyl) -1- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
, 4-d] pyrimidin-6-yl} imide dicarbonate (52 mg) and p-toluenesulfonyl chloride (86 mg) in the same manner as in Step 3) of Example 3, the crude title compound ( 29 mg, 44%) was obtained as an oil. The obtained compound was used in the next reaction without purification.
ESI-MS m / z: 731 (M + H) ^<+> .
3) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7-methyl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraaza Acenaphthylene
4-amine

While cooling with an ice bath, the above 2- {6- [bis (tert-butoxycarbonyl) amino] -4-
Chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H
-To a mixture of pyrazolo [3,4-d] pyrimidin-3-yl} -1-methylethyl 4-methylbenzenesulfonate (29 mg) and N, N-dimethylformamide (1 mL) The Japanese product (3.8 mg) was added and stirred for 20 minutes, then potassium carbonate (8.2 mg) was added, the ice bath was removed and the mixture was stirred for 10 hours. The reaction mixture was diluted with ethyl acetate, and washed with water and saturated brine in this order. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was stirred for 2 hr. After the reaction mixture was concentrated under reduced pressure, the resulting residue was dissolved in chloroform and washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to obtain the title compound (8.9 mg, 63%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.56 (3H, d), 2.22 (3H, s), 2.2
8 (3H, s), 2.84 (1H, dd), 3.20 (1H, dd), 3.74 (3H,
s), 3.84-3.93 (1H, m), 5.26 (2H, br. s), 5.44 (2H)
, S), 8.21 (1H, s).
ESI-MS m / z: 357 (M + H) ^<+> .
(Example 6)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7-prop-
1-in-1-yl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

1) 1-({6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3 , 4-d] pyrimidin-3-yl} methyl) but-2-yn-1-yl methanesulfonate

Di-tert-butyl of Step 1) of Example 3 under cooling with dry ice-acetone bath {4
-Chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -3
A solution of 1-propynylmagnesium bromide in 0.5 N tetrahydrofuran (0 mg .60 mL) was added dropwise and stirred for 1 hour. A saturated aqueous ammonium chloride solution (1 mL) was added dropwise to the reaction mixture, and then the dry ice-acetone bath was removed. To the reaction mixture ethyl acetate (30 mL)
And water (30 mL) were added for liquid separation, and the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was dichloromethane (6 m
L), methanesulfonyl chloride (46 μL) was added while cooling in an ice bath, and then a solution of triethylamine (96 μL) in dichloromethane was added dropwise. After removing the ice bath and stirring for 3 hours, the reaction mixture was diluted with dichloromethane and washed in turn with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (46 mg, 35%) as an oil.
ESI-MS m / z: 679 (M + H) ⁺ .
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7-prop-1-in-1-yl-7,8-dihydro-2H-6-thia-1, 2,3,5-tetraazaacenaphthylene-4-amine

1-({6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3, 4-d] pyrimidin-3-yl} methyl) but-2-
In-1-yl methanesulfonate (46 mg) and sodium hydrogen sulfide monohydrate (6.5
In the same manner as in Step 3 of Example 5, the title compound (7.2 mg, 28%
) Was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.85 (3H, d), 2.23 (3H, s), 2.2
7 (3H, s), 3.16 (1H, dd), 3.36 (1H, dd), 3.75 (3H,
s), 4.48-4.53 (1H, m), 5.44 (2H, s), 8.19 (1H, s)
ESI-MS m / z: 381 (M + H) ^<+> .
(Example 7)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-
Carboxamide

Di-tert-butyl {7-cyano-2-[(4-methoxy- of step 4) of Example 3
3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-
1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate (30 m
A mixture of g) and concentrated hydrochloric acid (1 mL) was stirred at room temperature for 1.5 hours. The reaction mixture was diluted with water and neutralized with saturated aqueous sodium hydrogen carbonate solution. The precipitate was collected by filtration, washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order, and the obtained solid was dried to give the title compound (18.5 mg, 91%).
¹ H-NMR (DMSO-d ₆ ) δ: 2.17 (3H, s), 2.21 (3H, s), 3
. 09 (1H, dd), 3.26 (1H, dd), 3.71 (3H, s), 4.56 (1
H, dd), 5.32 (2H, s), 6.94 (2H, s), 7.42 (1H, s), 7
. 75 (1H, s), 8.08 (1H, s).
ESI-MS m / z: 386 (M + H) ^<+> .
(Example 8)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-
Carboxylic acid

Di-tert-butyl {7-cyano-2-[(4-methoxy- of step 4) of Example 3
3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-
1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate (210
mg) and concentrated hydrochloric acid (6 mL) were stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure to remove the solvent. Diethyl ether was added to the residue, and the solid was pulverized and collected by filtration to obtain the hydrochloride of the title compound (171 mg). The obtained crude hydrochloride (4
2 mg) was purified by reverse phase liquid chromatography to give the title compound (6.1 mg
, 17%) as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.17 (3H, s), 2.21 (3H, s), 3
. 13 (1H, dd), 3.26 (2H, dd), 3.71 (3H, s), 4.71-4
. 80 (1H, m), 5.32 (2H, s), 6.94 (2H, s), 8.08 (1H,
s).
ESI-MS m / z: 387 (M + H) ^<+> .
Example 9
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-methyl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid hydrochloride (42 mg), methylamine hydrochloride (
13 mg), 1-hydroxybenzotriazole monohydrate (14 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (35 mg), diisopropylethylamine (79 μL) and dehydrated N, N-dimethylformamide ( 1 mL) was stirred at room temperature for 48 hours. 0.5N aqueous sodium hydroxide solution was added to the reaction mixture, and the solid was collected by filtration. The solid collected by filtration was dissolved in a mixed solvent of chloroform-methanol and purified by silica gel thin layer chromatography (chloroform: methanol) to obtain the title compound (17.9 mg, 49%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.28 (3H, s), 2.7
8 (3H, d), 3.25 (1 H, dd), 3.66 (1 H, dd), 3.75 (3H,
s), 4.33 (1H, dd), 5.38-5.46 (3H, m), 6.94 (1H, d)
), 8.15 (1H, s).
ESI-MS m / z: 400 (M + H) ^<+> .
(Example 10)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-ethyl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid hydrochloride (42 mg) and ethylamine hydrochloride (
The title compound (16.0 mg, 42%) was prepared in the same manner as in Example 9.
Was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.08 (3H, t), 2.21 (3H, s), 2.2
8 (3H, s), 3.15-3.35 (2H, m), 3.69 (2H, dd), 3.74
(3H, s), 4.29 (1H, dd), 5.38-5.46 (5H, m), 6.60 (
1H, br. s), 8.17 (1H, s).
ESI-MS m / z: 414 (M + H) ^<+> .
Example 11
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N, N-dimethyl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (5.9 mg, 16%) was prepared in the same manner as in Example 9 using tetraazaacenaphthylene-7-carboxylic acid hydrochloride (42 mg) and dimethylamine hydrochloride (16 mg).
Was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 3.0
3 (3H, s), 3.17 (3H, s), 3.23 (1H, dd), 3.48 (1H, d
d), 3.74 (3H, s), 4.73 (1H, dd), 5.26 (2H, s), 5.4
5 (2H, s), 8.20 (1 H, s).
ESI-MS m / z: 414 (M + H) ^<+> .
Example 12
4-Amino-N-cyclopropyl-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (80 mg), cyclopropylamine (0.0
29 mL), 1-hydroxybenzotriazole monohydrate (32 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (80 mg) and dehydrated N, N
-A mixture of dimethylformamide (10 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with ethyl acetate and washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel column chromatography (dichloromethane-methanol) to give the title compound (30 mg, 34%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.42 to 0.49 (2H, m), 0.74 to 0.76
(2H, m), 2.22 (3H, s), 2.29 (3H, s), 2.65-2.67 (1
H, m), 3.24 (1H, dd), 3.70 (1H, dd), 3.75 (3H, s),
4.24 (1H, dd), 5.24 (2H, s), 5.43 (2H, s), 6.60 (1
H, s), 8.18 (1H, s).
ESI-MS m / z: 426 (M + H) ^<+> .
(Example 13)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-prop-2-yn-1-yl-7,8-dihydro-2H-6-thia-1,2,3,5
-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (80 mg) and propargylamine (29 μL)
) To give the title compound (30 mg, 34%) as a solid in the same manner as in Example 12.
¹ H-NMR (CDCl ₃ ) δ: 2.21-2.22 (4H, m), 2.29 (3H, s
), 3.26 (1H, dd), 3.76-3.79 (4H, m), 3.86-3.91 (
1H, m), 4.08-4.13 (1H, m), 4.30 (1H, t), 5.24 (2H
, S), 5.43 (2H, d), 6.74-6.76 (1H, br. S), 8.19 (1
H, s)
ESI-MS m / z: 424 (M + H) ^<+> .
(Example 14)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (2-Phenylethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 2-phenylethylamine (3
In the same manner as in Example 12, the title compound (10 mg, 16%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.20 (3H, s), 2.30 (3H, s), 2.7
2 (2H, dd), 3.23 (1H, dd), 3.44-3.56 (2H, m), 3.7
0-3.74 (4H, m), 4.23-4.25 (1H, m), 5.24 (2H, s),
5.45-5.47 (2H, m), 6.49-6.51 (1H, m), 7.03 (2H, m)
d), 7.22-7.28 (3H, m), 8.16 (1H, s).
ESI-MS m / z: 490 (M + H) ⁺ .
(Example 15)
7-[(4-Isopropylpiperazin-1-yl) carbonyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia- 1,2,3,5-tetraazaacenaphthylene-4-amine

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (40 mg) and 1-isopropylpiperazine (
In the same manner as in Example 12, the title compound (6 mg, 12%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.01 (6H, d), 2.20 (3H, s), 2.2
7 (3H, s), 2.45-2.54 (4H, m), 2.68-2.72 (1H, m),
3.21 (1H, dd), 3.44-3.51 (3H, m), 3.71-3.73 (4H
M), 3.83 (1H, br.s), 4.68 (1H, dd), 5.16 (2H, s)
, 5.43 (2H, s), 8.18 (1H, s).
ESI-MS m / z: 497 (M + H) ⁺ .
(Example 16)
4-Amino-N- (2-chloroethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2, 3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (40 mg), 2-chloroethylamine hydrochloride (24 mg), 1-hydroxybenzotriazole monohydrate (24 mg), 1- (3-dimethylaminopropyl) -3- A mixture of ethyl carbodiimide hydrochloride (40 mg), triethylamine (44 μL) and dehydrated N, N-dimethylformamide (10 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with ethyl acetate and washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel column chromatography (dichloromethane-ethyl acetate) to give the title compound (
10 mg, 22%) was obtained as a solid.
ESI-MS m / z: 448 (M + H) ^<+> .
(Example 17)
4-Amino-N- (3-chloropropyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2 , 3,5-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (60 mg, 50 mg, 50) was prepared in the same manner as in Example 16 using tetraazaacenaphthylene-7-carboxylic acid (100 mg) and 2-chloropropylamine hydrochloride (60 mg).
%) As a solid.
ESI-MS m / z: 448 (M + H) ^<+> .
(Example 18)
4-Amino-N- [2- (isobutylamino) ethyl] -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2
, 3,5-Tetraazaacenaphthylene-7-carboxamide

4-Amino-N- (2-chloroethyl) -2-[(4-methoxy-3,5) of Example 16.
-Dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2
, 3,5-Tetraazaacenaphthylene-7-carboxamide (20 mg), isobutylamine (0.8 mL) and dioxane (3 mL) were heated to reflux for 16 hours, and then the reaction mixture was concentrated under reduced pressure. The obtained residue was purified by reverse phase liquid chromatography to give the title compound (6 mg, 28%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.86 (6H, d), 1.64 to 1.65 (1 H, m
), 2.19 (3H, s), 2.27 (3H, s), 2.32 (2H, d), 2.65-
2.67 (2H, m), 3.23-3.28 (3H, m), 3.62-3.69 (4H,
m), 4.30 (1H, dd), 5.24-5.28 (2H, m), 5.41 (2H, d)
), 7.07 (1H, s), 8.16 (1H, s).
ESI-MS m / z: 485 (M + H) ^<+> .
Example 19
4-Amino-N- [3- (isobutylamino) propyl] -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,
2,3,5-tetraazaacenaphthylene-7-carboxamide

4-Amino-N- (3-chloropropyl) -2-[(4-methoxy-3, of Example 17)
5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,
Using 2,3,5-tetraazaacenaphthylene-7-carboxamide (30 mg) and isobutylamine (2 mL), the reaction and post-treatment were carried out in the same manner as in Example 18, followed by NH silica gel column chromatography (dichloromethane- Purified with methanol) to give the title compound (2
0 mg, 62%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.87 (6H, d), 1.63-1.70 (3H, m
), 2.20 (3H, s), 2.27 (3H, s), 2.35 (2H, dd), 2.60.
-2.64 (2H, m), 3.23-3.33 (3H, m), 3.58 (1H, dd),
3.72 (3H, s), 4.26 (1H, dd), 5.19 (2H, s), 5.41 (2
H, s), 8.05 (1H, br), 8.17 (1H, s).
ESI-MS m / z: 499 (M + H) ^<+> .
(Example 20)
4-Amino-N- {3-[(2,2-dimethylpropyl) amino] propyl} -2-[(
4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2
H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-Amino-N- (3-chloropropyl) -2-[(4-methoxy-3, of Example 17)
5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,
Using 2,3,5-tetraazaacenaphthylene-7-carboxamide (30 mg) and neopentylamine (2.0 mL) in the same manner as in Example 19, the title compound (10 mg
29%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.86 (9H, s), 1.63-1.70 (2H, m
), 2.20-2.21 (4H, m), 2.27-2.28 (4H, m), 2.64 (2
H, m), 3.25 (1H, dd), 3.32-3.37 (2H, m), 3.57 (1H
, Dd), 3.72 (3H, s), 4.25 (1H, dd), 5.17 (2H, s), 5
. 41 (2H, s), 7.88-7.90 (1H, br), 8.17 (1H, s).
ESI-MS m / z: 513 (M + H) ^<+> .
(Example 21)
Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5- Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

1) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) pent-4-ene-1
-All

Under a nitrogen atmosphere, magnesium pieces (3.17 g) and dehydrated tetrahydrofuran (150 mL)
4-Bromo-1-butene (14.54 mL) was added over 1 hour.
After confirming the rise in internal temperature, the Grignard reagent was prepared by stirring at an internal temperature of 25 to 30 ° C. for 1 hour while cooling in an ice bath. The above-mentioned Grignard reagent was added to a mixture of 2-amino-4,6-dichloro-pyrimidine-5-carbaldehyde (5.00 g) and dehydrated tetrahydrofuran (100 mL) over 3 hours under cooling with dry ice-acetone. Thereafter, the mixture was stirred for 1.5 hours. Water (100 mL) was added to the reaction mixture, and the dry ice-acetone bath was removed.
A saturated aqueous ammonium chloride solution (200 mL) was added to the reaction mixture, and then ethyl acetate (20 mL) was added.
0 mL) was added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with saturated brine. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure and the solvent was distilled off to obtain a crude product of the title compound (5.06 g, 78%) as a solid. The obtained compound was used in the next reaction without purification.

2) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) pent-4-ene-1
-ON

Crude 1- (2-amino-4,6-dichloropyrimidin-5-yl) pent-4-en-1-ol (5.06 g), 1,2-dichloroethane (300 mL) and manganese dioxide (20.15 g) ) Was heated to reflux for 15 hours. After confirming the disappearance of the raw materials, the reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-chloroform) to give the title compound (1.22 g
24.3%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.48 (2H, dd), 2.94 (2H, t), 5.
01-5.06 (1H, m), 5.10 (1H, ddd), 5.41 (2H, s), 5.
93-5.80 (1H, m).

3) 3-But-3-en-1-yl-4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d Pyrimidine-6-amine

While cooling with an ice bath, the above-mentioned 1- (2-amino-4,6-dichloropyrimidin-5-yl) pent-4-en-1-one (4.92 g) and Step 4) of Example 1 (4) -Methoxy-3,5
-Dimethylpyridin-2-yl) methyl] hydrazine hydrochloride (8.72 g)
In the same manner as in Step 5) of Example 1, the title compound (4.40 g, 59%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.15 (3H, s), 2.19 (3H, s), 2
. 35-2.42 (2H, m), 2.87-2.93 (2H, m), 3.70 (3H, s
), 4.91-4.96 (1H, m), 4.99-5.06 (1H, m), 5.37 (2
H, s), 5.89-5.78 (1H, m), 7.17 (2H, S), 8.02 (1H,
s)

4) Di-tert-butyl {3-bute-3-en-1-yl-4-chloro-1-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4
-D] pyrimidin-6-yl} imide dicarbonate

3-but-3-en-1-yl-4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] Pyrimidine-6
Using the amine (4.40 g) and di-tert-butyl dicarbonate (15.46 g) in the same manner as in Step 6) of Example 1, the title compound (6.78 g, 100%) as a solid Obtained.
ESI-MS m / z: 573 (M + H) ⁺

5) Di-tert-butyl {4-chloro-3- (3,4-dihydroxybutyl) -1-
[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [
3,4-d] pyrimidin-6-yl} imide dicarbonate

3- (3-Butenyl) -6-di (tert-butoxycarbonyl) amino-4-chloro-1- (4-methoxy-3,5-dimethylpyridin-2-yl) methyl-1H-pyrazolo [3 4-d] pyrimidine (4.78 g), N-methylmorpholine-N-oxide (
5.04 g), tetrahydrofuran (60 mL), acetone (60 mL) and water (60
mL) was added osmium tetroxide (21 mg) and stirred at room temperature for 5 hours. To the reaction mixture was added ethyl acetate (300 mL) and 10% aqueous sodium thiosulfate solution (500 m
L) was added and stirred for an additional 30 minutes. The reaction mixture was separated, the aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure and the solvent was distilled off to give a crude product of the title compound (4.
60 g, 91%) was obtained as a solid. The obtained compound was used in the next reaction without purification.
¹ H-NMR (CDCl ₃ ) δ: 1.41 (18H, s), 1.98 (2H, dd), 2
. 20 (3H, s), 2.29 (3H, s), 3.08 (1H, d), 3.27 (2H,
t), 3.45-3.51 (1H, m), 3.58-3.64 (1H, m), 3.73-
3.76 (4H, m), 5.59-5.69 (2H, m), 8.03 (1H, s).
6) Di-tert-butyl {4-chloro-3- (3-hydroxypropyl) -1-[(
4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
4-d] pyrimidin-6-yl} imide dicarbonate

Under cooling in an ice bath, the above 6-di (tert-butoxycarbonyl) amino-4-chloro-3-
(3,4-Dihydroxybutyl) -1- (4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl-1H-pyrazolo [3,4-d] pyrimidine (225 mg) and sodium periodate (396 mg) in the same manner as in step 8) of Example 1 in the same manner as the title compound (128 mg, 60%) was obtained as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.41 (18H, s), 2.04-2.11 (2H,
m), 2.19 (3H, s), 2.28 (3H, s), 3.23 (2H, t), 3.70.
-3.73 (2H, m), 3.74 (3H, s), 5.65 (2H, s), 8.04 (1
H, s).
ESI-MS m / z: 577 (M + H) ^<+> .
7) Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

Di-tert-butyl {4-chloro-3- (3-hydroxypropyl) under ice bath cooling
-1-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (64 mg) and dehydrated dichloromethane (3 mL) ) To a mixture of triethylamine (0.12 mL), p-toluenesulfonyl chloride (152 mg) and 4-dimethylaminopyridine (1 mg).
The ice bath was removed and the mixture was stirred for 17 hours. Water (30 mL) and ethyl acetate (30 mL) were added to the reaction mixture, and the mixture was partitioned. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. N, N-dimethylformamide (1 mL) and potassium thioacetate (25 mg) were added to the resulting residue, and the mixture was heated to 50 ° C. and stirred for 15 minutes. After confirming the completion of the reaction, water and ethyl acetate were added to the reaction mixture for liquid separation. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (34 mg, 55%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.39 (18H, s), 2.21 (3H, s), 2.
26 (3H, s), 2.46 (2H, dt), 3.22-3.25 (4H, m), 3.7
3 (3H, s), 5.62 (2H, s), 8.17 (1H, s).
ESI-MS m / z: 557 (M + H) ⁺ .
(Example 22)
2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,
9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4
-Amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro of Example 7 step 7) under ice bath cooling. -6
-The title compound (28 mg, 62) was prepared in the same manner as in Example 2 using thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (71 mg).
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.26 (3H, s), 2.3
7-2.43 (2H, m), 3.11 (2H, t), 3.18 (2H, t), 3.74 (
3H, s), 5.16 (2H, s), 5.46 (2H, s), 8.20 (1H, s).
ESI-MS m / z: 357 (M + H) ^<+> .
(Example 23)
Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2, 3,5-
Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

1) Di-tert-butyl {4-chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -3- (3-oxopropyl) -1H-pyrazolo [3,4 −
d] pyrimidin-6-yl} imide dicarbonate

Di-tert-butyl {4-chloro-3- (3) of step 5) of Example 21 under ice bath cooling.
, 4-Dihydroxybutyl) -1-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (4.60 g) and sodium periodate (1.95 g), Step 1 of Example 3. ) To give a crude title compound (4.34 g, 100%). The obtained compound was used in the next reaction without purification.

2) Di-tert-butyl {4-chloro-3- (3-cyano-3-hydroxypropyl) -1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

Under cooling in an ice bath, the di-tert-butyl {4-chloro-1-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -3- (3-oxopropyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (1.55 g) and trimethylsilylcyanide ( In the same manner as in Step 2) of Example 3, a crude product containing the title compound (1.99 g) was obtained. The obtained compound is not purified,
Used as it is in the next reaction.
ESI-MS m / z: 602 (M + H) ⁺ .
3) 3- {6- [Bis (tert-butoxycarbonyl) amino] -4-chloro-1- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H-pyrazolo [3
, 4-d] pyrimidin-3-yl} -1-cyanopropyl 4-methylbenzenesulfonate

Crude di-tert-butyl {4-chloro-3- (3-cyano-3-hydroxypropyl) -1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H
-Pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (1.99 g)
And p-toluenesulfonyl chloride (945 mg) were used in the same manner as in Step 3) of Example 3 to obtain the title compound (2.32 g, 93%) as a solid.
ESI-MS m / z: 756 (M + H) ⁺ .

4) Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1, 2, 3,
5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

While cooling with an ice bath, the above 3- {6- [bis (tert-butoxycarbonyl) amino] -4-
Chloro-1-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -1H
Examples using pyrazolo [3,4-d] pyrimidin-3-yl} -1-cyanopropyl 4-methylbenzenesulfonate (2.32 g) and sodium hydrogen sulfide monohydrate (273 mg) The title compound (1.49 g, 84%) was obtained as an oil in the same manner as in Step 4) of Step 3.
¹ H-NMR (CDCl ₃ ) δ: 1.44 (18H, s), 2.22 (3H, s), 2.
28 (3H, s), 2.61-2.68 (1H, m), 2.84-2.92 (1H, m)
3.42-3.59 (2H, m), 3.74 (3H, s), 4.32 (1H, d), 5
. 65 (2H, s), 8.16 (1 H, s).
ESI-MS m / z: 582 (M + H) ^<+> .
(Example 24)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene-7-carbonitrile

Step 4 of Example 23) Di-tert-butyl {7-cyano-2-[(4-methoxy-
3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6
In the same manner as in Example 2 using thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (53 mg), the title compound (21.6 mg, 8
1%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.29 (3H, s), 2.5
1-2.61 (1H, m), 2.75-2.85 (1H, m), 3.28-3.45 (2
H, m), 3.76 (3H, s), 4.25 (1H, d), 5.34 (2H, br. S)
, 5.48 (2H, s), 8.22 (1H, s).
ESI-MS m / z: 382 (M + H) ^<+> .
(Example 25)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7- (1H-
Tetrazol-5-yl) -2,7,8,9-tetrahydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulen-4-amine

Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro- of Example 23, step 4) 6
-Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (53 mg), N, N-dimethylformamide (1 mL), triethylamine hydrochloride (14.5 m) and A mixture consisting of sodium chloride (6.8 mg) was sealed, and the mixture was heated and stirred at a bath temperature of 105 ° C. for 15 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and 0.
1N aqueous sodium hydroxide solution was added to separate the layers. The aqueous layer was acidified with 0.1N aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain a residue of dichloromethane (2 mL).
And trifluoroacetic acid (0.5 mL) was added and stirred at room temperature for 2 hours. The residue obtained by concentrating the reaction solution under reduced pressure was purified by silica gel thin layer chromatography (chloroform-methanol-water lower layer) to obtain the title compound (5.6 mg, 19%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.09 (3H, s), 2.18 (3H, s), 2.6
4-3.13 (4H, m), 3.66 (3H, s), 4.57-4.85 (1H, m),
5.29 (2H, s), 8.03 (1H, s).
ESI-MS m / z: 425 (M + H) ^<+> .
(Example 26)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene-7-carboxamide

Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro- of Example 23, step 4) 6
A mixture of -thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (53 mg) and concentrated hydrochloric acid (1 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase liquid chromatography to give the title compound (9.7 mg, 35%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.17 (3H, s), 2.21 (3H, s), 2.9
6-3.00 (2H, m), 3.71 (3H, s), 4.18 (1H, d), 5.32 (
1H, d), 5.37 (1H, d), 6.76 (2H, s), 7.32 (1H, s), 7
. 73 (1H, s), 8.07 (1H, s).
ESI-MS m / z: 400 (M + H) ^<+> .
(Example 27)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene e-7-carboxylic acid

Di-tert-butyl {7-cyano-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro- of Example 23, step 4) 6
A mixture of -thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (745 mg) and concentrated hydrochloric acid (30 mL) was stirred at room temperature for 4 days. After confirming disappearance of the raw materials, the reaction mixture was concentrated under reduced pressure, and the residue was diluted with water, and then neutralized with saturated aqueous sodium hydrogen carbonate. Acetic acid (4 mL) was added to the mixture and cooled in an ice bath for 30 minutes. The precipitate was collected by filtration and dried to give the title compound (420 mg, 82%) as a solid.
ESI-MS m / z: 401 (M + H) ⁺ .
(Example 28)
4-Amino-N-ethyl-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulene-7-carboxamide

4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 of Example 27 In a similar manner to Example 9 using 5-tetraazabenzo [cd] azulene e-7-carboxyl acid (32 mg) and ethylamine hydrochloride (14 mg), the title compound (22.3 g,
68%) was obtained as a white solid.
¹ H-NMR (CDCl ₃ ) δ: 1.12 (3H, t), 2.22 (3H, s), 2.2
6 (3H, s), 2.64-2.71 (2H, m), 3.02 (1H, dt), 3.17
(1H, dt), 3.24-3.33 (2H, m), 3.75 (3H, s), 4.05 (
1H, t), 5.42 (3H, s), 7.11-7.20 (1H, m), 8.12 (1H
, S).
ESI-MS m / z: 428 (M + H) ^<+> .
(Example 29)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N, N-dimethyl-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 of Example 27 In a similar manner to Example 9 using 5-tetraazabenzo [cd] azulene e-7-carboxyl acid (32 mg) and dimethylamine hydrochloride (14 mg), the title compound (22.6 m
g, 66%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.28 (3H, s), 2.5
1-2.63 (1H, m), 2.77-2.85 (1H, m), 2.93-3.01 (1
H, m), 3.02 (3H, s), 3.16 (3H, s), 3.23-3.31 (1H,
m), 3.74 (3H, s), 4.39 (1H, d), 5.27 (9H, br. s), 5
. 43 (1H, d), 5.49 (1 H, d), 8.19 (1 H, s).
ESI-MS m / z: 428 (M + H) ^<+> .
(Example 30)
4-Amino-N-isopropyl-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 of Example 27 In a similar manner to Example 9 using 5-tetraazabenzo [cd] azulene e-7-carboxyl acid (32 mg) and isopropylamine (0.014 mL), the title compound (27.
1 mg, 77%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.12 (3H, d), 1.16 (3H, d), 2.2
3 (3H, s), 2.25 (3H, s), 2.58-2.78 (2H, m), 2.96-
3.08 (1H, m), 3.12-3.23 (1H, m), 3.76 (3H, s), 3.
98-4.09 (2H, m), 5.42 (2H, s), 6.95 (1H, d), 8.12
(1H, s).
ESI-MS m / z: 442 (M + H) ^<+> .
(Example 31)
4-Amino-N- [2- (dimethylamino) ethyl] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulene-7-carboxamide

4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 of Example 27 5-Tetraazabenzo [cd] azulene-7-carboxyl acid (32 mg) and N, N-diethylethylenediamine (18 ul) were used in the same manner as in Example 9 to prepare the title compound (20.0 mg, 49%) was obtained as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.41 (3H, s), 2.50 (3H, s), 2.7
0-2.82 (2H, m), 2.94 (6H, s), 3.04-3.40 (6H, m),
3.56-3.75 (2H, m), 4.14 (3H, s), 4.75 (2H, d), 5.
72 (2H, s), 8.55 (1H, s).
ESI-MS m / z: 471 (M + H) ⁺ .
(Example 32)
Di-tert-butyl {8-hydroxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2, 3,
5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

Under ice bath cooling, di-tert-butyl {4-chloro-3- (2,
3-Dihydroxypropyl) -1-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (510 mg), 2,4,6-collidine (1.15 mL) and dehydrated dichloromethane (17 mL). Then, a dehydrated dichloromethane solution of methanesulfonyl chloride (73 μL) was added dropwise, followed by stirring for 15 hours. 0.5N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer is washed with water, dried over anhydrous sodium sulfate,
After filtration, the filtrate was concentrated under reduced pressure. The obtained residue was treated with N, N-dimethylformamide (10
After adding sodium hydrogen sulfide monohydrate (76 mg) with cooling in an ice bath,
Stir for 20 minutes. Potassium carbonate (142 mg) was added to the reaction mixture, the ice bath was removed and the mixture was stirred for 1 hour, then heated to 50 ° C. and further stirred for 2 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (453 mg, 92%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.44 (18H, s), 2.22 (3H, s), 2.
25 (3H, s), 3.29-3.41 (2H, m), 3.42-3.56 (2H, m)
, 3.73 (3H, s), 4.55-4.64 (1H, m), 5.60 (1H, d), 5
. 64 (1H, d), 8.15 (1H, s).
ESI-MS m / z: 573 (M + H) ^<+> .
(Example 33)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene 8-all

Di-tert-butyl of Example 32 {8-hydroxy-2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (40 mg ), Dichloromethane (1 mL), hydrochloric acid in 4N dioxane (0.5 mL)
And a mixture of methanol (0.5 mL) was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase liquid chromatography to give the title compound (12.5 mg, 48%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.26 (3H, s), 3.1
9-3.45 (4H, m), 3.74 (3H, s), 4.49-4.50 (1H, m),
5.33 (2H, br.s), 5.44 (2H, s), 8.17 (1H, s).
ESI-MS m / z: 373 (M + H) ⁺ .
(Example 34)
8-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]
-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd
Azulene 4-amine

Di-tert-butyl of Example 32 {8-hydroxy-2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (40 mg ) And dehydrated N, N-dimethylformamide (1 mL), sodium hydride (6.7 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture, methyl iodide (
6.5 μL) was added and stirred for 1.5 hours, followed by the addition of water (20 mL). The obtained mixture was extracted with ethyl acetate, and the organic layer was washed with water and dried over anhydrous sodium sulfate. After filtration, dichloromethane (2 mL) and trifluoroacetic acid (0.5 mL) were added to the residue obtained by concentrating the filtrate under reduced pressure, and the mixture was stirred at room temperature for 2 hours. The residue obtained by concentrating the reaction mixture under reduced pressure was purified by reverse phase liquid chromatography to give the title compound (4.8 mg, 18
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.28 (3H, s), 2.9
8 (3H, s), 3.18-3.25 (2H, m), 3.32 (1H, dd), 3.38
-3.45 (1H, m), 3.75 (3H, s), 4.48 (1H, dt), 5.44 (
1H, d), 5.50 (1H, d), 8.16 (1H, s).
ESI-MS m / z: 387 (M + H) ^<+> .
(Example 35)
4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulene 8-yl methanesulfonate

Di-tert-butyl {8-hydroxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro of Example 32 under ice bath cooling -6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (240 mg), dehydrated dichloromethane (6 mL) and triethylamine (
88 μL) was added dropwise methanesulfonyl chloride (39 μL), the ice bath was removed and the mixture was stirred for 2 hours. After confirming disappearance of the raw materials, the reaction mixture was diluted with chloroform and washed with water. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. Dichloromethane and hexane were added to the residue, and the precipitated solid was collected by filtration to give the title compound (253 mg, 93%). The obtained compound was directly used in the next reaction without purification.
ESI-MS m / z: 651 (M + H) ⁺ .
(Example 36)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene 4-amine

4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6 of Example 35 -A mixture of thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl methanesulfonate (65 mg), dehydrated N, N-dimethylformamide (1 mL) and potassium carbonate (14 mg) The mixture was stirred at 6 ° C. for 6 hours. The reaction mixture was cooled, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, dichloromethane (2 mL) and trifluoroacetic acid (1 mL) were added to the residue, and the mixture was mixed with 1 at room temperature.
Stir for hours. After confirming disappearance of the raw materials, the reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted with ethyl acetate. After washing the organic layer with saturated saline,
After drying over sodium sulfate and filtration, the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (12.9).
mg, 36%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.29 (3H, s), 3.7
2 (2H, d), 3.75 (3H, s), 5.51 (2H, s), 6.30 (1H, dt
), 6.81 (1H, d), 8.18 (1H, s).
ESI-MS m / z: 355 (M + H) ^<+> .
(Example 37)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene 8-yl methyl carbamate

Di-tert-butyl {8-hydroxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro of Example 32 under ice bath cooling Consists of -6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (40 mg), dehydrated dichloromethane (1 mL), pyridine (11 μL) and triphosgene (8.7 mg). The mixture was stirred for 3 hours. After adding a 2N tetrahydrofuran solution (0.6 mL) of methylamine to the reaction mixture, the ice bath was removed and the mixture was stirred for 17 hours. After confirming disappearance of the raw materials, the reaction mixture was diluted with chloroform and washed with water.
The aqueous layer was extracted with chloroform, and the combined organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, dichloromethane (2 mL) and trifluoroacetic acid (0.5 mL) were added to the resulting residue, and the mixture was stirred at room temperature for 15 hours. The residue obtained by concentrating the reaction mixture under reduced pressure was purified by reverse phase liquid chromatography to give the title compound (6.6 mg, 22%
) Was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.27 (3H, s), 2.7
8 (3H, d), 3.27-3.40 (3H, m), 3.55 (1H, dd), 3.75
(3H, s), 4.97-5.02 (1H, m), 5.19 (2H, br. S), 5.4
2 (1H, d), 5.47 (1H, d), 8.08 (1H, s), 8.19 (1H, s)
.
ESI-MS m / z: 430 (M + H) ⁺ .
(Example 38)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd]
Azulene 8-yl ethyl carbamate

Di-tert-butyl {8-hydroxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro of Example 32 under ice bath cooling Using 6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (60 mg), triphosgene (13 mg) and ethylamine in 2N tetrahydrofuran (0.25 mL) The title compound (18.5 mg, 40%) was obtained as a solid in the same manner as in Example 37.
¹ H-NMR (CDCl ₃ ) δ: 1.12 (3H, t), 2.23 (3H, s), 2.2
7 (3H, s), 3.16-3.24 (2H, m), 3.28-3.37 (3H, m),
3.54 (1H, dd), 3.75 (3H, s), 5.09-5.15 (1H, m), 5
. 25-5.52 (4H, m), 8.19 (1H, s).
ESI-MS m / z: 444 (M + H) ^<+> .
(Example 39)
4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulene 8-yl acetate

In a nitrogen atmosphere, di-tert-butyl {8-hydroxy-2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide Dicarbonate (778 mg), dimethyl sulfoxide (10 mL) and acetic anhydride (1
mL) was stirred at room temperature for 12 hours. After confirming the disappearance of the raw materials, the reaction mixture was diluted with ethyl acetate and washed with water and saturated brine in this order. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (507 mg, 61%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.43 (18H, s), 2.21 (3H, s), 2.
25 (3H, s), 2.27 (3H, s), 3.74 (3H, s), 3.90 (2H, s)
), 5.67 (2H, s), 6.70 (1H, s), 8.14 (1H, s).
ESI-MS m / z: 613 (M + H) ^<+> .
(Example 40)
Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia-1,2, 3,5-
Tetraazabenzo [cd] azulene 4-yl} imide dicarbonate

4- [Bis (tert-butoxycarbonyl) amino] -2 of Example 39 under ice bath cooling.
-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl acetate A mixture of (507 mg), methanol (12 mL) and potassium carbonate (57 mg) was stirred for 30 minutes. After confirming disappearance of the raw materials, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (430 mg, 91%) as an oil.
ESI-MS m / z: 571 (M + H) ^<+> .
(Example 41)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
2,9-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene 8 (
7H)-ON

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
In the same manner as in Example 2, the title compound (21.7 mg, 75%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.29 (3H, s), 3.7
5 (3H, s), 3.80 (2H, s), 4.12-4.13 (1H, m), 4.12 (
1H, s), 5.24 (1H, br. S), 5.48 (2H, s), 8.18 (1H, s)
).
ESI-MS m / z: 371 (M + H) ^<+> .
(Example 42)
Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} Imidodicarbonate

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (1
70 mg), dichloroethane (2 mL), acetic acid (0.034 mL), and 2,4-dimethoxybenzylamine (0.073 mL) were stirred at room temperature for 10 minutes,
Sodium triacetoxyborohydride (126 mg) was added and stirred for 2 hours. To the reaction mixture was added sodium triacetoxyborohydride (63 mg), and the mixture was further stirred for 1 hour. Methanol (3 drops) was added dropwise to the reaction mixture, and chloroform and a 0.5 N aqueous sodium hydroxide solution were added for liquid separation. The aqueous layer was extracted with chloroform, and the combined organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol-chloroform) to obtain the title compound (108 mg, 50%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.43 (18H, s), 2.21 (3H, s), 2.
25 (3H, s), 3.19-3.36 (4H, m), 3.43-3.48 (1H, m)
, 3.72 (3H, s), 3.78 (6H, s), 5.60 (2H, s), 6.41-6
. 44 (2H, m), 7.12 (1H, d), 8.16 (1H, s).
ESI-MS m / z: 722 (M + H) ⁺ .
(Example 43)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen 8-yl} acetamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] of Example 42 under ice bath cooling -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [c
d] To a mixture of azulene-4-yl} imide dicarbonate (36 mg), pyridine (40 μL) and dehydrated dichloromethane (0.7 mL), acetyl chloride (18 μL) was added dropwise, the ice bath was removed and the mixture was stirred for 3 hours. did. After diluting the reaction mixture with chloroform,
. The organic layer was washed with 2N aqueous hydrochloric acid and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, dichloromethane (1 mL) and 1,3-dimethoxybenzene (12 μL) were added to the residue, trifluoroacetic acid (1 mL) was added, and the mixture was stirred at room temperature for 16 hours. did. The residue obtained by concentrating the reaction mixture under reduced pressure was dissolved in chloroform, and washed with a saturated aqueous sodium bicarbonate solution and saturated brine in this order. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (15.6 mg, 76%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.96 (3H, s), 2.22 (3H, s), 2.3
0 (3H, s), 3.19 (1H, dd), 3.38 (1H, dd), 3.43-3.5
1 (2H, m), 3.75 (3H, s), 4.76-4.84 (1H, m), 5.21 (
2H, br. s), 5.40 (1H, d), 5.45 (1H, d), 6.37 (1H, d)
), 8.13 (1H, s).
ESI-MS m / z: 414 (M + H) ^<+> .
(Example 44)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen 8-yl} acetamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (36 mg) and propionyl chloride (0.022 mL)
) To give the title compound (14.6 mg, 68%) as a solid in the same manner as in Example 43.
¹ H-NMR (CDCl ₃ ) δ: 1.13 (3H, t), 2.20 (2H, dd), 2.
22 (3H, s), 2.31 (3H, s), 3.21 (1H, dd), 3.36 (1H,
dd), 3.44 (1H, d), 3.57 (1H, dd), 3.77 (3H, s), 4.
75-4.81 (1H, m), 5.18 (1H, d), 5.39 (1H, d), 5.53
(1H, d), 6.89 (1H, d), 8.05 (1H, s).
ESI-MS m / z: 428 (M + H) ^<+> .
(Example 45)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulene 8-yl} cyclopropanecarboxamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (36 mg) and cyclopropanecarbonyl chloride (2
In the same manner as in Example 43, the title compound (12 mg, 55%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.71-0.76 (2H, m), 0.93-0.97
(2H, m), 1.50-1.58 (1H, m), 2.23 (3H, s), 2.32 (3
H, s), 3.30-3.49 (2H, m), 3.60 (1H, dd), 3.79 (3H
, S), 4.69-4.76 (1H, m), 5.36 (1H, d), 5.58 (1H, d)
), 7.84 (1H, d), 7.99 (1H, s).
ESI-MS m / z: 440 (M + H) ^<+> .
(Example 46)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -N ⁸ -methyl-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetra Azabenzo [cd
Azulene-4,8-diamine hydrochloride

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (2
8 mg), dichloroethane (0.5 mL), a mixture of methylamine in 2N tetrahydrofuran (0.1 mL) and acetic acid (6 μL) were added sodium triacetoxyborohydride (16 mg) and stirred at room temperature for 17 hours. . Methanol (3
Then, 0.2N aqueous sodium hydroxide solution was added, and the mixture was extracted with ethyl acetate.
The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 mL) and trifluoroacetic acid (0.5 mL) were added to the resulting residue, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase liquid chromatography. To the obtained solid was added a 4N dioxane solution (20 μL) of hydrochloric acid, methanol and diethyl ether were added, and the precipitated solid was collected by filtration to give the title compound (5.7 g,
28%) was obtained as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.24 (3H, s), 2.27 (3H, s), 2.6
8 (3H, s), 3.27 (1H, dd), 3.39 (1H, dd), 3.51-3.5
4 (2H, m), 3.79 (3H, s), 5.46 (2H, s), 8.04 (1H, s)
.
ESI-MS m / z: 386 (M + H) ^<+> .
(Example 47)
2 - [(4-methoxy-3,5-dimethyl-2-yl) ^methyl] -N ^{8, N} 8 -
Dimethyl-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine hydrochloride

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (2
8 mg) and a 2N tetrahydrofuran solution (0.1 mL) of dimethylamine,
In the same manner as in Example 46, the title compound (11.9 mg, 56%) was obtained as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.24 (3H, s), 2.25 (3H, s), 2.6
3 (6H, s), 3.42 (1H, d), 3.49 (1H, dd), 3.63-3.69
(1H, m), 3.78 (3H, s), 5.45 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 400 (M + H) ^<+> .
(Example 48)
N ⁸ - ethyl 2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl]
-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd
Azulene-4,8-diamine hydrochloride

4-di (tert-butoxycarbonyl) amino-2- (4-methoxy- of Example 40
3,5-dimethyl-pyridin-2-ylmethyl) -8-oxo-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene (28 mg) The title compound (2.4 mg, 11%) was obtained as a solid in the same manner as in Example 46 using 2N tetrahydrofuran solution (0.1 mL) of ethylamine.
¹ H-NMR (CD ₃ OD) δ: 1.21 (3H, t), 2.24 (3H, s), 2.2
6 (3H, s), 2.81-3.00 (2H, m), 3.16 (1H, dd), 3.38
-3.48 (1H, m), 3.62-3.68 (1 H, m), 3.78 (3H, s), 5
. 45 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 400 (M + H) ^<+> .
(Example 49)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-pyrrolidin-1-yl-2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulene 4-amine hydrochloride

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (2
8 mg) and pyrrolidine (8.2 μL) were used in the same manner as in Example 44 to obtain the title compound (12.1 mg, 53%) as a solid.
¹ H-NMR (CD ₃ OD) δ: 1.91-1.98 (4H, m), 2.24 (3H, s
), 2.25 (3H, s), 2.96-3.04 (2H, m), 3.12-3.21 (2
H, m), 3.33-3.38 (2H, m), 3.48 (1H, dd), 3.56-3.
64 (2H, m), 3.78 (3H, s), 5.43 (1H, d), 5.47 (1H, d
), 8.05 (1H, s).
ESI-MS m / z: 426 (M + H) ^<+> .
(Example 50)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-morpholin-4-yl-2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulene 4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (2
8 mg) and morpholine (8.6 μL) were used in the same manner as in Example 46 to obtain the title compound (11.2 mg, 48%) as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.21 (3H, s), 2.24 (3H, s), 2.5
3-2.59 (2H, m), 2.65-2.72 (2H, m), 3.14-3.24 (4
H, m), 3.34-3.37 (2H, m), 3.64-3.69 (4H, m), 3.7
7 (3H, s), 5.43 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 442 (M + H) ^<+> .
(Example 51)
N ⁸ - cyclopropyl-2 - [(4-methoxy-3,5-dimethyl-2-yl)
Methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine hydrochloride

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (2
The title compound (5.5 mg, 22%) was obtained as a solid in the same manner as in Example 46 using 8 mg) and pyrrolidine (6.8 μL).
¹ H-NMR (CD ₃ OD) δ: 2.21 (3H, s), 2.24 (3H, s), 2.5
3-2.59 (2H, m), 2.65-2.72 (2H, m), 3.14-3.24 (4
H, m), 3.34-3.37 (2H, m), 3.64-3.69 (4H, m), 3.7
7 (3H, s), 5.43 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 412 (M + H) ⁺ .
(Example 52)
2 ′-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2 ′, 9 ′
-Dihydrospiro [1,3-dioxolane-2,8 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4'-amine

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,9-dihydro-6-thia-1,2,3,5-tetraaza of Example 41 Benzo [cd
P-toluenesulfonic acid monohydrate (16 mg) was added to a mixture of azulene 8 (7H) -one (16 mg), ethylene glycol (24 μl) and toluene (0.5 ml), and then heated under reflux for 18 hours. did. After cooling to room temperature, saturated aqueous sodium hydrogen carbonate was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the residue obtained by concentrating the filtrate was purified by silica gel thin layer chromatography (chloroform-methanol) to obtain the title compound (8.6 mg, 48%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.27 (3H, s), 3.3
8 (2H, s), 3.39 (2H, s), 3.74 (3H, s), 4.06 to 4.09 (
4H, m), 5.11 (2H, s), 5.44 (2H, s), 8.19 (1H, s).
ESI-MS m / z: 415 (M + H) ⁺
(Example 53)
2 ′-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2 ′, 9 ′
-Dihydrospiro [1,3-dioxane-2,8 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4'-amine

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,9-dihydro-6-thia-1,2,3,5-tetraaza of Example 41 Benzo [cd
The title compound (5.1 mg, 28%) was obtained as a solid in the same manner as in Example 52 using azulene 8 (7H) -one (16 mg) and 1,3-propanediol (31 μl). .
¹ H-NMR (CDCl ₃ ) δ: 1.61-1.70 (1H, m), 1.85-1.96
(1H, m), 2.22 (3H, s), 2.27 (3H, s), 3.44 (2H, s),
3.55 (2H, s), 3.74 (3H, s), 3.96-4.02 (4H, m), 5.
06 (2H, s), 5.44 (2H, s), 8.19 (1H, s).
ESI-MS m / z: 429 (M + H) ⁺
(Example 54)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-8-oxa-6-thia-1,2,3,5,9-pentaazabenzo [ cd] cyclopenta [h] azulene 4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg), dimethylformamide-dimethylacetal (56 μl) and toluene (0
. 5 ml) was stirred at 80 ° C. for 1 hour. After confirming the disappearance of the raw materials, the reaction solution was concentrated under reduced pressure. Ethanol (0.5 ml) and hydroxylamine hydrochloride (9 mg) were added to the obtained residue, and the mixture was stirred with heating at 80 ° C. for 4 hr. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the residue obtained by concentrating the reaction solution under reduced pressure, and the mixture was stirred at room temperature for 2 hours. After the reaction solution was concentrated under reduced pressure, the residue was dissolved in chloroform and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium bicarbonate solution in this order. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by reverse phase liquid chromatography to give the title compound (15.1 mg, 55%) as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.17 (3H, s), 2.27 (3H, s), 3
. 73 (3H, s), 4.74 (2H, s), 5.48 (2H, s), 7.07 (2H,
s), 8.05 (1H, s), 8.97 (1H, s).
ESI-MS m / z: 396 (M + H) ⁺
(Example 55)
Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -9,9-dimethyl-8-oxo-2,7,8,9-tetrahydro-6 Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (8
6 mg), methyl iodide (38 μl), potassium carbonate (83 mg) and dehydrated dimethyl sulfoxide (1 ml) were stirred at room temperature for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate, and the organic layer was washed with water. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (ethyl acetate-hexane) to give the title compound (28 mg
, 31%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.44 (18H, s), 1.63 (6H, s), 2.
22 (3H, s), 2.27 (3H, s), 3.74 (3H, s), 3.90 (2H, s)
), 5.67 (2H, s), 8.11 (1H, s).
ESI-MS m / z: 599 (M + H) ⁺
(Example 56)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
9,9-dimethyl-2,9-dihydro-6-thia-1,2,3,5-tetraazabenzo [
cd] azulene 8 (7H) -on

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -9,9-dimethyl-8-oxo-2,7,8,9- in Example 55 Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (28 mg) was used in the same manner as in Example 2 to prepare the title compound (12.3
mg, 66%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.57 (6H, s), 2.23 (3H, s), 2.3
0 (3H, s), 3.75 (3H, s), 3.82 (2H, s), 5.25 (2H, br)
. s), 5.49 (2H, s), 8.17 (1H, s).
ESI-MS m / z: 399 (M + H) ⁺
(Example 57)
Di-tert-butyl {2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8'-oxo-7', 8'-dihydro-2'H-spiro [cyclopropane -1,9 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4'
-Il} imide dicarbonate

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg), dibromoethane (9.1 μl), potassium carbonate (28.7 mg) and dimethyl sulfide (0.5 ml) were stirred at room temperature for 38 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the organic layer was washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (ethyl acetate-hexane) to give the title compound (21 mg, 50%
) Was obtained as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.45 (18H, s), 1.77-1.81 (2H,
m), 1.89-1.93 (2H, m), 2.21 (3H, s), 2.28 (3H, s)
, 3.74 (3H, s), 3.94 (2H, s), 5.59 (2H, s), 8.10 (1
H, s).
ESI-MS m / z: 597 (M + H) ⁺
(Example 58)
4'-amino-2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2'H-spiro [cyclopropane-1,9'-[6] thia [1,2 , 3,5] tetraazabenzo [cd] azulene] -8 ′ (7′H) -one

Di-tert-butyl {2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8'-oxo-7', 8'-dihydro-2'H- of Example 57 Spyro[
Similar to Example 2, using cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4′-yl} imide dicarbonate (21 mg). Gave the title compound (12.0 mg, 86%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.70-1.73 (2H, m), 1.81-1.85
(2H, m), 2.22 (3H, s), 2.31 (3H, s), 3.75 (3H, s),
3.87 (2H, s), 5.26 (2H, br. S), 5.42 (2H, s), 8.16
(1H, s).
ESI-MS m / z: 397 (M + H) ⁺
(Example 59)
N- {4′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -7 ', 8'-dihydro-2'H-spiro [cyclopropane-1,9'-[6]
Thia [1,2,3,5] tetraazabenzo [cd] azulene] -8′-yl} acetamide 1) Di-tert-butyl {8′-hydroxy-2 ′-[(4-methoxy-3,5 -Dimethylpyridin-2-yl) methyl] -7 ', 8'-dihydro-2'H-spiro [cyclopropane-1,9'-[6] thia [1,2,3,5] tetraazabenzo [ cd] azulene] -4'-yl} imide dicarbonate

Di-tert-butyl {2 ′-[(4-methoxy-3,5) of Example 57 under ice bath cooling.
-Dimethylpyridin-2-yl) methyl] -8'-oxo-7 ', 8'-dihydro-2'
H-spiro [cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4′-yl} imidodicarbonate (100 mg) and methanol (4 ml) After adding sodium borohydride (19 mg) to the mixture consisting of
Stir for minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude product of the title compound (91 mg, 9
1%) was obtained as an oil.
ESI-MS m / z: 599 (M + H) ⁺
2) 4 ′-[bis (tert-butoxycarbonyl) amino] -2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H -Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [c
d] azulene] -8'-yl methanesulfonate

The crude di-tert-butyl {8′-hydroxy-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2 was cooled with an ice bath. 'H
-Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4'-yl} imide dicarbonate (91 mg), triethylamine (42 [mu] l) and After adding methanesulfonyl chloride (14 μl) to a mixture consisting of dichloromethane (4 ml), the ice bath was removed and the mixture was stirred for 3 hours. The reaction solution was cooled again in an ice bath, methanesulfonyl chloride (6 μl) was added, the ice bath was removed, and the mixture was stirred for 4 hours. The reaction solution was washed with water, and then the organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give a crude title compound (115 mg) as an oil. The obtained compound was directly used in the next reaction without purification.
ESI-MS m / z: 677 (M + H) ⁺
3) Di-tert-butyl {8′-azido-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H-spiro [ Cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] −
4'-yl} imide dicarbonate

Crude 4 ′-[bis (tert-butoxycarbonyl) amino] -2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H
-Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -8'-yl methanesulfonate (33 mg), sodium azide (37 mg ) And N-methylpyrrolidone (0.5 ml) at 80 ° C.
Stir for hours. After cooling to room temperature, 0.2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine (30 ml) and then dried over sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give a crude title compound (35 m
g) was obtained as an oil. The obtained compound was directly used in the next reaction without purification.
4) N- {4′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H-spiro [cyclopropane- 1,9 '-[
6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -8′-yl} acetamide

Crude di-tert-butyl {8′-azido-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H-spiro [ Cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4'-yl} imide dicarbonate (35 mg), tetrahydrofuran (0.9 ml
) And water (0.1 ml), triphenylphosphine (22 mg) was added, and the mixture was stirred with heating at 50 ° C. for 3 hr. After cooling to room temperature, water (3 ml) and 1N aqueous hydrochloric acid (0.6 ml) were added to the reaction mixture, and the mixture was washed with ethyl acetate. 1 in the resulting aqueous layer
A normal aqueous sodium hydroxide solution (1.2 ml) was added, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and dehydrated dichloromethane (0.5 ml), pyridine (18
ul) and acetic anhydride (16 ul) were added and stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml).
ml) was added and stirred at room temperature for 3 hours. The residue obtained by concentrating the reaction mixture under reduced pressure was dissolved in chloroform, and washed with a saturated aqueous sodium bicarbonate solution and saturated brine in this order. The organic layer was dried over sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (4.2 mg, 17%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 0.97-1.05 (2H, m), 1.9-1-1.15
(1H, m), 1.70-1.76 (1H, m), 1.99 (3H, s), 2.22 (3
H, s), 2.32 (3H, s), 3.46 (1H, dd), 3.71 (1H, d), 3
. 76 (3H, s), 3.85 (1H, t), 5.10 (2H, s), 5.35 (1H,
d), 5.43 (1H, d), 6.39 (1H, d), 8.13 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 60)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo
[Cd] azulen-8-yl} -N-cyclopropylacetamide 1) di-tert-butyl {8- (cyclopropylamino) -2-[(4-methoxy-
3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6
Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
. 71 g), methanol (50 mL), tetrahydrofuran (25 mL), cyclopropylamine (1.04 mL) and acetic acid (1.72 mL) were added with sodium cyanoborohydride (1.89 g) under ice-cooling and stirring. Stir at room temperature for 14 hours. The reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, and washed with saturated aqueous sodium hydrogen carbonate and then saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the title compound (5.9
1 g, 97%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 0.32-0.56 (4H, m), 1.44 (18H,
s), 2.17-2.21 (1H, m), 2.21 (3H, s), 2.26 (3H, s)
, 3.24-3.43 (4H, m), 3.69-3.64 (1H, m), 3.73 (3H
, S), 5.62 (2H, s), 8.16 (1H, s).
ESI-MS m / z: 612 (M + H) ^<+> .
2) N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} -N-cyclopropylacetamide

Di-tert-butyl {8- (cyclopropylamino) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6
-A mixture of thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (100 mg), dichloromethane (2 mL), triethylamine (42 μL) was stirred under ice-cooling and acetyl chloride. (14 μL) was added and stirred at room temperature for 15 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a residue of dichloromethane (4 mL).
) And trifluoroacetic acid (1 mL) were added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate was added to the residue obtained under ice-cooling, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform-methanol) to give the title compound (55 mg, 75%). Obtained as an oil.
¹ H-NMR (CDCl 3) δ: 0.76-1.00 (4H, m), 2.21 (3H, s
), 2.22 (3H, s), 2.27 (3H, s), 2.71-2.76 (1H, m),
2.97 (1H, d, J = 15.9 Hz), 3.14 (1 H, d, J = 16.6 Hz),
3.74 (3H, s), 3.88-3.99 (2H, m), 4.38-4.33 (1H,
m), 5.16 (2H, s), 5.45 (2H, dd, J = 26.4, 15.1 Hz),
8.19 (1H, s).
ESI-MS m / z: 454 (M + H) ^<+> .
(Example 61)
N ⁸ - cyclopropyl-2 - [(4-methoxy-3,5-dimethyl-2-yl)
Methyl] -N ⁸ - methyl-2,7,8,9-tetrahydro-6-thia-1,2,3,5
Tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {8- (cyclopropylamino) -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} Imidodicarbonate (400 mg), methanol (2 mL), 35% formalin solution (111
μL), acetic acid (156 μL), and molecular sieves 3A were stirred at room temperature for 40 minutes, sodium cyanoborohydride (163 mg) was added, and the mixture was stirred at room temperature for 14 hours. After the molecular sieves were filtered off, the solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate and then with saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were added to the resulting residue, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate was added to the residue obtained under ice-cooling, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform-methanol) to give the title compound (233m
g, 84%) as an oil.
¹ H-NMR (CDCl 3) δ: 0.38-0.52 (4H, m), 1.85-1.90
(1H, m), 2.22 (3H, s), 2.27 (3H, s), 2.40 (3H, s),
3.12-3.36 (4H, m), 3.55-3.49 (1H, m), 3.74 (3H,
s), 5.19 (2H, s), 5.42 (1H, d, J = 15.1 Hz), 5.49 (1
H, d, J = 15.4 Hz), 8.20 (1H, s).
ESI-MS m / z: 426 (M + H) ^<+> .
(Example 62)
N ⁸ - cyclobutyl-2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5- Azabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg), dichloroethane (0.7 ml), cyclobutylamine (15 μl) and acetic acid (10 μl) were added sodium triacetoxyborohydride (16 mg) and stirred overnight at room temperature. Methanol (3 drops) was added dropwise to the reaction mixture, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the resulting residue, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase liquid chromatography. The obtained oil was dissolved in dioxane and lyophilized to give the title compound (6.3 mg, 25%) as a colorless amorphous.
ESI-MS m / z: 426 (M + H) ⁺
(Example 63)
N ⁸ - (cyclopropylmethyl) -2 - [(4-methoxy-3,5-dimethylpyridine -
2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and cyclopropylmethylamine (17 mg) were used in the same manner as in Example 62 to obtain the title compound (6.0 mg, 24%) as amorphous.
ESI-MS m / z: 426 (M + H) ⁺
(Example 64)
4- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} piperazin-2-one

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and 2-piperidinone (18 mg) were used in the same manner as in Example 62 to obtain the title compound (5.2 mg, 19%) as amorphous.
ESI-MS m / z: 455 (M + H) ⁺
(Example 65)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-piperidin-1-yl-2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulen-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and piperidine (18 μl) were used in the same manner as in Example 62 to obtain the title compound (13.7 mg, 52%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 1.57-1.65 (2H, m), 1.68-1.82
(4H, m), 2.93-3.07 (4H, m), 3.38-3.45 (1H, m), 3
. 51 (1H, dd, J = 15.3, 7.2 Hz), 3.64-3.67 (2H, m),
3.78 (3H, s), 5.43-5.47 (2H, m), 8.06 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
Example 66
8-azetidin-1-yl-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulen-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg), azetidine hydrochloride (17 mg), triethylamine (17 μl),
In the same manner as in Example 62, the title compound (18.5 mg, 75%) was obtained as amorphous.
¹ H-NMR (CD ₃ OD) δ: 2.26 (4H, d, J = 9.8 Hz), 2.32-2
. 43 (2H, m), 3.05-3.13 (1H, m), 3.40-3.48 (1H, m
), 3.79 (3H, s), 3.88-3.97 (1H, m), 3.97-4.07 (1
H, m), 5.46 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 412 (M + H) ⁺
(Example 67)
1- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} -L-prolinamide

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and (S) -pyrrolidinecarboxylic acid amide (17 mg) were used in the same manner as in Example 62 to obtain the title compound (12.3 mg, 43%) as amorphous.
ESI-MS m / z: 469 (M + H) ⁺
Example 68
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-[(2S
) -2- (Methoxymethyl) pyrrolidin-1-yl] -2,7,8,9-tetrahydro-
6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and (S) -2-methoxymethylpyrrolidine (24 μl).
In the same manner as in 2, the title compound (11.0 mg, 39%) was obtained as amorphous.
ESI-MS m / z: 470 (M + H) ⁺
(Example 69)
N-[(3S) -1- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia- 1,2,3,5-tetraazabenzo [cd] azulen-8-yl} pyrrolidin-3-yl] acetamide

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and (3S)-(−)-3-acetamidopyrrolidine (24 μl) were used in the same manner as in Example 62 to obtain the title compound (22.6 mg, 78%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 1.86-1.90 (2H, m), 1.90-1.93
(1H, m), 2.23-2.28 (6H, m), 2.29-2.39 (1H, m), 2
. 94-3.10 (1H, m), 3.11-3.26 (1H, m), 3.33-3.39
(2H, m), 3.45-3.54 (2H, m), 3.62-3.67 (2H, m), 3
. 66 (3H, s), 3.80 (3H, s), 4.29-4.38 (1H, m), 5.4
3-5.50 (2H, m), 8.07 (1H, s).
ESI-MS m / z: 483 (M + H) ⁺
(Example 70)
2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] ^-N 8 - [(3
R) -tetrahydrofuran-3-yl] -2,7,8,9-tetrahydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
4 mg) and (R)-(+)-3-pyrrolidinol (19 μl) were used in the same manner as in Example 62 to obtain the title compound (17.4 mg, 65%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 1.87-1.96 (1H, m), 2.07-2.21
(1H, m), 3.03-3.18 (2H, m), 3.18-3.27 (1H, m), 3
. 32-3.40 (4H, m), 3.51-3.61 (3H, m), 3.70-3.76
(1H, m), 3.78 (3H, s), 4.42-4.48 (1H, m), 5.46 (2
H, s), 8.06 (1H, s).
ESI-MS m / z: 442 (M + H) ⁺
(Example 71)
N ⁸ - isopropyl-2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5- Azabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
0 mg), methanol (0.4 ml), tetrahydrofuran (0.2 ml) and acetic acid (
Isopropylamine (5.5 μl) was added to the mixture consisting of 12 μl) and stirred at room temperature for 2 hours. A solution of sodium cyanoborohydride (10 mg) dissolved in methanol (0.4 ml) was added to the reaction mixture, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, 0.2N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (1 ml) and trifluoroacetic acid (0.25 ml) were added to the resulting residue, and the mixture was stirred at room temperature for 2 hours. . The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by NH silica gel chromatography (chloroform-methanol). The obtained oil was dissolved in dioxane and lyophilized to give the title compound (6.3 mg, 29%) as an amorphous substance.
¹ H-NMR (CD ₃ OD) δ: 1.08 (3H, d, J = 4.2 Hz), 1.10 (3
H, d, J = 4.2 Hz), 2.24 (6H, s), 2.99-3.07 (2H, m),
3.23 (1H, dd, J = 16.8, 3.4 Hz), 3.32-3.38 (1H, m)
, 3.52-3.57 (1H, m), 3.78 (3H, s), 5.44 (2H, s), 8
. 05 (1H, s).
ESI-MS m / z: 414 (M + H) ⁺
(Example 72)
N ⁸ - isobutyl-2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5- Azabenzo [
cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (19.9 mg, 88%) was obtained as an amorphous form in the same manner as in Example 71 using 0 mg) and izobutylamine (7.9 μl).
¹ H-NMR (CD ₃ OD) δ: 0.92 (6H, dd, J = 6.7, 2.6 Hz), 1
. 69-1.79 (1H, m), 2.23 (3H, s), 2.23 (3H, s), 2.4
5 (1H, dd, J = 11.3, 6.5 Hz), 2.53 (1H, dd, J = 11.3,
7.1 Hz), 3.01-3.10 (1H, m), 3.20-3.39 (4H, m), 3
. 77 (3H, s), 5.42 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 428 (M + H) ⁺
(Example 73)
N ⁸ - (2,2-dimethylpropyl) -2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1, 2,3,5-
Tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
0 mg) and neopentylamine (9.2 μl) in the same manner as in Example 71,
The title compound (20.6 mg, 89%) was obtained as amorphous.
¹ H-NMR (CD ₃ OD) δ: 0.90 (9H, s), 2.22 (3H, s), 2.2
3 (3H, s), 2.38 (1H, d, J = 11.3 Hz), 2.50 (1H, d, J =
11.0 Hz), 3.04-3.11 (1H, m), 3.19-3.40 (4H, m),
3.77 (3H, s), 5.42 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 442 (M + H) ⁺
(Example 74)
N ⁸ - (1-ethylpropyl) -2 - [(4-methoxy-3,5-dimethyl-pyridin-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (11.4 mg, 49%) was obtained as an amorphous form in the same manner as in Example 71 using 1 mg) and 1-ethylpropylamine (9.2 μl).
¹ H-NMR (CD ₃ OD) δ: 0.82 (3H, t, J = 7.5 Hz), 0.91 (3
H, t, J = 7.5 Hz), 1.38-1.53 (4H, m), 2.56 (1H, dt,
J = 11.8, 5.6 Hz), 3.07 (1H, dd, J = 16.8, 8.5 Hz), 3
. 19 (1H, dd, J = 16.8, 3.4 Hz), 3.26-3.38 (2H, m),
3.50-3.56 (1H, m), 3.78 (3H, s), 5.43 (2H, s), 8.
06 (1H, s).
ESI-MS m / z: 442 (M + H) ⁺
(Example 75)
N ⁸ - cyclohexyl-2 - [(4-methoxy-3,5-dimethyl-2-yl)
Methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (15.8 mg, 66%) was obtained as an amorphous product in the same manner as in Example 71, using 0 mg) and cyclohexylamine (9.0 μl).
¹ H-NMR (CD ₃ OD) δ: 1.02-1.31 (4H, m), 1.60-1.77
(4H, m), 1.84-1.97 (2H, m), 2.58-2.66 (1H, m), 3
. 02 (1H, dd, J = 16.9, 8.9 Hz), 3.21 (1H, dd, J = 16.3.
9, 3.2 Hz), 3.27-3.37 (2H, m), 3.55-3.62 (1 H, m)
, 3.77 (3H, s), 5.43 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 454 (M + H) ⁺
(Example 76)
N ⁸ - cyclopentyl-2 - [(4-methoxy-3,5-dimethyl-2-yl)
Methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (16.2 mg, 70%) was obtained as an amorphous product in the same manner as in Example 71, using 0 mg) and cyclopentylamine (7.7 μl).
¹ H-NMR (CD ₃ OD) δ: 1.29-1.39 (2H, m), 1.51-1.60
(2H, m), 1.67-1.75 (2H, m), 1.87-1.95 (2H, m), 2
. 24 (6H, s), 3.04 (1H, dd, J = 16.1, 9.9 Hz), 3.21-
3.38 (4H, m), 3.44-3.50 (1H, m), 3.77 (3H, s), 5.
43 (2H, s), 8.05 (1 H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 77)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -N ⁸ -propyl-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetra Azabenzo [c
d] Azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
0 mg) and n-propylamine (6.5 μl) in the same manner as in Example 71,
The title compound (15.1 mg, 70%) was obtained as amorphous.
¹ H-NMR (CD ₃ OD) δ: 0.93 (3H, t, J = 7.4 Hz), 1.48-1
. 59 (2H, m), 2.23 (6H, s), 2.55-2.72 (2H, m), 3.0
5 (1H, dd, J = 16.9, 8.8 Hz), 3.21-3.43 (4H, m), 3.
77 (3H, s), 5.43 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 414 (M + H) ⁺
(Example 78)
N ⁸ - butyl 2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl]
-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd
Azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (16.7 mg, 74%) was obtained as an amorphous form in the same manner as in Example 71, using 0 mg) and n-butylamine (7.8 μl).
¹ H-NMR (CD ₃ OD) δ: 0.92 (3H, t, J = 7.4 Hz), 1.31-1
. 41 (2H, m), 1.46-1.54 (2H, m), 2.23 (6H, s), 2.5
8-2.66 (1H, m), 2.68-2.75 (1H, m), 3.05 (1H, dd,
J = 16.9, 8.8 Hz), 3.21-3.42 (4H, m), 3.77 (3H, s)
, 5.42 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 428 (M + H) ⁺
(Example 79)
2 - [(4-methoxy-3,5-dimethyl-2-yl) ^methyl] -N 8 - (2-
Methoxyethyl) -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (17.7 mg, 78%) was obtained as an amorphous product in the same manner as in Example 71 using 0 mg) and 2-methoxyethylamine (6.9 μl).
¹ H-NMR (CD ₃ OD) δ: 2.23 (3H, s), 2.23 (3H, s), 2.7
7-2.84 (1H, m), 2.87-2.94 (1H, m), 3.07 (1H, dd,
J = 16.8, 8.7 Hz), 3.19-3.29 (2H, m), 3.32 (3H, s)
, 3.34-3.52 (4H, m), 3.77 (3H, s), 5.42 (2H, s), 8
. 06 (1H, s).
ESI-MS m / z: 430 (M + H) ⁺
(Example 80)
2 - [(4-methoxy-3,5-dimethyl-2-yl) ^methyl] -N 8 - (3-
Methylbutyl) -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
The title compound (16.1 mg, 69%) was obtained as an amorphous product in the same manner as in Example 71, using 0 mg) and isoamylamine (9.1 μl).
¹ H-NMR (CD ₃ OD) δ: 0.88-0.94 (6H, m), 1.36-1.45
(4H, m), 1.55-1.66 (1H, m), 2.24 (6H, s), 2.59-2
. 67 (1H, m), 2.70-2.77 (1H, m), 3.06 (1H, dd, J = 1)
6.8, 8.7 Hz), 3.21-3.44 (4H, m), 3.77 (3H, s), 5.
43 (2H, s), 8.05 (1 H, s).
ESI-MS m / z: 442 (M + H) ⁺
(Example 81)
N ⁸ - butene-3-en-1-yl-2 - [(4-methoxy-3,5-dimethylpyridine -
2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
0 mg) and 1-amino-3-butene hydrochloride (8.5 mg) were used in the same manner as in Example 71 to obtain the title compound (7.6 mg, 34%) as amorphous.

¹ H-NMR (CD ₃ OD) δ: 2.23 (3H, s), 2.24 (3H, s), 2.
25-2.30 (2H, m), 2.65-2.72 (1H, m), 2.75-2.84 (
1H, m), 3.07 (1H, dd, J = 16.9, 8.6 Hz), 3.19-3.26
(1H, m), 3.33-3.47 (3H, m), 3.78 (3H, s), 4.96-5
. 01 (1H, m), 5.02-5.10 (1 H, m), 5.43 (2H, s), 5.8
0 (1H, ddt, J = 17.4, 10.3, 6.9 Hz), 8.06 (1H, s).
ESI-MS m / z: 426 (M + H) ⁺
(Example 82)
2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] ^-N 8 - (3,
3,3-trifluoropropyl) -2,7,8,9-tetrahydro-6-thia-1,2,
3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (3
0 mg) and 3,3,3-trifluoropropylamine hydrochloride (11.8 mg) were used in the same manner as in Example 71 to obtain the title compound (10.6 mg, 43%) as amorphous.

¹ H-NMR (CD ₃ OD) δ: 2.24 (6H, s), 2.31-2.44 (2H,
m), 2.82-2.89 (1H, m), 2.93-3.01 (1H, m), 3.09 (
1H, dd, J = 16.9, 8.1 Hz), 3.22 (1H, dd, J = 16.9, 3.
2Hz), 3.33-3.37 (2H, m), 3.41-3.47 (1H, m), 3.7
8 (3H, s), 5.43 (2H, s), 8.05 (1H, s).
ESI-MS m / z: 468 (M + H) ⁺
(Example 83)
(3S) -3-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) piperidin-2-one

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (S) -3-aminopiperidin-2-one hydrochloride (21 mg) were used in the same manner as in Example 71 to obtain the title compound (18.3 mg, 56%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 1.55-1.71 (1H, m), 1.77-2.01
(2H, m), 2.18-2.31 (7H, m), 3.12-3.29 (3H, m), 3
. 40-3.62 (4H, m), 3.68-3.90 (4H, m), 5.44 (2H, s
), 8.07 (1H, s), 8.19 (1H, brs).
ESI-MS m / z: 469 (M + H) ⁺
(Example 84)
(3S) -3-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) pyrrolidin-2-one

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (S) -3-aminopyrrolidin-2-one hydrochloride (19 mg) were used in the same manner as in Example 71 to obtain the title compound (18.3 mg, 56%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 1.84-1.99 (1H, m), 2.24-2.26
(6H, m), 2.44-2.53 (1H, m), 3.12-3.22 (1H, m), 3
. 26-3.39 (3H, m), 3.40-3.47 (2H, m), 3.68-3.77
(2H, m), 3.79 (3H, s), 3.90-3.97 (1H, m), 5.45 (2
H, s), 8.07 (1H, s), 8.12 (1H, brs).
ESI-MS m / z: 455 (M + H) ⁺
(Example 85)
(3R) -3-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) pyrrolidin-2-one

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0mg) and (R) -3-aminopyrrolidin-2-one hydrochloride (19mg) were used in the same manner as in Example 71 to obtain the title compound (12.7mg, 40%) as an amorphous substance.
¹ H-NMR (CD ₃ OD) δ: 1.84-1.99 (1H, m), 2.24-2.26
(6H, m), 2.44-2.53 (1H, m), 3.12-3.22 (1H, m), 3
. 26-3.39 (3H, m), 3.40-3.47 (2H, m), 3.68-3.77
(2H, m), 3.79 (3H, s), 3.90-3.97 (1H, m), 5.45 (2
H, s), 8.07 (1H, s), 8.12 (1H, brs).
ESI-MS m / z: 455 (M + H) ⁺
(Example 86)
(3S) -3-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) -1-methylpyrrolidine-2- on

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (S) -3-amino-1-methylpyrrolidin-2-one hydrochloride (17 mg) in the same manner as in Example 71, the title compound (21.6 mg, 66%) was converted to amorphous Got as.
¹ H-NMR (CD ₃ OD) δ: 1.75-1.90 (1H, m), 2.23-2.26
(6H, m), 2.37-2.46 (1H, m), 2.84 (3H, s), 3.08-3
. 19 (1H, m), 3.23-3.49 (4H, m), 3.65-3.74 (1H, m
), 3.79 (3H, s), 3.87-3.94 (1H, m), 5.44 (2H, s),
8.06 (1H, brs), 8.13 (1H, s).
ESI-MS m / z: 469 (M + H) ⁺
(Example 87)
(3R) -3-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) -1-methylpyrrolidine-2- on

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (R) -3-amino-1-methylpyrrolidin-2-one hydrochloride (16 mg) in the same manner as in Example 71, the title compound (21.2 mg, 60%) was converted to amorphous Got as.
¹ H-NMR (CD ₃ OD) δ: 1.75-1.90 (1H, m), 2.23-2.26
(6H, m), 2.37-2.46 (1H, m), 2.84 (3H, s), 3.08-3
. 19 (1H, m), 3.23-3.49 (4H, m), 3.65-3.74 (1H, m
), 3.79 (3H, s), 3.87-3.94 (1H, m), 5.44 (2H, s),
8.06 (1H, brs), 8.13 (1H, s).
ESI-MS m / z: 469 (M + H) ⁺
(Example 88)
2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -N ⁸ - (tetrahydro -2H- pyran-4-yl) 2,7,8,9-tetrahydro-6-thia -1,
2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
0 mg), 4-aminotetrahydropyran hydrochloride (36 mg), triethylamine (24
The title compound (6.5 mg, 16%) was obtained as an amorphous product in the same manner as in Example 62.
¹ H-NMR (CDCl ₃ ) δ: 1.33-1.49 (2H, m), 1.81 (2H, t
, J = 12.9 Hz), 2.22 (3H, s), 2.28 (4H, s), 2.79-2.
88 (1H, m), 3.11-3.44 (6H, m), 3.62-3.67 (1H, m)
, 3.74 (3H, s), 3.94-3.99 (2H, m), 5.10 (2H, s), 5
. 45 (2H, s), 8.18 (1H, s).
ESI-MS m / z: 456 (M + H)
Example 89
2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] ^-N 8 - [(3
R) -tetrahydrofuran-3-yl] -2,7,8,9-tetrahydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
0 mg) and (R) -3-aminotetrahydrofuran p-toluenesulfonate (68 m
g) and triethylamine (24 μl) were used in the same manner as in Example 62 to obtain the title compound (7.5 mg, 23%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.63-1.78 (1H, m), 2.05-2.19
(1H, m), 2.22 (3H, s), 2.28 (3H, s), 3.12-3.37 (4
H, m), 3.46-3.58 (3H, m), 3.74 (3H, s), 3.75-3.9.
6 (3H, m), 5.07 (2H, brs), 5.43 (2H, d, J = 15.9 Hz)
, 5.47 (2H, d, J = 15.9 Hz), 8.19 (1H, s).
ESI-MS m / z: 442 (M + H)
(Example 90)
2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulen-8-yl} amino) propane-1,3-diol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and 2-aminopropane-1,3-diol (13 mg).
In the same manner as described above, the title compound (13.1 mg, 42%) was obtained as amorphous.
¹ H-NMR (CD ₃ OD) δ: 2.23 (3H, s), 2.24 (3H, s), 2.8
5-2.90 (1H, m), 3.10 (1H, dd, J = 16.7, 8.7 Hz), 3.
23 (1H, dd, J = 16.7, 3.3 Hz), 3.34-3.41 (2H, m), 3
. 47-3.55 (2H, m), 3.57-3.68 (3H, m), 3.78 (2H, s
), 5.43 (2H, s), 8.06 (1H, s).
ESI-MS m / z: 446 (M + H)
(Example 91)
trans-4-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} amino) cyclohexanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and trans-4-aminocyclohexanol (16 mg) were used in the same manner as in Example 71 to obtain the title compound (7.3 mg, 22%) as amorphous.
¹ H-NMR (CD ₃ OD + CDCl ₃ ) δ: 1.12-1.39 (5H, m), 1.8
9-2.02 (4H, m), 2.26 (6H, s), 2.60-2.69 (1H, m),
3.10 (1H, dd, J = 16.7, 8.4 Hz), 3.20-3.40 (2H, m)
3.50-3.60 (1H, m), 3.60-3.69 (1H, m), 3.79 (3H
, S), 5.44 (2H, s), 8.10 (1H, s).
ESI-MS m / z: 470 (M + H)
(Example 92)
2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulen-8-yl} amino) ethanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and 2-aminoethanol hydrochloride (14 mg) were used in the same manner as in Example 71 to obtain the title compound (3.6 mg, 12%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 2.24 (6H, s), 2.75-2.92 (2H, m
), 3.11 (1H, dd, J = 16.9, 8.5 Hz), 3.25 (1H, dd, J =
16.9, 3.5 Hz), 3.31-3.43 (2H, m), 3.46-3.52 (1H
M), 3.66 (2H, t, J = 5.6 Hz), 3.78 (3H, s), 5.44 (2
H, s), 8.06 (1H, s).
ESI-MS m / z: 416 (M + H) ^<+> .
(Example 93)
(1R, 2R) -2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia- 1,2,3,5-
Tetraazabenzo [cd] azulen-8-yl} amino) cyclohexanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (1R, 2R) -2-aminocyclohexanol (12 mg) were used in the same manner as in Example 71 to obtain the title compound (5.9 mg, 18%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.02-1.10 (1H, m), 1.18-1.32
(3H, m), 1.67-1.82 (3H, m), 1.96-2.11 (2H, m), 2
. 20-2.29 (6H, m), 2.30-2.39 (1H, m), 3.09-3.23
(3H, m), 3.24-3.38 (2H, m), 3.55-3.71 (1H, m), 3
. 74 (3H, s), 5.04-5.10 (2H, m), 5.41-5.50 (2H, m
), 8.16-8.19 (1H, m).
ESI-MS m / z: 470 (M + H)
(Example 94)
(1S, 2S) -2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia- 1,2,3,5-
Tetraazabenzo [cd] azulen-8-yl} amino) cyclohexanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (1S, 2S) -2-aminocyclohexanol (12 mg) were used in the same manner as in Example 71 to obtain the title compound (6.8 mg, 21%) as amorphous.
ESI-MS m / z: 470 (M + H)
(Example 95)
2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] ^-N 8 - [(3
S) -Tetrahydrofuran-3-yl] -2,7,8,9-tetrahydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
0 mg) and (S) -3-aminotetrahydrofuran p-toluenesulfonate (68 m
g) and triethylamine (24 μl) were used in the same manner as in Example 62 to obtain the title compound (17.9 mg, 46%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.66-1.77 (1H, m), 2.04-2.18
(1H, m), 2.22 (3H, s), 2.27 (3H, s), 3.11-3.36 (4
H, m), 3.46-3.58 (3H, m), 3.74 (6H, s), 3.75-3.9.
6 (3H, m), 5.16 (2H, brs), 5.45 (2H, s), 8.18 (1H,
s).
ESI-MS m / z: 442 (M + H)
Example 96
(1R, 2R) -2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia- 1,2,3,5-
Tetraazabenzo [cd] azulen-8-yl} amino) cyclopentanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0mg) and (1R, 2R) -2-aminocyclopentanol (15mg) were used in the same manner as in Example 71 to obtain the title compound (2.1mg, 7%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 0.76 to 2.07 (6H, m), 2.21 (3H, s
), 2.27 (3H, s), 2.94-3.03 (1H, m), 3.17-3.38 (4
H, m), 3.53-3.69 (1H, m), 3.74 (2H, s), 3.81-3.9
0 (1H, m), 5.03-5.10 (2H, m), 5.41-5.46 (2H, m),
8.13-8.19 (1H, m).
ESI-MS m / z: 456 (M + H)
(Example 97)
(1S, 2S) -2-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia- 1,2,3,5-
Tetraazabenzo [cd] azulen-8-yl} amino) cyclopentanol

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (4
0 mg) and (1S, 2S) -2-aminocyclopentanol (15 mg) were used in the same manner as in Example 71 to obtain the title compound (3.4 mg, 11%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 0.77-2.15 (6H, m), 2.21 (3H, s
), 2.6-2.28 (3H, m), 2.97-3.07 (1H, m), 3.19-3
. 41 (4H, m), 3.55-3.72 (1H, m), 3.74 (3H, s), 3.8
2-3.96 (1H, m), 5.11 (2H, s), 5.40-5.49 (2H, m),
8.12-8.21 (1H, m).
ESI-MS m / z: 456 (M + H)
(Example 98)
2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,
9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4
, 8-diamine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
0 mg), ammonium acetate (68 mg), molecular sieves 4A (50 mg) and methanol (1.5 ml) were stirred at room temperature for 4 hours. Sodium cyanoborohydride (12 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 3 days. The insoluble material in the reaction mixture was removed by celite filtration, washed twice with methanol (4 ml), and the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the obtained residue, and the mixture was stirred at room temperature for 4 hours. Diethyl ether (20 ml) was added to the residue obtained by concentrating the reaction mixture under reduced pressure, and after slurry washing, the solvent was removed by decantation. The obtained residue was purified by reverse phase liquid chromatography to give the title compound (14.1 mg, 43%) as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.24 (3H, s), 2.28 (3H, s), 3.2
5-3.33 (1H, m), 3.40-3.50 (2H, m), 3.57 (1H, dd,
J = 15.4, 8.0 Hz), 3.79 (3H, s), 4.12 (1H, dt, J = 3.
2, 8.0 Hz), 5.44 (1 H, d, J = 15.9 Hz), 5.49 (1 H, d, J
= 15.9 Hz), 8.04 (1H, s), 8.22 (1H, brs).
ESI-MS m / z: 372 (M + H) ⁺
Example 99
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} -N-methylacetamide

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6-thia- of Example 40 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (5
7 mg), dichloroethane (1 ml), 2N methylamine tetrahydrofuran solution (0
. 2 ml) and acetic acid (23 μl) were added sodium triacetoxyborohydride (32 mg) and stirred overnight at room temperature. Methanol (1 drop) was added dropwise to the reaction mixture, 0.2N aqueous sodium hydroxide solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) was added to the resulting residue, and pyridine (24 μl) and acetyl chloride (14 μm) were added under ice cooling.
l) was added dropwise, 4-dimethylaminopyridine (1 mg) was added, and the mixture was stirred under ice-cooling for 10 minutes and at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (ethyl acetate), and then subjected to the same procedure as in Example 2 for the title compound (
19 mg, 79%) was obtained as an oil.
¹ H-NMR (CD ₃ OD) δ: 2.11 (3H, s), 2.23 (3H, t, J = 11
. 7 Hz), 2.24 (3H, s), 3.06 (3H, s), 3.11 (2H, d, J =
14.6 Hz), 3.45 (1H, dd, J = 16.5, 12.1 Hz), 3.72 (1
H, dd, J = 14.6, 8.1 Hz), 3.78 (3H, s), 3.79 (3H, s)
, 5.01-5.08 (1H, m), 5.40-5.50 (2H, m), 8.07 (1H
, S).
ESI-MS m / z: 428 (M + H) ⁺
(Example 100)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} methanesulfonamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
Using 8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (47 mg), triethylamine (36 μl) and mesylic chloride (22 μl) In the same manner as in Example 43, the title compound (7.1 m
g, 24%) was obtained as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.23 (3H, s), 2.26 (3H, s), 3.0
1 (3H, s), 3.19-3.26 (1H, m), 3.28-3.34 (1H, m),
3.44-3.47 (2H, m), 3.78 (3H, s), 4.25-4.31 (1H,
m), 5.40 (1H, d, J = 15.9 Hz), 5.47 (1H, d, J = 15.9H)
z), 8.03 (1H, s).
ESI-MS m / z: 450 (M + H) ⁺
(Example 101)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} benzenesulfonamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (47 mg) and triethylamine (36 μl), 4-dimethylaminopyridine (0.8 mg ) And benzenesulfonic acid chloride (25 μl) in the same manner as in Example 43 to give the title compound (22 mg, 65%) as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.16 (3H, s), 2.18 (3H, s), 2
. 90-3.01 (2H, m), 3.07-3.16 (1H, m), 3.29-3.44
(2H, m), 3.70 (3H, s), 3.71-3.79 (1H, m), 5.30 (2
H, s), 6.78 (2H, s), 7.57-7.69 (3H, m), 7.85 (2H,
d, J = 7.6 Hz), 8.04 (1H, s), 8.24-8.29 (1H, m).
ESI-MS m / z: 512
(Example 102)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} -1-methyl-1H-imidazole-4-sulfonamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (42 mg) and triethylamine (41 μl), 4-dimethylaminopyridine (0.7 mg ) And 1-methylimidazol-4-ylsulfonyl chloride (32 μl) in the same manner as in Example 43, the title compound (18 mg, 6
0%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.27 (3H, s), 3.1
4-3.28 (2H, m), 3.37 (1H, d, J = 14.7 Hz), 3.44 (1H
, Dd, J = 14.5, 7.8 Hz), 3.74 (3H, s), 3.76 (3H, s),
4.19-4.26 (1H, m), 5.39 (1H, d, J = 15.7 Hz), 5.46
(1H, d, J = 15.7 Hz), 7.49 (1H, s), 7.51 (1H, s), 8.
08 (1H, s).
ESI-MS m / z: 516 (M + H) ⁺
(Example 103)
N- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} pyridine-3-sulfonamide

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (42 mg) and triethylamine (41 μl), 4-dimethylaminopyridine (0.7 mg ), Pyridine-3-sulfonyl chloride (31 mg)
In the same manner as in Example 43, the title compound (15 mg, 50%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.21 (3H, s), 2.25 (3H, s), 3.1
4 (1H, dd, J = 17.1, 3.7 Hz), 3.19-3.30 (2H, m), 3.
43 (1H, d, J = 14.9 Hz), 3.75 (3H, s), 5.29 (2H, s),
5.35 (2H, s), 6.57-6.63 (1H, brm), 7.36 (1H, dd,
J = 8.1, 4.9 Hz), 8.11 (1H, s), 8.13 (1H, ddd, J = 8.
1, 2.4, 1.8 Hz), 8.74 (1H, dd, J = 4.9, 1.8 Hz), 9.0
6 (1H, d, J = 2.4 Hz).
ESI-MS m / z: 513 (M + H) ⁺
(Example 104)
1- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} pyrrolidin-2-one

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (47 mg), triethylamine (36 μl), dichloromethane (1 ml) and 4-chlorobuty A mixture of ril chloride (14 μl) was stirred at room temperature for 12 hours. To the reaction mixture was added 0.1N aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in dehydrated dichloromethane (1.5 ml), 1,3-dimethoxybenzene (16 μl) and trifluoroacetic acid (1.5 ml) were added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, 0.1N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. To the resulting residue was added dimethylformamide (1 ml) and potassium te
rt-Butoxide (15 mg) was added and stirred at room temperature for 2 hours. Water and chloroform were added to the reaction mixture, and the mixture was separated. The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to obtain the title compound (13 mg, 46%) as a solid.
¹ H-NMR (CD ₃ OD + CDCl ₃ ) δ: 2.06-2.14 (2H, m), 2.2
5 (3H, s), 2.26 (3H, s), 2.43 (2H, t, J = 8.4 Hz), 3.
15 (1H, d, J = 14.8 Hz), 3.21 (1H, dd, J = 17.0, 3.4H
z), 3.42 (1H, dd, J = 17.0, 10.6 Hz), 3.47-3.54 (2
H, m), 3.68 (1H, dd, J = 14.8, 8.2 Hz), 3.79 (3H, s)
4.73-4.80 (1H, m), 5.45 (2H, s), 8.10 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 105)
1- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5 -Tetraazabenzo [
cd] azulen-8-yl} imidazolidin-2-one

Di-tert-butyl {8-[(2,4-dimethoxybenzyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7, of Example 42
8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (47 mg), dichloromethane (1 ml) and 2-chloroethyl isocyanate (8 μl) The mixture consisting of was stirred at room temperature for 12 hours. To the reaction mixture was added 0.1N aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in dehydrated dichloromethane (1.5 ml), 1,3-dimethoxybenzene (16 μl) and trifluoroacetic acid (1.5 ml) were added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, 0.1N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dimethylformamide (1 ml) and potassium tert-butoxide (15 mg) were added to the resulting residue, and the mixture was stirred at room temperature for 2 hours. Water and chloroform were added to the reaction mixture, and the mixture was separated. The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (9
mg, 31%) was obtained as a solid.
¹ H-NMR (CD ₃ OD) δ: 2.24 (3H, s), 2.24 (3H, s), 3.1
3-3.19 (2H, m), 3.35-3.44 (3H, m), 3.48-3.60 (2
H, m), 3.64 (1H, dd, J = 14.6, 8.3 Hz), 3.78 (3H, s)
, 4.45-4.52 (1H, m), 5.45 (2H, s), 8.07 (1H, s).
ESI-MS m / z: 441 (M + H) ⁺
(Example 106)
1) Di-tert-butyl {8′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H-spiro [ Cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] −
4′-yl} imide dicarbonate and tert-butyl {8′-amino-2 ′-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ', 8'-dihydro-
Mixture of 2′H-spiro [cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4′-yl} carbonate

Di-tert-butyl {2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8'-oxo-7', 8'-dihydro-2'H- of Example 57 Spyro[
Cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4′-yl} imide dicarbonate (203 mg), ammonium acetate (36
7 mg), molecular sieves 4A (500 mg) and methanol (4 ml) were stirred at room temperature for 2 days. To the reaction mixture was added sodium cyanoborohydride (68
mg) was added, followed by stirring with heating at a bath temperature of 55 ° C. for 16 hours. Insoluble matters in the reaction mixture were removed by Celite filtration, and the insoluble matters were washed with methanol (10 ml). The filtrate and washings were concentrated under reduced pressure, 0.2N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The title compound (177 mg) was obtained as an oily residue as a concentrated residue. The resulting product was used for the next reaction without further purification.
2) N- {4′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2′H-spiro [cyclopropane- 1,9 '-[
6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -8′-yl} -N ²
-Methylglycinamide

Di-tert-butyl {8'-amino-2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7', 8'-dihydro-2'H-spiro [cyclo Propane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene]
-4′-yl} imide dicarbonate and tert-butyl {8′-amino-2 ′-[(
4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ', 8'-dihydro-2'H-spiro [cyclopropane-1,9'-[6] thia [1,2,3 , 5] tetraazabenzo [cd] azulen] -4′-yl} carbonate (35 mg), dichloromethane (0.8 ml), N- (tert-butoxycarbonyl) -N-methylglycine (20 mg), 1- A mixture of hydroxybenzotriazole monohydrate (11 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (27 mg) and diisopropylethylamine (36 μl) was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, 0.2N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the residue obtained by concentrating the organic layer under reduced pressure, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol). The obtained oil was dissolved in dioxane and lyophilized to give the title compound (4.8 mg, 15%) as an amorphous product.
¹ H-NMR (CDCl ₃ ) δ: 0.99-1.06 (2H, m), 1.9-1.16
(1H, m), 1.69-1.75 (1H, m), 2.22 (3H, s), 2.29 (3
H, s), 2.38 (3H, s), 3.33 (2H, s), 3.45 (1H, dd, J =
14.5, 8.2 Hz), 3.72 (1H, d, J = 14.5 Hz), 3.74 (3H,
s), 3.87 (1H, t, J = 7.9 Hz), 5.19 (2H, s), 5.39 (2H)
, S), 7.92 (1H, d, J = 7.8 Hz), 8.13 (1H, s).
ESI-MS m / z: 469 (M + H) ⁺
(Example 107)
N- {4′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -7 ', 8'-dihydro-2'H-spiro [cyclopropane-1,9'-[6]
Thia [1,2,3,5] tetraazabenzo [cd] azulene] -8′-yl} -N ² , N
^2- dimethylglycinamide

Di-tert-butyl {8′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2 of Example 106-1) 'H-
Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [
cd] azulene] -4′-yl} imide dicarbonate and tert-butyl {8′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′
, 8′-dihydro-2′H-spiro [cyclopropane-1,9 ′-[6] thia [1,2,
3,5] tetraazabenzo [cd] azulene] -4'-yl} carbonate (3
5 mg) and N, N-dimethylglycine (11 mg) were used in the same manner as in Example 106-2) to obtain the title compound (12 mg, 85%) as amorphous.
¹ H-NMR (CD ₃ OD) δ: 0.96-1.15 (3H, m), 1.61-1.71
(1H, m), 2.24-2.28 (12H, m), 3.05 (2H, s), 3.53 (
1H, dd, J = 14.6, 8.3 Hz), 3.74-3.83 (4H, m), 5.37
(1H, d, J = 15.6 Hz), 5.45 (1H, d, J = 15.6 Hz), 8.04
(1H, s).
ESI-MS m / z: 483 (M + H) ⁺
(Example 108)
N- {4′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -7 ', 8'-dihydro-2'H-spiro [cyclopropane-1,9'-[6]
Thia [1,2,3,5] tetraazabenzo [cd] azulene] -8′-yl} azetidine-3-carboxamide

Di-tert-butyl {8′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8′-dihydro-2 of Example 106-1) 'H-
Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [
cd] azulene] -4′-yl} imide dicarbonate and tert-butyl {8′-amino-2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′
, 8′-dihydro-2′H-spiro [cyclopropane-1,9 ′-[6] thia [1,2,
3,5] tetraazabenzo [cd] azulene] -4'-yl} carbonate (3
5 mg) and tert-butoxycarbonylazetidine-3-carboxylic acid (21 mg) were used, and the title compound (1.9 mg, 6%) was obtained as amorphous in the same manner as in Example 106-2).
¹ H-NMR (CDCl ₃ ) δ: 0.96-1.14 (4H, m), 1.69-1.77
(1H, m), 2.22 (3H, s), 2.31 (3H, s), 3.35-3.45 (1
H, m), 3.51 (1H, dd, J = 14.6, 8.3 Hz), 3.61-3.78 (
6H, m), 3.78-3.97 (3H, m), 5.08 (2H, brs), 5.34 (
1H, d, J = 15.4 Hz), 5.43 (1H, d, J = 15.4 Hz), 6.74 (
1H, d, J = 5.9 Hz), 8.11 (1H, s).
ESI-MS m / z: 481 (M + H) ⁺
(Example 109)
2 ′-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7 ′, 8 ′
-Dihydro-2'H-spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5
] Tetraazabenzo [cd] azulene] -4 ', 8'-diamine

Di-tert-butyl {2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8'-oxo-7', 8'-dihydro-2'H- of Example 57 Spyro[
Cyclopropane-1,9 ′-[6] thia [1,2,3,5] tetraazabenzo [cd] azulene] -4′-yl} imide dicarbonate (29 mg), ammonium acetate (45 m
A mixture of g) and methanol (0.5 ml) was stirred at room temperature for 12 hours. Sodium cyanoborohydride (6.4 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 hours. Further, sodium cyanoborohydride (6.4 mg) was added, and 3 hours at 45 ° C. for 5 hours.
The mixture was heated and stirred at 5 ° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, 0.5N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the obtained residue, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel chromatography (chloroform-methanol). The oil obtained was dissolved in dioxane and lyophilized to give the title compound (8.7 mg, 45%) as an amorphous substance. .
¹ H-NMR (CD ₃ OD) δ: 0.86-0.97 (2H, m), 1.00-1.06
(1H, m), 1.61-1.67 (1H, m), 2.23 (3H, s), 2.24 (3
H, s), 2.79 (1H, d, J = 7.8 Hz), 3.24 (1H, dd, J = 14.
8, 7.8 Hz), 3.77 (1 H, s), 3.79 (1 H, d, J = 14.8 Hz),
5.35 (1H, d, J = 15.5 Hz), 5.41 (1 H, d, J = 15.5 Hz),
8.03 (1H, s).
ESI-MS m / z: 398 (M + H) ⁺
(Example 110)
4'-amino-2 '-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7', 8'-dihydro-2'H-spiro [cyclopropane-1,9'- [6] Cheer [
1,2,3,5] tetraazabenzo [cd] azulene] -8′-ol

4 di-tert-butyl {2 ′-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8′-oxo-7 ′, 8′-dihydro-2′H of Example 57 -Spiro [cyclopropane-1,9 '-[6] thia [1,2,3,5] tetraazabenzo [cd]
Azulene] -4′-yl} imide dicarbonate (29 mg) and methanol (2 ml) were mixed with sodium borohydride (6 mg) under ice-cooling and stirred at 0 ° C. for 30 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the obtained residue, and the mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (16 mg
, 81%) as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 0.91-0.99 (1H, m), 1.0
2-1.17 (2H, m), 1.56-1.63 (1H, m), 2.23 (3H, s),
2.27 (3H, s), 3.34 (2H, dd, J = 14.6, 8.3 Hz), 3.65
(1H, d, J = 14.6 Hz), 3.68 (1H, d, J = 8.3 Hz), 3.76 (
3H, s), 5.33 (1H, d, J = 15.6 Hz), 5.41 (1H, d, J = 15)
. 4 Hz), 8.06 (1 H, s).
ESI-MS m / z: 399 (M + H) ⁺
(Example 111)
Methyl {4- [bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetate

1) Di-tert-butyl of Example 40 {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-6- Cheer
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (
752 mg), methyl triphenylphosphanylidene acetate (617 mg) and toluene (14 ml) were heated and stirred at 60 ° C. for 10 hours. Ethyl acetate was added to the reaction mixture, washed with water, the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Silica gel column chromatography of the concentrated residue (ethyl acetate-chloroform)
To give the title compound (275 mg, 33%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.43 (18H, s), 2.21 (3H, s), 2.
27 (3H, s), 3.39 (2H, s), 3.73 (3H, s), 3.74 (3H, s)
), 3.86 (2H, s), 5.67 (2H, s), 6.80 (1H, s), 8.14 (
1H, s).
ESI-MS m / z: 627 (M + H) ⁺
2) {4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-
3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2
, 3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid

The methyl {4- [bis (tert-butoxycarbonyl) amino] -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} acetate (69
mg), methanol (2 ml) and 1N aqueous sodium hydroxide solution (0.22 ml) were stirred at room temperature for 16 hours. 1N sodium hydroxide aqueous solution (0.5ml
) Was added, and after stirring for 3 hours, 1N aqueous sodium hydroxide solution (0.3 ml) was further added and stirred for 3 hours. A 1N aqueous hydrochloric acid solution (1.5 ml) was added dropwise to the reaction mixture, water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. An oil (60 mg, 89%) was obtained as a residue. This product contained by-products but was used for the next reaction without further purification.
ESI-MS m / z: 613 (M + H) ⁺
3) Di-tert-butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-
3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2
, 3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

{4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,
2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (
60 mg) and tetrahydrofuran (2 ml) were mixed with N-methylmorpholine (22 μl) under ice-cooling, then isobutyl chloroformate (39 μl) was added, and the mixture was stirred at 0 ° C. for 1 hour. N-methylmorpholine (44 μl) and isobutyl chloroformate (39 μl) were added to the reaction mixture, and the mixture was further stirred at 0 ° C. for 30 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Tetrahydrofuran (2 ml) and water (0.4 ml) were added to the resulting residue, sodium borohydride (15 mg) was added under ice cooling, and the mixture was stirred at 0 ° C. for 1 hr. Methanol (2 ml) was added dropwise to the reaction mixture, which was then returned to room temperature and stirred for 16 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (hexane-ethyl acetate) to give the title compound (16 mg, 27%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.43 (18H, s), 2.21 (3H, s), 2.
27 (3H, s), 2.62 (2H, t, J = 6.0 Hz), 3.73 (3H, s), 3
. 79 (2H, s), 3.89 (2H, t, J = 6.0 Hz), 5.66 (2H, s),
6.76 (1H, s), 8.15 (1H, s).
ESI-MS m / z: 599 (M + H) ⁺
4) 2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} ethanol

Di-tert-butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,
2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (1
6 mg), dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel chromatography (chloroform-methanol). The oil obtained was dissolved in dioxane and lyophilized to give the title compound (8.3 mg, 78%) as an amorphous substance. .
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.28 (3H, s), 2.5
9 (2H, t, J = 6.0 Hz), 3.72 (2H, s), 3.74 (3H, s), 3.
87 (2H, t, J = 6.0 Hz), 5.18 (2H, brs), 5.50 (2H, s)
, 6.64 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 399 (M + H) ⁺
(Example 112)
Di-tert-butyl {8- (aminomethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3 , 5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

1) Methyl {4- [bis (tert-butoxycarbonyl) amino]-of Example 111
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-8- Yl} acetate (121 mg), diphenylphosphoryl azide (64 μl), triethylamine (
69 μl) and benzene (2 ml) were stirred with heating at a bath temperature of 55 ° C. for 2 hours. The reaction mixture was concentrated under reduced pressure, tetrahydrofuran (8 ml) and 1N aqueous sodium hydroxide solution (4 ml) were added to the resulting residue, and the mixture was heated with stirring at a bath temperature of 55 ° C. for 1 hour.
A 0.2N aqueous sodium hydroxide solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (chloroform-methanol) to give the title compound (41m
g) was obtained as a brown oil. The resulting product contained impurities but was used for the next reaction without further purification.
ESI-MS m / z: 584 (M + H) ^<+> .
2) 8- (Aminomethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetra Azabenzo [cd
Azulene-4-amine

Di-tert-butyl {8- (aminomethyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (8.6 mg
) Was used in the same manner as in Example 111 to obtain the title compound (2.6 mg) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 3.5
5 (2H, s), 3.73 (2H, s), 3.74 (3H, s), 5.14 (2H, s)
, 5.51 (2H, s), 6.73 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 384 (M + H) ⁺
(Example 113)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (morpholin-4-ylmethyl) -2,7-dihydro-6-thia-1,2,3,5- Tetraazabenzo [cd] azulen-4-amine

Di-tert-butyl {8- (aminomethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 112
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (
20 mg), 90% bis (2-bromoethyl) ether (10 μl), potassium carbonate (9
. 5 mg) and acetonitrile (0.3 ml) were heated and stirred at 55 ° C. for 24 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 m) was added to the resulting residue.
l) and trifluoroacetic acid (0.5 ml) were added, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The residue obtained is N
The oily substance obtained by purification by H silica gel chromatography (chloroform-methanol) was dissolved in dioxane and freeze-dried to obtain the title compound (5.6 mg) as an amorphous substance.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.30 (3H, s), 2.4
5-2.48 (4H, m), 3.14 (2H, s), 3.70 (4H, t, J = 4.5H)
z), 3.74 (3H, s), 5.14 (2H, s), 5.50 (2H, s), 6.70.
(1H, s), 8.20 (1H, s).
ESI-MS m / z: 454 (M + H) ⁺
(Example 114)
N-({4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraaza Benzo [cd] azulen-8-yl} methyl) acetamide

Di-tert-butyl {8- (aminomethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 112
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (
20 mg), pyridine (8.3 μl), acetic anhydride (5 μl) and dichloromethane (0.
5 ml) was stirred at room temperature for 20 hours. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the residue obtained by concentrating the reaction mixture under reduced pressure,
Stir at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel thin layer chromatography (chloroform-
Purification with methanol) gave the title compound (3.7 mg) as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 2.04 (3H, s), 2.24 (3H,
s), 2.27 (3H, s), 3.68 (2H, s), 3.76 (3H, s), 4.09
(2H, d, J = 4.8 Hz), 5.48 (2H, s), 6.62 (1H, s), 6.9
2 (1H, t, J = 4.8 Hz), 8.14 (1H, s).
ESI-MS m / z: 426 (M + H) ⁺
(Example 115)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} acetamide

{4- [Bis (tert-butoxycarbonyl) amino] -2-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-
Thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic
Acid (24 mg), dimethylformamide (0.7 ml), ammonium chloride (13
mg), 1-hydroxybenzotriazole monohydrate (6 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (15 mg) and diisopropylethylamine (34 μl) at room temperature for 3 days. Stir. The solvent in the reaction mixture was distilled off by blowing, and 0.2N aqueous sodium hydroxide solution was added to the residue obtained and the mixture was extracted with ethyl acetate. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the residue obtained by concentrating the organic layer under reduced pressure, and the mixture was stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to give the title compound (16.
1 mg, 70%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 2.24 (3H, s), 2.27 (3H,
s), 3.27 (2H, s), 3.77 (3H, s), 3.82 (2H, s), 5.48
(2H, s), 6.67 (1H, s), 8.13 (1H, s).
ESI-MS m / z: 412 (M + H) ⁺
(Example 116)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-methylacetamide

{4- [Bis (tert-butoxycarbonyl) amino] -2-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-
Thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic
Synthesis in the same manner as in Example 115 using acid (24 mg) and methylamine hydrochloride (17 mg) gave the title compound (12.5 mg, 75%) as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 2.24 (3H, s), 2.28 (3H,
s), 2.79 (3H, d, J = 4.7 Hz), 3.24 (2H, s), 3.76 (3H
, S), 3.80 (2H, s), 5.49 (2H, s), 6.59-6.64 (1H, m
), 6.66 (1H, s), 8.14 (1H, s).
ESI-MS m / z: 426 (M + H) ⁺
(Example 117)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N, N-dimethylacetamide

{4- [Bis (tert-butoxycarbonyl) amino] -2-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-
Thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic
Synthesis in the same manner as in Example 115 using acid (24 mg) and dimethylamine hydrochloride (20 mg) gave the title compound (8.7 mg, 50%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.28 (3H, s), 2.9
7 (3H, s), 3.05 (3H, s), 3.41 (2H, s), 3.74 (3H, s)
, 3.81 (2H, s), 5.13 (2H, brs), 5.50 (2H, s), 6.61
(1H, s), 8.19 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 118)
{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulen-8-yl} acetic acid

1) Methyl {4- [bis (tert-butoxycarbonyl) amino]-of Example 111
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-8- Yl} acetate (218 mg), methanol (8 ml) and 1N aqueous sodium hydroxide solution (0
. 22 ml) was stirred at room temperature for 8 hours. A 1N aqueous hydrochloric acid solution (2.5 ml) was added dropwise to the reaction mixture under ice-cooling, and methanol in the reaction mixture was distilled off under reduced pressure. A 0.5 N aqueous hydrochloric acid solution was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was concentrated to dryness under reduced pressure to give the title compound (173 mg, 97%) as amorphous.
ESI-MS m / z: 513 (M + H) ⁺
2) 2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} -N-ethylacetamide

{4-[(tert-butoxycarbonyl) amino] -2-[(4-methoxy-3)
, 5-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,
3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (21
mg) and ethylamine hydrochloride (11 mg) were synthesized in the same manner as in Example 115 to obtain the title compound (8.3 mg, 46%) as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.13 (3H, t, J = 7.4 Hz),
2.23 (3H, s), 2.29 (3H, s), 3.25 (2H, s), 3.29 (2H
, Dt, J = 13.0, 7.4 Hz), 3.75 (3H, s), 3.78 (2H, s),
5.3-2.35 (2H, m), 5.50 (2H, s), 6.06-6.12 (1H,
m), 6.68 (1H, s), 8.16 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 119)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-[(3R) -tetrahydrofuran-3-yl] acetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (21 mg) and (R) -3-aminotetrahydrofuran p-toluenesulfonate (
The title compound (9.7 mg, 4 mg) was synthesized in the same manner as in Example 115.
9%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.78-1.86 (1H, m), 2.2
0-2.28 (1H, m), 2.23 (3H, s), 2.28 (3H, s), 3.23 (
2H, s), 3.66 (1H, dd, J = 9.4, 2.6 Hz), 3.73-3.84 (
3H, m), 3.76 (3H, s), 3.80 (2H, s), 3.91 (1H, q, J =
7.8 Hz), 4.45-4.53 (1H, m), 5.40 (2H, brs), 5.49.
(2H, s), 6.66 (1H, s), 6.80 (1H, d, J = 7.1 Hz), 8.1
5 (1H, s).
ESI-MS m / z: 482 (M + H) ⁺
(Example 120)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-morpholin-4-yl-2-oxoethyl) -2,7-dihydro-6-thia-1, 2, 3,
5-tetraazabenzo [cd] azulen-4-amine

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (21 mg) and morpholine (11 μl) were synthesized in the same manner as in Example 115, and the title compound (7. 2 mg, 36%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.29 (3H, s), 3.4
2 (2H, d, J = 1.2 Hz), 3.48-3.52 (2H, m), 3.62-3.7
0 (6H, m), 3.75 (3H, s), 3.81 (2H, s), 5.24 (2H, s)
, 5.50 (2H, s), 6.62 (1H, t, J = 1.2 Hz), 8.19 (1H, s)
).
ESI-MS m / z: 482 (M + H) ⁺
(Example 121)
2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-oxo-2-piperazin-1-ylethyl) -2,7-dihydro-6-thia-1, 2, 3,
5-tetraazabenzo [cd] azulen-4-amine

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (21 mg) and N- (tert-butoxycarbonyl) -piperazine (23 mg) in the same manner as in Example 115 To give the title compound (15.3 mg, 78%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.8
4 (4H, dd, J = 10.1, 5.0 Hz), 3.42 (2H, s), 3.46 (2H
, T, J = 5.0 Hz), 3.60 (2H, t, J = 5.0 Hz), 3.74 (3H, s
), 3.81 (2H, s), 5.24 (2H, brs), 5.50 (2H, s), 6.6
2 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 481 (M + H) ⁺
(Example 122)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N- (trans-4-hydroxycyclohexyl) acetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (21 mg) and trans-4-aminocyclohexanol (14 mg) were synthesized in the same manner as in Example 115. The title compound (7.1 mg, 34%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.14-1.25 (2H, m), 1.33-1.43
(2H, m), 1.92-2.00 (4H, m), 2.23 (3H, s), 2.29 (3
H, s), 3.23 (2H, s), 3.50-3.58 (1H, m), 3.68-3.7
5 (1H, m), 3.76 (3H, s), 3.78 (2H, s), 5.49 (2H, s)
, 6.21 (1H, d, J = 8.1 Hz), 6.66 (1H, s), 8.15 (1H, s)
).
ESI-MS m / z: 510 (M + H) ⁺
(Example 123)
8- (2-azetidin-1-yl-2-oxoethyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-amine

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and azetidine hydrochloride (14 mg) were synthesized in the same manner as in Example 115, and the title compound ( 9.2 mg, 42%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.28 (3H, s), 2.2
8 (1H, q, J = 7.7 Hz), 3.15 (2H, s), 3.72 (1H, q, J = 7
. 7 Hz), 3.75 (3H, s), 3.83 (2H, s), 4.05 (2H, t, J =
7.7 Hz), 4.20 (2H, t, J = 7.7 Hz), 5.34 (2H, brs), 5
. 51 (2H, s), 6.61 (1H, s), 8.21 (1H, s).
ESI-MS m / z: 452 (M + H) ⁺
(Example 124)
[(2S) -1-({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl} acetyl) azetidin-2-yl] methanol

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and (2S) -azetidin-2-ylmethanol oxalate (26 mg
) And the title compound (11.2 mg, 48%)
Was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.25-2.34 (1 H, m
), 2.29 (3H, s), 3.17 (2H, s), 3.68-3.80 (3H, m),
3.75 (3H, s), 3.82 (2H, s), 4.04-4.19 (2H, m), 4.
60-4.68 (1H, m), 5.29 (1H, s), 5.50 (2H, s), 6.63
(1H, s), 8.20 (1H, s).
ESI-MS m / z: 482 (M + H) ⁺
(Example 125)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-[(3S) -tetrahydrofuran-3-yl] acetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and (R) -3-aminotetrahydrofuran p-toluenesulfonate (38 mg) The title compound (12.6 mg
, 54%) as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.77-1.86 (1H, m), 2.1
9-2.27 (1H, m), 2.23 (3H, s), 2.29 (3H, s), 3.23 (
2H, s), 3.66 (1H, dd, J = 9.6, 2.6 Hz), 3.73-3.84 (
3H, m), 3.76 (3H, s), 3.79 (2H, s), 3.91 (1H, q, J =
7.8 Hz), 4.46-4.53 (1H, m), 5.39 (2H, brs), 5.50.
(2H, s), 6.66 (1H, s), 8.16 (1H, s).
ESI-MS m / z: 482 (M + H) ⁺
(Example 126)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-[(1R, 2R) -2-hydroxycyclopentyl] acetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and (1R, 2R) -2-aminocyclopentanol hydrochloride (14 mg)
And the title compound (9.1 mg, 38%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.37-1.47 (1H, m), 1.5
8-1.71 (2H, m), 1.73-1.84 (1H, m), 1.91-2.01 (1
H, m), 2.07-2.17 (1H, m), 2.23 (3H, s), 2.29 (3H,
s), 3.26 (2H, s), 3.76 (3H, s), 3.79 (2H, s), 3.80
-3.88 (1H, m), 3.95 (1H, dd, J = 12.7, 5.9 Hz), 5.4
0 (2H, s), 5.49 (2H, s), 6.62 (1H, d, J = 4.9 Hz), 6.
67 (1H, s), 8.15 (1H, s).
ESI-MS m / z: 496 (M + H) ⁺
(Example 127)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-[(1R, 2R) -2-hydroxycyclopentyl] acetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and (1S, 2S) -2-aminocyclopentanol hydrochloride (14 mg)
And the title compound (7.4 mg, 31%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.37-1.47 (1H, m), 1.5
9-1.71 (2H, m), 1.74-1.84 (1H, m), 1.92-2.02 (1
H, m), 2.07-2.17 (1H, m), 2.23 (3H, s), 2.29 (3H,
s), 3.26 (2H, s), 3.76 (3H, s), 3.80 (2H, s), 3.82
−3.87 (1H, m), 3.95 (1H, dd, J = 12.7, 5.9 Hz), 5.4
9 (2H, s), 6.61 (1H, d, J = 4.9 Hz), 6.67 (1H, s), 8.
15 (1H, s).
ESI-MS m / z: 496 (M + H) ⁺
(Example 128)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-cyclopropylacetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and cyclopropylamine (10 μl) were synthesized in the same manner as in Example 115, and the title compound ( 11.8 mg, 53%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 0.47-0.53 (2H, m), 0.7
2-0.78 (2H, m), 2.23 (3H, s), 2.28 (3H, s), 2.65-
2.73 (1H, m), 3.21 (2H, s), 3.76 (3H, s), 3.79 (2H
, S), 5.49 (2H, s), 6.63 (1H, s), 8.15 (1H, s).
ESI-MS m / z: 452 (M + H) ⁺
(Example 129)
1-({4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraaza Benzo [cd] azulen-8-yl} acetyl) piperidin-4-ol

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (25 mg) and piperidin-4-ol (15 mg) were synthesized in the same manner as in Example 115, and the title The compound (10.2 mg, 42%) was obtained as a solid.
¹ H-NMR (CDCl ₃ + CD ₃ OD) δ: 1.45 to 1.57 (2H, m), 1.7
9-1.92 (2H, m), 2.23 (3H, s), 2.28 (3H, s), 3.19-
3.30 (2H, m), 3.44 (2H, s), 3.76 (3H, s), 3.80 (2H
, S), 3.86-3.93 (2H, m), 4.02-4.10 (1H, m), 5.50.
(2H, s), 6.61 (1H, s), 8.18 (1H, s).
ESI-MS m / z: 496 (M + H) ⁺
(Example 130)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N, N-diethylacetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (28 mg) and diethylamine (17 μl) were synthesized in the same manner as in Example 115, and the title compound (8. 2 mg, 32%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.13 (3H, t, J = 7.1 Hz), 1.20 (3
H, t, J = 7.1 Hz), 2.22 (3H, s), 2.28 (3H, s), 3.31-
3.41 (4H, m), 3.39 (2H, s), 3.74 (3H, s), 3.84 (2H
, S), 5.20 (2H, brs), 5.50 (2H, s), 6.62 (1H, s), 8
. 20 (1H, s).
ESI-MS m / z: 468 (M + H) ⁺
(Example 131)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-oxo-2-pyrrolidin-1-ylethyl) -2,7-dihydro-6-thia-1, 2, 3,
5-tetraazabenzo [cd] azulen-4-amine

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (28 mg) and pyrrolidine (14 μl) were synthesized in the same manner as in Example 115, and the title compound (7. 0 mg, 27%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.82-1.89 (2H, m), 1.92-1.98
(2H, m), 2.22 (3H, s), 2.28 (3H, s), 3.35 (2H, s),
3.48 (4H, td, J = 6.7, 4.1 Hz), 3.74 (4H, s), 3.85 (
2H, s), 5.19 (2H, brs), 5.50 (2H, s), 6.62 (1H, s)
, 8.19 (1H, s).
ESI-MS m / z: 466 (M + H) ⁺
(Example 132)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N- (2-methoxyethyl) -N-methylacetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-Tetraazabenzo [cd] azulen-8-yl} acetic acid (28 mg) and 2-methoxy-N-methylethanamine (15 μl) in the same manner as in Example 115. Synthesis gave the title compound (11.8 mg, 48%) as a solid.
¹ H-NMR (CDCl 3) δ: 8.19 (1H, s), 6.66-6.60 (1 H, m
), 5.50 (2H, s), 5.19 (2H, s), 3.81-3.80 (2H, m),
3.74 (3H, s), 3.59-2.97 (12H, m), 2.29-2.22 (6H
, M).
ESI-MS m / z: 484 (M + H) ⁺
(Example 133)
2- {4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} -N-isopropylacetamide

{4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 118 , 2,3,5-tetraazabenzo [cd] azulen-8-yl} acetic acid (28 mg) and isopropylamine (14 μl) were synthesized in the same manner as in Example 115, and the title compound (8 .9 mg, 36%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.14 (3H, s), 1.15 (3H, s), 2.2
2 (3H, s), 2.31 (3H, s), 3.24 (2H, s), 3.75 (3H, s)
, 3.77 (2H, s), 4.04-4.14 (1H, m), 5.23 (2H, brs)
5.51 (2H, s), 5.60 (1 H, d, J = 7.8 Hz), 6.70 (1 H, s)
), 8.20 (1H, s).
ESI-MS m / z: 454 (M + H) ⁺
(Example 134)
1) tert-butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-4-yl} carbonate

Methyl {4- [bis (tert-butoxycarbonyl) amino] -2 of Example 111
-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-8-yl } To a mixture of acetate (957 mg) and dehydrated tetrahydrofuran (18 ml) was added lithium borohydride (67 mg) under ice cooling, and the mixture was stirred at 0 ° C. for 2 hours, then returned to room temperature and stirred overnight. The mixture was ice-cooled again, lithium borohydride (33 mg) was added, and the mixture was stirred at 0 ° C. for 2 hr. To the reaction mixture was added methanol (6 ml) and 1N aqueous sodium hydroxide solution (6
ml), and the mixture was returned to room temperature and stirred for 4 hours. The organic solvent in the reaction mixture was distilled off under reduced pressure, 0.2N aqueous hydrochloric acid solution was added, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (chloroform-methanol) to give the title compound (301 mg, 40%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (10H, s), 2.21 (3H, s), 2.
31 (3H, s), 2.60 (2H, t, J = 6.1 Hz), 3.74 (3H, s), 3
. 75 (2H, s), 3.88 (2H, s), 5.63 (2H, s), 6.70 (1H,
s), 7.42 (1H, s), 8.18 (1H, s).
ESI-MS m / z: 499 (M + H) ⁺
2) tert-butyl {8- (2-azidoethyl) -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulen-4-yl} carbamate

The above tert-butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3
, 5-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,
To a mixture consisting of 3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (25 mg), triethylamine (15 μl) and dehydrated dichloromethane (0.5 ml), mesylic acid chloride (5 μl) was added dropwise under ice cooling. And stirred at 0 ° C. for 20 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over sodium sulfate and filtered, and then the solvent of the filtrate was distilled off under reduced pressure. Sodium azide (5.3 mg) was added to the resulting residue.
) And dehydrated dimethylformamide (0.5 ml) were added, and the mixture was stirred at a bath temperature of 55 ° C. for 16 hours. After the solvent was distilled off, 0.2N aqueous sodium hydroxide solution (4 ml) was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. Title compound (3
1 mg) was obtained as an oil. This grade was used for the next reaction as it was.
ESI-MS; m / z: 524 (M + H) ⁺ .
3) tert-butyl {8- (2-aminoethyl) -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulen-4-yl} carbamate

The above tert-butyl {8- (2-azidoethyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} carbamate (31 mg), triphenylphosphine (23 mg), tetrahydrofuran (0.9 ml) and water (0.1 m
The mixture consisting of l) was stirred at room temperature for 5 hours. To the reaction mixture was added 0.2N aqueous sodium hydroxide solution (2.5 ml), and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and then the solvent of the filtrate was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (using NH silica, ethyl acetate: chloroform) to give the title compound (17
mg) was obtained as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.21 (3H, s), 2.
31 (3H, s), 2.49 (2H, t, J = 6.5 Hz), 2.96 (2H, t, J =
6.5 Hz), 3.71 (2H, s), 3.74 (3H, s), 5.63 (2H, s)
), 6.66 (1H, s), 7.52 (1H, brs), 8.18 (1H, s).
ESI-MS; m / z: 498 (M + H) ⁺ .
4) 8- (2-Aminoethyl) -2-[(4-methoxy-3,5-dimethylpyridine-2)
-Yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [
cd] azulen-4-amine

The above tert-butyl {8- (2-aminoethyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} carbamate (17 mg) and
Trifluoroacetic acid (0.5 ml) was added to a mixture consisting of dichloromethane (2 ml), and the mixture was stirred at room temperature for 6 hours. The solvent of the reaction mixture was distilled off, 0.2N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the solvent of the filtrate was distilled off under reduced pressure. The obtained residue was purified by NH silica gel column chromatography (chloroform: methanol) to obtain an oil. This was dissolved in dioxane (0.5 ml) and freeze-dried to obtain the title compound (9.4 mg) as an amorphous substance.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.4
7 (2H, t, J = 6.4 Hz), 2.96 (2H, t, J = 6.4 Hz), 3.68 (
2H, s), 3.74 (3H, s), 5.19 (2H, brs), 5.50 (2H, s)
, 6.61 (1H, s), 8.19 (1H, s).
ESI-MS; m / z: 398 (M + H) ⁺ .
(Example 135)
1) tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-morpholin-4-ylethyl) -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (25
mg), dehydrated dichloromethane (0.5 ml) and triethylamine (14 μl) were added dropwise mesylic acid chloride (5 μl) under ice cooling, and the mixture was stirred at 0 ° C. for 10 minutes. After confirming disappearance of the raw materials, the solvent in the reaction mixture was distilled off by spraying. Dioxane (0.
2 ml) and morpholine (44 μl) as an amine were added and stirred at 60 ° C. for 6 hours. The reaction mixture was concentrated under reduced pressure, 0.5N aqueous sodium hydroxide solution was added to the resulting residue, and the mixture was extracted with ethyl acetate. The residue obtained by concentrating the organic layer was purified by NH silica gel column chromatography (hexane-ethyl acetate) to give the title compound (1
7 mg, 60%) was obtained as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.22 (3H, s), 2.3
1 (3H, s), 2.47-2.62 (8H, m), 3.70-3.73 (6H, m),
3.74 (3H, s), 5.62 (2H, s), 6.65 (1H, s), 7.46 (1H
, S), 8.18 (1H, s).
ESI-MS m / z: 568 (M + H) ⁺
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2
-Morpholin-4-ylethyl) -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-morpholin-4-ylethyl) -2,7-dihydro-6-thia-1 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (17
mg) in the same manner as in Example 111, and the title compound (11.6 mg, 68
%) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.4
7-2.61 (8H, m), 3.70-3.73 (6H, m), 3.74 (3H, s),
5.16 (2H, s), 5.50 (2H, s), 6.60 (1H, s), 8.19 (1H
, S).
ESI-MS m / z: 468 (M + H) ⁺
(Example 136)
1) tert-butyl {8- [2- (dimethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia- 1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (27
mg) and a 2N dimethylamine tetrahydrofuran solution (0.2 ml) as an amine, and was synthesized in the same manner as in Example 135 to obtain the title compound (17 mg, 60%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.21 (3H, s), 2.2
6 (6H, s), 2.30 (3H, s), 2.51 (2H, s), 3.72-3.75 (
5H, m), 5.62 (2H, s), 6.65 (1H, s), 7.46 (1H, s), 8
. 18 (1H, s).
ESI-MS m / z: 526 (M + H) ⁺
2) 8- [2- (Dimethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2, 3,5-tetraazabenzo [cd] azulen-4-amine

Tert-Butyl {8- [2- (dimethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (17 m
g), and the title compound (7.9 mg, 57%) was synthesized in the same manner as in Example 111.
Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.26 (6H, s), 2.2
8 (3H, s), 2.47-2.51 (4H, m), 3.70 (2H, s), 3.74 (
3H, s), 5.14 (2H, brs), 5.49 (2H, s), 6.60 (1H, s)
, 8.19 (1H, s).
ESI-MS m / z: 426 (M + H) ⁺
(Example 137)
1) tert-butyl {8- [2- (1H-imidazol-1-yl) ethyl] -2-
[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} Carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (27
mg) and imidazole (37 mg) as an amine in the same manner as in Example 135 to give the title compound (11 mg, 37%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.22 (3H, s), 2.3
1 (3H, s), 2.80 (2H, t, J = 7.1 Hz), 3.67 (2H, s), 3.
75 (3H, s), 4.19 (2H, t, J = 7.1 Hz), 5.61 (2H, s), 6
. 58-6.58 (1H, m), 6.95 (1H, t, J = 1.2 Hz), 7.04 (1
H, t, J = 1.2 Hz), 7.45 (1H, s), 7.49-7.52 (1H, m),
8.17 (1H, s).
ESI-MS m / z: 549 (M + H) ⁺
2) 8- [2- (1H-imidazol-1-yl) ethyl] -2-[(4-methoxy-3)
, 5-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,
3,5-tetraazabenzo [cd] azulen-4-amine

The above tert-butyl {8- [2- (1H-imidazol-1-yl) ethyl] -2
-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl } Using carbonate (11 mg), the title compound (6.1) was synthesized in the same manner as in Example 111.
mg, 68%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.7
8 (2H, t, J = 7.0 Hz), 3.65 (2H, s), 3.74 (3H, s), 4.
18 (2H, t, J = 7.0 Hz), 5.16 (2H, brs), 5.49 (2H, s)
6.52 (1H, s), 6.95-6.96 (1H, m), 7.04-7.04 (1H
, M), 7.51 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 449 (M + H) ⁺
(Example 138)
1) tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- [2- (methylamino) ethyl] -2,7-dihydro-6-thia- 1,
2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (27
mg) and a 2N methylamine tetrahydrofuran solution (0.2 ml) as an amine in the same manner as in Example 135 to give the title compound (9 mg, 33%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.22 (3H, s), 2.3
1 (3H, s), 2.45 (3H, s), 2.54 (2H, t, J = 6.7 Hz), 2.
83 (2H, t, J = 6.7 Hz), 3.72 (2H, s), 3.74 (3H, s), 5
. 62 (2H, s), 6.66 (1H, s), 7.50 (1H, brs), 8.18 (1
H, s).
ESI-MS m / z: 512 (M + H) ⁺
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- [2
-(Methylamino) ethyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- [2- (methylamino) ethyl] -2,7-dihydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (9 mg)
Was used in the same manner as in Example 111 to obtain the title compound (7.4 mg, 100%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.4
5 (3H, s), 2.53 (2H, t, J = 6.5 Hz), 2.82 (2H, t, J = 6)
. 5Hz), 3.69 (2H, s), 3.74 (3H, s), 5.16 (2H, brs)
, 5.50 (2H, s), 6.61 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 412 (M + H) ⁺
(Example 139)
1) tert-butyl {8- [2- (ethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia- 1,
2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and a 2N ethylamine tetrahydrofuran solution (0.5 ml) as an amine, and was synthesized in the same manner as in Example 135 to obtain the title compound (17 mg, 56%) as an oil.
ESI-MS m / z: 526 (M + H) ⁺
2) 8- [2- (Ethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2, 3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {8- [2- (ethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (17 mg
The title compound (4.4 mg, 31%) was obtained as a solid by triturating with diethyl ether in the same manner as in Example 111.
¹ H-NMR (CDCl ₃ ) δ: 1.31 (3H, t, J = 7.2 Hz), 2.21 (3
H, s), 2.28 (3H, s), 2.75 (2H, t, J = 7.6 Hz), 2.97 (
2H, q, J = 7.2 Hz), 3.07 (2H, t, J = 7.6 Hz), 3.69 (2H
, S), 3.74 (3H, s), 5.26 (2H, brs), 5.48 (2H, s), 6
. 61 (1H, s), 8.18 (1H, s), 8.46 (1H, brs).
ESI-MS m / z: 426 (M + H) ⁺
(Example 140)
1) tert-butyl {8- [2- (cyclopropylamino) ethyl] -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and cyclopropylamine (20 μl) as an amine and tetrahydrofuran (0.5 ml) as a reaction solvent for the amination reaction, and synthesized in the same manner as in Example 135 to give the title compound (16 mg, 51%) as an oil Got as.
ESI-MS m / z: 538 (M + H) ⁺
2) 8- [2- (Cyclopropylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2 , 3,5-
Tetraazabenzo [cd] azulen-4-amine

Tert-Butyl {8- [2- (cyclopropylamino) ethyl] -2-[(4
-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-
Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (
16 mg) and the title compound (6.3 mg, 4
8%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 0.60-0.66 (2H, m), 0.69-0.74
(2H, m), 2.22 (3H, s), 2.29 (3H, s), 2.32-2.38 (1
H, m), 2.66 (2H, t, J = 7.5 Hz), 3.09 (2H, t, J = 7.5H)
z), 3.70 (2H, s), 3.75 (3H, s), 5.33 (2H, brs), 5.
49 (2H, s), 6.62 (1H, s), 8.19 (1H, s), 8.26 (1H, b
rs).
ESI-MS m / z: 438 (M + H) ⁺
(Execution 141)
1) tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-pyrrolidin-1-ylethyl) -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and pyrrolidine (24 μl) as an amine and tetrahydrofuran (0.5 ml) as a reaction solvent for the amination reaction, were synthesized in the same manner as in Example 135, and the title compound (1
1 mg, 34%) was obtained as an oil.
ESI-MS m / z: 552 (M + H) ⁺
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2
-Pyrrolidin-1-ylethyl) -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-pyrrolidin-1-ylethyl) -2,7-dihydro-6-thia-1 , 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (11
mg), and the title compound (4.8 mg, 53%) was synthesized in the same manner as in Example 111.
) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.99-2.03 (4H, m), 2.22 (4H, s
), 2.29 (3H, s), 2.73-2.79 (2H, m), 3.06-3.12 (6
H, m), 3.73 (2H, s), 3.74 (3H, s), 5.19 (2H, brs),
5.49 (2H, s), 6.59 (1H, s), 8.19 (1H, s), 8.47 (1H
, Brs).
ESI-MS m / z: 452 (M + H) ⁺
(Example 142)
1) tert-butyl {8- [2- (isopropylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia- 1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and isopropylamine (25 μl) as the amine and tetrahydrofuran (0.5 ml) as the reaction solvent for the amination reaction, and synthesized in the same manner as in Example 134 to give the title compound (16 mg, 51%) as an oil Obtained.
ESI-MS m / z: 540 (M + H) ⁺
2) 8- [2- (Isopropylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2, 3,5-tetraazabenzo [cd] azulen-4-amine

The above tert-butyl {8- [2- (isopropylamino) ethyl] -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (1
6 mg), and the title compound (4.4 mg, 36) was synthesized in the same manner as in Example 111.
%) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.07 (6H, d, J = 6.1 Hz), 2.22 (3
H, s), 2.30 (3H, s), 2.54 (2H, t, J = 6.5 Hz), 2.80-
2.88 (3H, m), 3.70 (2H, s), 3.74 (3H, s), 5.12 (2H
, Brs), 5.50 (2H, s), 6.62 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 440 (M + H) ⁺
(Example 143)
1) tert-butyl {8- [2- (cyclobutylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia -1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and cyclobutylamine (25 μl), tetrahydrofuran (0.5
ml) and the title compound (20 mg, 62%) was obtained as an oil.
ESI-MS m / z: 552 (M + H) ⁺
2) 8- [2- (Cyclobutylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2 , 3,5-tetraazabenzo [cd] azulen-4-amine

The above tert-butyl {8- [2- (cyclobutylamino) ethyl] -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (2
Was synthesized in the same manner as in Example 111, and the title compound (8.0 mg, 49
%) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.74-1.59 (4H, m), 2.19-2.23
(2H, m), 2.22 (3H, s), 2.30 (3H, s), 2.50 (2H, t, J
= 6.8 Hz), 2.77 (2H, t, J = 6.8 Hz), 3.24-3.32 (1H,
m), 3.69 (2H, s), 3.74 (3H, s), 5.15 (2H, brs), 5.
50 (2H, s), 6.61 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 452 (M + H) ⁺
(Example 144)
1) tert-butyl (2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- {2-[(3R) -tetrahydrofuran-3-ylamino] ethyl}-
2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4
-Il) Carbanate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg), (R) -3-aminotetrahydrofuran p-toluenesulfonate (91 mg), diisopropylethylamine (50 μl) as an amine, and dehydrated dimethylformamide (0.5 ml) as a reaction solvent for the amination reaction The title compound (10 mg, 30%) was obtained as an oil by synthesis in the same manner as in 135.
ESI-MS m / z: 568 (M + H) ⁺
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- {2
-[(3R) -tetrahydrofuran-3-ylamino] ethyl} -2,7-dihydro-6
-Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

The above tert-butyl (2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- {2-[(3R) -tetrahydrofuran-3-ylamino] ethyl}
-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-
The title compound (6.0 mg, 73%) was obtained as an amorphous form by synthesis in the same manner as in Example 111 using 4-yl) carbonate (10 mg).
¹ H-NMR (CDCl ₃ ) δ: 1.68-1.76 (1H, m), 2.04-2.14
(1H, m), 2.22 (3H, s), 2.30 (3H, s), 2.53 (2H, t, J
= 6.5 Hz), 2.80-2.88 (2H, m), 3.37-3.43 (1H, m),
3.57 (1H, dd, J = 8.9, 4.0 Hz), 3.70 (2H, d, J = 3.7H)
z), 3.74 (3H, s), 3.75-3.84 (2H, m), 3.87-3.93 (
1H, m), 5.14 (2H, brs), 5.50 (2H, s), 6.62 (1H, s)
, 8.19 (1H, s).
ESI-MS m / z: 468 (M + H) ⁺
(Example 145)
1) tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-piperidin-1-ylethyl) -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg), piperidine (29 μl), and tetrahydrofuran (0.5 ml) as a reaction solvent were synthesized in the same manner as in Example 135 to obtain the title compound (25 mg, 75%) as an oil.
ESI-MS m / z: 566 (M + H) ⁺
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2
-Piperidin-1-ylethyl) -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- (2-piperidin-1-ylethyl) -2,7-dihydro-6-thia-1 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (25
mg), and the title compound (16.8 mg, 83) was synthesized in the same manner as in Example 111.
%) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.40-1.47 (2H, m), 1.56-1.62
(4H, m), 2.21 (3H, s), 2.28 (3H, s), 2.39-2.46 (4
H, m), 2.48-2.56 (4H, m), 3.70 (2H, s), 3.74 (3H,
s), 5.23 (2H, brs), 5.49 (2H, s), 6.58 (1H, s), 8.
19 (1H, s).
ESI-MS m / z: 466 (M + H) ⁺
(Example 146)
1) tert-butyl {8- [2- (3-fluoroazetidin-1-yl) ethyl]-
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4- Il} Carbanate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and amine as 3-fluoroazetidine hydrochloride (23 mg), 1,8-diazabicyclo [5.4.0] -7-undecene (26 μl), dehydrated dimethyl sulfoxide (0.5 ml) as a reaction solvent for amination reaction ) To give the title compound (9 mg, 27%) as an oil.
ESI-MS m / z: 556 (M + H) ⁺
2) 8- [2- (3-Fluoroazetidin-1-yl) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6 -Chia-1,
2,3,5-tetraazabenzo [cd] azulen-4-amine

The above tert-butyl {8- [2- (3-fluoroazetidin-1-yl) ethyl]-
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4- Yl} carbonate (9 mg) was synthesized in the same manner as in Example 111, and the title compound (4.6
mg, 65%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 2.3
7 (2H, t, J = 7.3 Hz), 2.72 (2H, t, J = 7.3 Hz), 3.09−
3.19 (2H, m), 3.65-3.75 (2H, m), 3.68 (2H, s), 3.
74 (3H, s), 5.00-5.20 (1H, m), 5.11 (2H, s), 5.50
(2H, s), 6.58 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 456 (M + H) ⁺
(Example 147)
1) tert-butyl {8- [2- (diethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and diethylamine (90 μl), tetrahydrofuran (0.5 ml) as a reaction solvent
) To give the title compound (14 mg, 44%) as an oil.
ESI-MS m / z: 554 (M + H) ⁺
2) 8- [2- (Diethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3 , 5-Tetraazabenzo [cd] azulen-4-amine

Tert-butyl {8- [2- (diethylamino) ethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate (14 m
g), and the title compound (8.9 mg, 77%) was synthesized in the same manner as in Example 111.
Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.03 (6H, t, J = 7.2 Hz), 2.22 (3
H, s), 2.28 (3H, s), 2.47 (2H, dd, J = 9.2, 6.2 Hz),
2.56 (4H, q, J = 7.2 Hz), 2.68 (2H, dd, J = 9.2, 6.2H)
z), 3.70 (2H, s), 3.74 (3H, s), 5.15 (2H, s), 5.49.
(2H, s), 6.58 (1H, s), 8.20 (1H, s).
ESI-MS m / z: 454 (M + H) ⁺
(Example 148)
1) tert-butyl {8- (2-azetidin-1-ylethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbonate

Tert-Butyl {8- (2-hydroxyethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 of Example 134 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (29
mg) and azetidine hydrochloride (27 mg) as amine, 1,8-diazabicyclo [5.4
. 0] -7-undecene (39 μl) and dehydrated dimethyl sulfoxide (0.5 ml) as a reaction solvent for the amination reaction were synthesized in the same manner as in Example 135, and the title compound (10
mg, 31%) was obtained as an oil.
ESI-MS m / z: 538 (M + H) ⁺
2) 8- (2-Azetidin-1-ylethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2, 3,5-tetraazabenzo [cd] azulen-4-amine

Tert-butyl {8- (2-azetidin-1-ylethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 , 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbonate (10
mg), and the title compound (7.7 mg, 75%) was synthesized in the same manner as in Example 111.
) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.03-2.10 (2H, m), 2.22 (3H, s
), 2.28 (3H, s), 2.33 (2H, t, J = 7.6 Hz), 2.60 (2H,
t, J = 7.4 Hz), 3.20 (4H, t, J = 7.0 Hz), 3.68 (2H, s)
, 3.74 (3H, s), 5.11 (2H, s), 5.49 (2H, s), 6.57 (1
H, s), 8.19 (1H, s).
ESI-MS m / z: 438 (M + H) ⁺
(Example 149)
2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,9,10
, 11-Tetrahydro-2H-8-oxa-6-thia-1,2,3,5-tetraazadibenzo [cd, h] azulen-4-amine

4-di (tert-butoxycarbonyl) amino-2- (4-methoxy- of Example 40
3,5-dimethyl-pyridin-2-ylmethyl) -8-oxo-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene (40 mg),
A mixture consisting of 1,3-dibromopropane (11 μl), potassium carbonate (19 mg) and dimethyl sulfoxide (0.5 ml) was stirred at room temperature for 20 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the organic layer was washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 m) was added to the resulting residue.
l) and trifluoroacetic acid (0.5 ml) were added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel thin layer chromatography (chloroform-methanol) to obtain the title compound (13.3 mg, 46%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.94 (2H, tt, J = 6.4, 5.0 Hz), 2
. 23 (3H, s), 2.33 (3H, s), 2.50 (2H, t, J = 6.4 Hz),
3.69 (2H, s), 3.76 (3H, s), 4.10 (2H, t, J = 5.0 Hz)
, 5.41 (2H, brs), 5.48 (2H, s), 8.19 (1H, s).
ESI-MS m / z: 411 (M + H) ⁺
(Example 150)
1) Di-tert-butyl {9,9-difluoro-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro- 6
-Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

4-di (tert-butoxycarbonyl) amino-2- (4-methoxy- of Example 40
3,5-dimethyl-pyridin-2-ylmethyl) -8-oxo-2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene (57 mg) and To a mixture of dehydrated dimethylformamide (1.5 ml) was added 60% sodium hydride (8 mg) under ice-cooling, and the mixture was stirred at 0 ° C. for 15 minutes, and then N-fluorobenzenesulfimide (63 mg) (0.5 ml) The solution was added dropwise and stirred at 0 ° C. for 20 minutes. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the organic layer was washed with water. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The title compound (83 mg) was obtained as an oil as a residue. The resulting product contained impurities but was used in the next reaction as it was.
2) 4-Amino-9,9-difluoro-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1, 2,3,5-
Tetraazabenzo [cd] azulen-8-ol

Di-tert-butyl {9,9-difluoro-2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -8-oxo-2,7,8,9-tetrahydro-
To a mixture of 6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (41 mg) and methanol (2 ml) was added sodium borohydride (6 mg) under ice-cooling. And stirred at 0 ° C. for 30 minutes. Add water to the reaction mixture,
Extracted with ethyl acetate. The organic layer was washed with water. The organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. Dichloromethane (2 ml) and trifluoroacetic acid (0.5 ml) were added to the obtained residue, and the mixture was stirred at room temperature for 4 hours. The residue obtained by concentrating the reaction mixture under reduced pressure was purified by reverse phase liquid chromatography to give the title compound (8.7 mg, 42% in total from Example 110) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.31 (3H, s), 3.4
7 (2H, dd, J = 15.9, 7.6 Hz), 3.53 (1H, d, J = 15.9 Hz)
), 3.75 (3H, s), 4.59-4.66 (1H, m), 5.34 (2H, brs)
), 5.57 (2H, s), 8.14 (1H, s).
ESI-MS m / z: 409 (M + H) ⁺
(Example 151)
1) 1- (2-Amino-4,6-dichloropyrimidin-5-yl) prop-2-en-1
-All

2-Amino-4,6-dichloropyrimidine-5-carbaldehyde (100 g) was suspended in tetrahydrofuran (4000 ml), and 1N tetrahydrofuran solution (2200 g) of vinylmagnesium bromide was added dropwise under ice cooling. To 2 hours under ice-cooling. Water (2000 ml) was added to the reaction mixture, 1N aqueous hydrochloric acid solution (2500 ml) was added to make the solution acidic, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated. Methanol was added to the resulting residue and stirred for 1 hour. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate-chloroform) to give the title compound (50 g, 49%) as a solid.
ESI-MS m / z: 220 (M + H) ⁺ .
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2H-6
-Thia-1,2,3,5-tetraazaacenaphthylene-4-amine

1- (2-Amino-4,6-dichloropyrimidin-5-yl) prop-2-ene-
The title compound was synthesized by applying the same method as in Example 1-7), Example 32, Example 35, and Example 36 to 1-ol.
ESI-MS m / z: 341 (M + H) ⁺ .
¹ H-NMR (CDCl ₃ ) δ: 8.22 (1H, s), 7.06 (1H, d, J = 9.
8 Hz), 6.72 (1 H, d, J = 9.8 Hz), 5.45 (2 H, s), 5.15 (
2H, brs), 3.74 (3H, s), 2.29 (3H, s), 2.23 (3H, s)
.
(Example 152)
1) 4-Chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1- (4-methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidine- 6-amine

Under cooling in an ice bath, 1- (2-amino-4,6-dichloropyrimidin-5-yl) -2- (2
, 2-Dimethyl- [1,3] dioxolan-4-yl) ethane-1-one (16 g), (
4-methoxybenzyl) -hydrazine hydrochloride (14.1 g) and dichloromethane (40
0 ml) was added to a solution of triethylamine (29.1 ml) in dichloromethane (
100 ml) was added over 15 minutes. After stirring for 1.5 hours under cooling in an ice bath, 0.2N aqueous hydrochloric acid (1000 ml) was added to the reaction mixture, and the mixture was extracted with dichloromethane (400 ml). The organic layer was washed with saturated brine (500 ml) and dried over anhydrous magnesium sulfate. After filtration, the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (ethyl acetate-chloroform) to obtain the title compound (16.5 g, 78%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.36 (4H, s), 1.43 (3H, s), 3.1
0 (1H, dd, J = 14.6, 8.2 Hz), 3.43 (1H, dd, J = 14.6,
5.4 Hz), 3.75 (1H, dd, J = 8.3, 6.6 Hz), 3.77 (3H, s
), 4.07 (1H, dd, J = 8.3, 5.9 Hz), 4.54-4.61 (1H, m
), 5.22 (2H, s), 5.30 (2H, s), 6.82 (2H, d, J = 8.5H)
z), 7.24 (2H, d, J = 8.5 Hz).
ESI-MS m / z: 404 (M + H) ^<+> .
2) Di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1- (4-methoxybenzyl) -1H-pyrazolo [3 4
-D] pyrimidin-6-yl} imide dicarbonate

4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1- (4-methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidine-6 −
To a mixture of amine (16.5 g) and tetrahydrofuran (400 mL) was added 4-dimethylaminopyridine (500 mg) and di-tert-butyl dicarbonate (53.5 g).
) And then stirred at room temperature for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (22 g, 89%) as an oil. .
¹ H-NMR (CDCl ₃ ) δ: 1.37 (3H, s), 1.40 (3H, s), 1.4
5 (18H, s), 3.25 (1H, dd, J = 15.1, 7.1 Hz), 3.52 (1
H, dd, J = 15.1, 5.0 Hz), 3.73-3.81 (1H, m), 3.77 (
3H, s), 4.12 (1H, t, J = 7.1 Hz), 4.58-4.66 (1H, m)
, 5.46 (1H, d, J = 15.1 Hz), 5.51 (1 H, d, J = 15.1 Hz)
6.81 (2H, d, J = 7.8 Hz), 7.28 (2H, d, J = 7.8 Hz).
ESI-MS m / z: 604 (M + H) ⁺ .
3) Di-tert-butyl {4-chloro-3- (2,3-dihydroxypropyl) -1
-(4-Methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

Di-tert-butyl {4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl) methyl] -1- (4-methoxybenzyl) -1H-pyrazolo [3
4-d] pyrimidin-6-yl} imide dicarbonate (22 g) with methanol (400
p-toluenesulfonic acid pyridine salt (10 g) was added and stirred at room temperature for 16 hours. The reaction mixture was concentrated, water (100 ml) was added to the resulting residue, and ethyl acetate (50 ml) was added.
0 ml). The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (19.5 g, 95%) as amorphous.
ESI-MS m / z: 564 (M + H) ^<+> .
4) Di-tert-butyl {4-chloro-3- (2-hydroxyethyl) -1- (4-
Methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate

Under cooling in an ice bath, the above di-tert-butyl {4-chloro-3- (2,3-dihydroxypropyl) -1- (4-methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidine-6- Yl} imide dicarbonate (10 g), tetrahydrofuran (100 ml), methanol (100 ml) and water (100 ml) were added to sodium periodate (
19 g) was added and stirred at room temperature for 1 hour. Water (600 mL) and ethyl acetate (400 mL) were added to the reaction mixture to separate the layers. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Methanol (200 m
L) was added, and sodium borohydride (1000 mg) was added under ice bath cooling, followed by stirring for 1 hour. Water (400 ml) was added to the reaction mixture, followed by extraction twice with ethyl acetate (300 ml), and the organic layer was washed with saturated brine. After drying over anhydrous sodium sulfate and filtration, the filtrate was concentrated under reduced pressure and the solvent was evaporated to give the title compound (8.5 g, 90%) as an oil.
ESI-MS m / z: 534 (M + H) ^<+> .
5) Di-tert-butyl {2- (4-methoxybenzyl) -7,8-dihydro-2H
-6-thia-1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate

Di-tert-butyl {4-chloro-3- (2-hydroxyethyl) -1- (4
-Methoxybenzyl) -1H-pyrazolo [3,4-d] pyrimidin-6-yl} imide dicarbonate (8.5 g) was dissolved in dichloromethane (100 ml), triethylamine (4.5 ml) was added, and the mixture was cooled in an ice bath. Methanesulfonyl chloride (1.9 ml) was added and stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane and ethyl acetate, washed with water,
The organic layer was dried over anhydrous sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in N, N-dimethylformamide (100 mL), sodium hydrogen sulfide monohydrate (1.5 g) was added under ice bath cooling, the ice bath was removed, and the mixture was stirred for 1 hr. After potassium carbonate (3.3 g) was added to the reaction mixture, the mixture was further stirred for 16 hours. Water (1000
ml) and extracted twice with dichloromethane (500 ml). The organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (6.0 g, 74%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.46 (18H, s), 3.23 (2H, t, J = 6
. 1 Hz), 3.50 (2H, t, J = 6.1 Hz), 3.77 (3H, s), 5.44
(2H, s), 6.82-6.84 (2H, m), 7.28-7.31 (2H, m).
ESI-MS m / z: 514 (M + H) ^<+> .
6) 7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-
4-amine

Di-tert-butyl {2- (4-methoxybenzyl) -7,8-dihydro-2
H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-yl} imide dicarbonate (6.0 g) was added with anisole (2.5 ml) and trifluoroacetic acid (30 ml) at room temperature. And then stirred at 55 ° C. for 6 hours. The reaction solution was concentrated under reduced pressure, and ethyl acetate was added to the resulting residue and stirred. The precipitated solid was filtered and washed with ethyl acetate to obtain the title compound (1.75 g, 78%) as a solid.
¹ H-NMR (DMSO-D ₆ ) δ: 3.06 (2H, s), 3.52 (2H, s).
ESI-MS m / z: 194 (M + H) ⁺ .
7) 2- (Quinolin-2-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,
3,5-tetraazaacenaphthylene-4-amine

7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (30 mg), 2- (chloromethyl) quinoline hydrochloride (51 mg), potassium carbonate ( 98 mg) and dimethylformamide (1 mL) were stirred at 60 ° C. overnight. The insoluble material was filtered off, the solvent was evaporated under a nitrogen stream, and the residue was purified by reverse phase liquid chromatography (acetonitrile-formic acid) to give the title compound (19 mg, 35%
) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.15 (2H, t, J = 6.1 Hz), 3.46 (2
H, t, J = 6.1 Hz), 5.44 (2H, s), 5.68 (2H, s), 7.17 (
1H, d, J = 8.5 Hz), 7.52 (1H, dd, J = 7.6, 7.6 Hz), 7.
69-7.78 (2H, m), 8.11-8.07 (2H, m).
ESI-MS m / z: 335 (M + H) ^<+> .
(Example 153)
2- (Isoquinolin-3-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,
3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (30 mg) and 2- (chloromethyl) isoquinoline hydrochloride of Example 152-6) ( 49 mg) in the same manner as in Example 152-7), and the title compound (19 mg,
35%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.16 (2H, t, J = 6.1 Hz), 3.47 (2
H, t, J = 6.1 Hz), 5.42 (2H, s), 5.65 (2H, s), 7.45 (
1H, s), 7.57 (1H, dd, J = 8.0, 8.0 Hz), 7.66 (1H, dd
, J = 8.0, 8.0 Hz), 7.75 (1H, d, J = 8.0 Hz), 7.95 (1H
, D, J = 8.0 Hz), 9.23 (1H, s).
ESI-MS m / z: 335 (M + H) ^<+> .
(Example 154)
2-[(3-Bromo-6-ethoxypyridin-2-yl) methyl] -7,8-dihydro-
2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 3-bromo-2-bromomethyl-6ethoxy of Example 152-6) The title compound (2 mg, 4%) was obtained as an amorphous form in the same manner as in Example 152-7) using pyridine odorate (59 mg).
¹ H-NMR (CDCl ₃ ) δ: 1.41 (3H, t, J = 7.0 Hz), 3.19-3
. 13 (1H, m), 3.48-3.45 (1H, m), 3.79 (1H, q, J = 7.
0 Hz), 4.00 (1H, brs), 4.38 (2H, q, J = 7.0 Hz), 4.6
7 (2H, s), 6.58 (1H, d, J = 8.6 Hz), 7.68 (1H, d, J = 8)
. 6 Hz).
ESI-MS m / z: 407 (M + H) ^<+> .
(Example 155)
2-[(5-Methylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-5-methylpyridine hydrochloride of Example 152-6) The title compound (5 mg) was prepared in the same manner as in Example 152-7) using the salt (38 mg).
, 14%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.38 (3H, s), 3.14 (2H, t, J = 6.
1 Hz), 3.45 (2H, t, J = 6.1 Hz), 5.47 (2H, s), 7.00 (
1H, d, J = 7.8 Hz), 7.44 (1H, d, J = 7.8 Hz), 8.24 (1H
, S), 8.41 (1H, s).
ESI-MS m / z: 299 (M + H) ^<+> .
(Example 156)
2-[(5-Bromopyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-5-bromopyridine hydrochloride of Example 152-6) The title compound (8 mg) was prepared in the same manner as in Example 152-7) using the salt (38 mg).
16%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.15 (2H, t, J = 6.0 Hz), 3.46 (2
H, t, J = 6.0 Hz), 5.20 (2H, s), 5.45 (2H, s), 7.01 (
1H, d, J = 8.3 Hz), 7.75 (1H, dd, J = 8.3, 2.2 Hz), 8.
63 (1H, d, J = 2.2 Hz).
ESI-MS m / z: 363 (M + H) ⁺ .
(Example 157)
2-[(5-Bromo-3-methylpyridin-2-yl) methyl] -7,8-dihydro-2
H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2-chloromethyl-3-methyl-5 -The title compound (40 mg) was used in the same manner as in Example 152-7) using
4 mg, 8%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.38 (3H, s), 3.12 (2H, t, J = 6.
1 Hz), 3.44 (2H, t, J = 6.1 Hz), 5.23 (2H, s), 5.43 (
2H, s), 7.63 (1H, s), 8.45 (1H, s).
ESI-MS m / z: 377 (M + H) ^<+> .
(Example 158)
2-[(3,4-Dimethoxypyridin-2-yl) methyl] -7,8-dihydro-2H-
6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-3,4-dimethoxy of Example 152-6) The title compound (4 mg, 9%) was obtained as an amorphous form in the same manner as in Example 152-7) using pyridine hydrochloride (35 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.12 (2H, t, J = 6.1 Hz), 3.43 (2
H, t, J = 6.1 Hz), 3.84 (3H, s), 3.91 (3H, s), 5.51 (
2H, s), 6.79 (1H, d, J = 5.4 Hz), 8.03 (1H, s), 8.18
(1H, d, J = 5.4 Hz).
ESI-MS m / z: 345 (M + H) ^<+> .
(Example 159)
2- (1,3-Benzothiazol-2-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2-bromomethylbenzothiazole (59
mg)) and the title compound (15 mg, 34%
) Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.18 (2H, t, J = 6.1 Hz), 3.47 (2
H, t, J = 6.1 Hz), 5.26 (2H, s), 5.78 (2H, s), 7.38-
7.37 (1H, m), 7.47-7.45 (1H, m), 7.81 (1H, d, J = 8)
. 0 Hz), 8.03 (1H, d, J = 8.3 Hz).
ESI-MS m / z: 341 (M + H) ⁺ .
(Example 160)
2-[(3,5-Dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6
-Thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-3,5-dimethyl of Example 152-6) The title compound (5 mg, 12%) was obtained as an amorphous form in the same manner as in Example 152-7) using -pyridine hydrochloride (50 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.26 (3H, s), 2.34 (3H, s), 3.1
2 (2H, t, J = 6.1 Hz), 3.42 (2H, t, J = 6.1 Hz), 5.15−
5.10 (2H, m), 5.45 (2H, s), 7.18 (1H, s), 8.24 (1H
, S).
ESI-MS m / z: 313 (M + H) ^<+> .
(Example 161)
2- [4-Chloro-3- (trifluoromethyl) benzyl] -7,8-dihydro-2H-
6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 1-chloro-4-chloromethyl-2 of Example 152-6) -In the same manner as in Example 152-7) using trifluoromethylbenzene (60 mg),
The title compound (5 mg, 10%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.13 (2H, t, J = 6.1 Hz), 3.45 (2
H, t, J = 6.1 Hz), 5.18 (2H, s), 5.35 (2H, s), 7.46-
7.43 (2H, m), 7.68-7.68 (1H, m).
ESI-MS m / z: 386 (M + H) ^<+> .
(Example 162)
2- [2-Methyl-5- (trifluoromethyl) benzyl] -7,8-dihydro-2H-
6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-1-methyl-4 of Example 152-6) -In the same manner as in Example 152-7) using trifluoromethylbenzene (56 mg),
The title compound (5 mg, 10%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.14 (2H, t, J = 6.1 Hz), 3.46 (2
H, t, J = 6.1 Hz), 5.17 (2H, s), 5.36 (2H, s), 7.29 (
1H, d, J = 8.0 Hz), 7.38 (1H, s), 7.44 (1H, d, J = 8.0)
Hz).
ESI-MS m / z: 366 (M + H) ^<+> .
(Example 163)
2- (3,4-Dichlorobenzyl) -7,8-dihydro-2H-6-thia-1,2,3
5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 1,2-dichloro-4-chloromethyl of Example 152-6) -In the same manner as in Example 152-7) using benzene (51 mg), the title compound (5 m
g, 10%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.14 (2H, t, J = 6.1 Hz), 3.45 (2
H, t, J = 6.1 Hz), 5.17 (2H, s), 5.29 (2H, s), 7.15 (
1H, dd, J = 8.2, 2.1 Hz), 7.40-7.38 (2H, m).
ESI-MS m / z: 352 (M + H) ^<+> .
(Example 164)
2-[(4-Methoxy-3-methylpyridin-2-yl) methyl] -7,8-dihydro-
2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 2-chloromethyl-4-methoxy-3 of Example 152-6) -The title compound (5 mg, 12%) was obtained as an amorphous form in the same manner as in Example 152-7) using -methyl-pyridine hydrochloride (45 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 3.12 (2H, t, J = 6.
1 Hz), 3.43 (2H, t, J = 6.1 Hz), 3.86 (3H, s), 5.46 (
2H, s), 6.71 (1H, d, J = 5.6 Hz), 8.30 (1H, d, J = 5.6)
Hz).
ESI-MS m / z: 329 (M + H) ⁺ .
(Example 165)
3-[(4-Amino-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-2-yl) methyl] -1-methylquinoline-2 (1H) -ON

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (15 mg) and 3-chloromethyl-1-methyl-1H of Example 152-6) -The title compound (5 mg, 18%) was obtained as amorphous in the same manner as in Example 152-7) using quinolin-2-one (33 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.18 (2H, t, J = 6.2 Hz), 3.48 (2
H, t, J = 6.2 Hz), 3.75 (3H, s), 5.30 (2H, s), 5.40 (
2H, s), 7.20 (1H, dd, J = 7.8, 7.8 Hz), 7.32 (1H, s)
7.35 (1H, d, J = 8.7 Hz), 7.48 (1H, dd, J = 7.8, 1.4)
Hz), 7.57-7.52 (1 H, m).
ESI-MS m / z: 365 (M + H) ^<+> .
(Example 166)
2- (2,3-Dihydro-1,4-benzodioxin-6-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (15 mg) and 6-chloromethyl-2,3-dihydro of Example 152-6) -The title compound (5 mg, 19%) was obtained as amorphous in the same manner as in Example 152-7) using benzo [1,4] dioxin (29 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.13 (2H, t, J = 6.0 Hz), 3.43 (2
H, t, J = 6.0 Hz), 4.24-4.22 (4H, m), 5.22 (2H, s),
6.82-6.81 (3H, m).
ESI-MS m / z: 342 (M + H) ^<+> .
(Example 167)
2- (1,3-Benzodioxol-5-ylmethyl) -7,8-dihydro-2H-6
Thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (15 mg) of Example 152-6) and 5-chloromethylbenzo [1,3] The title compound (5m) was prepared in the same manner as in Example 152-7) using dioxole (27mg).
g, 20%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.13 (2H, t, J = 6.2 Hz), 3.44 (2
H, t, J = 6.2 Hz), 5.19 (2H, s), 5.25 (2H, s), 5.92 (
2H, s), 6.75 (1H, d, J = 7.8 Hz), 6.84-6.82 (2H, m)
.
ESI-MS m / z: 328 (M + H) ⁺ .
(Example 168)
6-[(4-Amino-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-2-yl) methyl] -3-methyl-1,3-benzo Oxazole-2 (
3H)-ON

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 6-chloromethyl-3-methyl-3H of Example 152-6) The title compound (5 mg, 14%) was obtained as an amorphous form in the same manner as in Example 152-7) using -benzoxazol-2-one (39 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.13 (2H, t, J = 6.1 Hz), 3.39 (3
H, s), 3.46 (2H, t, J = 6.1 Hz), 5.36 (2H, s), 6.94 (
1H, d, J = 8.1 Hz), 7.23-7.21 (2H, m).
ESI-MS m / z: 355 (M + H) ^<+> .
(Example 169)
2- (1,3-Benzothiazol-6-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 6-chloromethylbenzothiazole (39) from Example 152-6)
mg) and the title compound (5 mg, 14%) in the same manner as in Example 152-7).
Was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.14 (2H, t, J = 6.1 Hz), 3.47 (2
H, t, J = 6.1 Hz), 5.50 (2H, s), 7.52 (1H, d, J = 8.3H)
z), 7.91 (1H, s), 8.07 (1H, d, J = 8.3 Hz), 9.01 (1H
, S).
ESI-MS m / z: 341 (M + H) ⁺ .
(Example 170)
2- (3-Fluoro-2,4-dimethylbe, 3.12 (2H, t, J = 6.1 Hz) ndil) -7,8-dihydro-2H-6-thia-1,2,3,5- Tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 1-chloromethyl-3-fluoro-2 of Example 152-6) , 4
-The title compound (10 mg, 29%) was obtained as amorphous in the same manner as in Example 152-7) using dimethylbenzene (36 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.29 (3H, s), 3.4
4 (2H, t, J = 6.1 Hz), 5.17 (2H, s), 5.30 (2H, s), 6.
81 (1H, d, J = 7.8 Hz), 6.95 (1H, m).
ESI-MS m / z: 330 (M + H) ⁺ .
(Example 171)
2-[(7-Bromo-2,3-dihydro-1,4-benzodioxin-6-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraaza Acenaphthylene
4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 6-bromo-7-chloromethyl-2 of Example 152-6) , 3-
The title compound (5 mg, 12%) was obtained as an amorphous form in the same manner as in Example 152-7) using dihydrobenzo [1,4] dioxin (55 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.16 (2H, t, J = 6.1 Hz), 3.46 (2
H, t, J = 6.1 Hz), 4.20-4.18 (4H, m), 5.16 (2H, s),
5.35 (2H, s), 6.40 (1H, s), 7.09 (1H, s).
ESI-MS m / z: 420 (M + H) ⁺ .
(Example 172)
2- (2,3-dihydro [1,4] dioxino [2,3-c] pyridin-7-ylmethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraaza Acenaphthylene
4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 6-chloromethyl-2,3-dihydro of Example 152-6) -The title compound (2 mg, 5.7%) was obtained as amorphous in the same manner as in Example 152-7) using benzo [1,4] dioxin (39 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.15 (2H, t, J = 6.1 Hz), 3.45 (2
H, t, J = 6.1 Hz), 4.29-4.25 (4H, m), 5.32 (2H, s),
5.37 (2H, s), 6.61 (1H, s), 8.13 (1H, s).
ESI-MS m / z: 343 (M + H) ^<+> .
(Example 173)
2-{[5- (1,3-benzodioxol-5-yl) -1,3-thiazol-2-yl] methyl} -7,8-dihydro-2H-6-thia-1,2, 3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (20 mg) and 5-benzo [1,3] dioxole- of Example 152-6) 5-
The title compound (5 mg, 12%) was obtained as an amorphous form in the same manner as in Example 152-7) using yl-2-chloromethylthiazole (53 mg).
¹ H-NMR (CDCl ₃ ) δ: 3.18 (2H, t, J = 6.1 Hz), 3.48 (2
H, t, J = 6.1 Hz), 5.70 (2H, s), 5.99 (2H, s), 6.85 (
1H, d, J = 8.3 Hz), 7.27 (1H, s), 7.35 (1H, d, J = 1.7)
Hz), 7.39 (1H, dd, J = 8.3, 1.7 Hz).
ESI-MS m / z: 411 (M + H) ⁺ .
(Example 174)
2-[(7-Chloro-1,3-benzothiazol-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4- Amine

7,152-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (10 mg) and 2-bromomethyl-7-chlorobenzothiazole (Example 152-6) 20 mg) and the title compound (2m) in the same manner as in Example 152-7).
g, 10%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 3.19 (2H, t, J = 6.1 Hz), 3.49 (2
H, t, J = 6.1 Hz), 5.24 (2H, s), 5.77 (2H, s), 7.37 (
1H, d, J = 7.8 Hz), 7.42 (1H, dd, J = 7.8, 7.8 Hz), 7.
93 (1H, d, J = 7.8 Hz).
ESI-MS m / z: 375 (M + H) ^<+> .
(Example 175)
2-[(4-Chloro-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4- Amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) and 4-chloro-2-chloromethyl-3 of Example 152-6) , 5-
The title compound (5.1 mg, 11%) was obtained as an amorphous form in the same manner as in Example 152-7) using dimethylpyridine (44 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.32 (3H, s), 2.43 (3H, s), 3.1
2 (2H, t, J = 6.1 Hz), 3.43 (2H, t, J = 6.1 Hz), 5.20 (
2H, brs), 5.49 (2H, s), 8.25 (1H, s).
ESI-MS m / z: 347 (M + H) ^<+> .
(Example 176)
2-[(4-Ethyl-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4- Amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2- Chloromethyl
Example 152- with 4-ethyl-3,5-dimethylpyridine hydrochloride (51 mg)
In the same manner as in 7), the title compound (9.1 mg, 21%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 1.09 (3H, t, J = 7.6 Hz), 2.25 (3
H, s), 2.31 (3H, s), 2.65 (2H, q, J = 7.6 Hz), 3.12 (
2H, t, J = 6.1 Hz), 3.43 (2H, t, J = 6.1 Hz), 5.34 (2H
, S), 5.47 (2H, s), 8.17 (1H, s).
ESI-MS m / z: 341 (M + H) ⁺ .
(Example 177)
2-[(3,4-Dichloro-5-methylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4- Amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2- Chloromethyl
Example 152- with 3,4-dichloro-5-methylpyridine hydrochloride (57 mg)
In the same manner as in 7), the title compound (8.0 mg, 17%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 2.36 (3H, s), 3.14 (2H, t, J = 6.
1 Hz), 3.45 (2H, t, J = 6.1 Hz), 5.22 (2H, s), 5.61 (
2H, s), 8.25 (1H, s).
ESI-MS m / z: 367 (M + H) ^<+> .
(Example 178)
2-[(3-Chloro-4-methoxy-5-methylpyridin-2-yl) methyl] -7,8
-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,152-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2- Chloromethyl
The title compound (16 mg, 34%) was obtained as an amorphous product in the same manner as in Example 152-7) using 3-chloro-4-methoxy-5-methylpyridine hydrochloride (56 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 3.14 (2H, t, J = 6.
1 Hz), 3.45 (2H, t, J = 6.1 Hz), 3.90 (3H, s), 5.26 (
2H, s), 5.58 (2H, s), 8.20 (1H, s).
ESI-MS m / z: 363 (M + H) ⁺ .
(Example 179)
2-[(5-Chloro-4-methoxy-3-methylpyridin-2-yl) methyl] -7,8
-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine

7,8-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-4-amine (25 mg) of Example 152-6) and 2- Chloromethyl
The title compound (16 mg, 34%) was obtained as an amorphous product in the same manner as in Example 152-7) using 5-chloro-4-methoxy-3-methylpyridine hydrochloride (56 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.33 (3H, s), 3.13 (2H, t, J = 6.
1 Hz), 3.44 (2H, t, J = 6.1 Hz), 3.89 (3H, s), 5.19 (
2H, s), 5.44 (2H, s), 8.35 (1H, s).
ESI-MS m / z: 363 (M + H) ⁺ .
(Example 180)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
7-prop-2-yn-1-yl-7,8-dihydro-2H-6-thia-1,2,3,5
-Tetraazaacenaphthylene-7-carbonitrile

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 4 Tetraazaacenaphthylene-7-carbonitrile (50 mg) was dissolved in tetrahydrofuran (5 ml),
2N tetrahydrofuran solution of lithium diisopropylamide at 78 degrees (0.050 m
l) was added, and the mixture was stirred at the same temperature for 15 minutes, then propargyl bromide (0.015 ml) was added, and the mixture was stirred at the same temperature for 3 hours. Water was added to the reaction solution, and the mixture was warmed to room temperature, extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated. The resulting residue was purified by reverse phase liquid chromatography. The obtained solid was mixed with 50% trifluoroacetic acid-dichloromethane solution (1
ml) and stirred for 1 hour. Concentrate the reaction under reduced pressure, azeotrope with ethanol,
The obtained solid was washed with ether to give the title compound (2 mg, 99%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.28 (3H, s), 3.3
4 (1H, dd, J = 16.6, 8.5 Hz), 3.44 (1H, dd, J = 16.6,
4.6 Hz), 3.74 (3H, s), 3.78 (2H, s), 4.49 (1H, dd,
J = 8.5, 4.6 Hz), 5.20 (2H, s), 5.45 (2H, d, J = 3.2H)
z), 8.20 (1H, s).
ESI-MS; m / z: 406 (M + H) ⁺
(Example 181)
1) Di-tert-butyl {8- [cyclopropyl (trifluoroacetyl) amino]
-2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8
, 9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-
4-yl} imide dicarbonate

Di-tert-butyl {8- (cyclopropylamino) -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} To a mixture consisting of imidodicarbonate (3.0 g) and dichloromethane (60 ml) was added a solution of dichloromethane (30 ml) containing trifluoroacetic anhydride (1.55 g) under ice cooling, and the mixture was stirred for 2 hours under ice cooling. . Pour into ice water, extract with ethyl acetate, dry over magnesium sulfate, filter and concentrate. The obtained residue was purified by silica gel column chromatography (ethyl acetate: n-hexane; 1: 1, v / v) to give the title compound (2.9 g, 84%)
Was obtained as a colorless solid.
ESI-MS; m / z: 708 (M + H) ⁺
2) Di-tert-butyl {8- (S)-[cyclopropyl (trifluoroacetyl)
Amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2
, 7,8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate di-tert-butyl {8- (R)-[cyclo Propyl (trifluoroacetyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7
, 8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

Di-tert-butyl {8- [cyclopropyl (trifluoroacetyl) amino]-
2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,
9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4
-Il} imide dicarbonate (1.0 g) was dissolved in ethanol (20 ml), and optical resolution was performed with an AD column 50 × 500 mm (15% ethanol / n-hexane 50.0 ml / min). By repeating this operation three times, di-tert-butyl {8- (S)-
[Cyclopropyl (trifluoroacetyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (
RT = 70 min) (1.3 g, 43%) with di-tert-butyl {8- (R)-[
Cyclopropyl (trifluoroacetyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,
2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (R
T = 130 min) (1.0 g, 33%).
^{3) N} 8 - (S) - cyclopropyl-2 - [(4-methoxy-3,5-dimethyl-2-yl) methyl] -2,7,8,9-tetrahydro-6-thia-1, 2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {8- (S)-[cyclopropyl (trifluoroacetyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,
7,8,9-Tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (400 mg) in hydrochloric acid-methanol (50 ml)
Dissolve in nitrogen, purge with nitrogen, seal and stir at 65 ° C. for 2 days. The reaction mixture was concentrated, diluted with ethyl acetate (300 ml), added with 30 ml of 0.5N aqueous sodium hydroxide solution under ice-cooling, and after separation, the aqueous layer was extracted with ethyl acetate (50 ml). Were combined, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel chromatography (chloroform) to obtain the title compound (150 mg, 65%) as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 0.37-0.48 (4H, m), 2.22 (4H, s
), 2.26 (3H, s), 3.16-3.32 (4H, m), 3.58-3.60 (1
H, brm), 3.73 (3H, s), 5.02 (2H, s), 5.45 (2H, s),
8.19 (1H, s).
(Example 182)
N ⁸ - (R) - cyclopropyl-2 - [(4-methoxy-3,5-dimethyl-pyridin-2
-Yl) methyl] -2,7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4,8-diamine

Di-tert-butyl {8- (R)-[cyclopropyl (trifluoroacetyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,
The title compound (7,8,9-tetrahydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (450 mg) was prepared in the same manner as in Example 181. 150 mg, 57%) was obtained as amorphous.
¹ H-NMR (CDCl ₃ ) δ: 0.35-0.51 (4H, m), 2.19 (4H, s
), 2.27 (3H, s), 3.15-3.32 (4H, m), 3.58-3.62 (1
H, m), 3.74 (3H, s), 5.01 (2H, s), 5.45 (2H, s), 8.
19 (1H, s).
(Example 183)
4-Amino-N-cyclohexyl-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (40 mg) and cyclohexylamine (0.0
In the same manner as in Example 12, the title compound (6 mg, 10%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.11-1.17 (2H, m), 1.30-1.37
(2H, m), 1.55-1.69 (6H, m), 2.26 (3H, s), 2.29 (3
H, s), 3.27 (1H, dd, J = 16.7, 4.3 Hz), 3.60 (1H, dd)
, J = 16.7, 7.7 Hz), 3.69-3.70 (1H, m), 3.80 (3H, s
), 4.34 (1H, dd, J = 7.7, 4.3 Hz), 5.47 (2H, d, J = 3.
5 Hz), 6.62 (1H, brs), 8.22 (1H, s).
ESI-MS m / z: 468 (M + H) ^<+> .
(Example 184)
4-Amino-N-cyclohexyl-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -N-methyl-7,8-dihydro-2H-6-thia-1,2,3,5
-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title compound (6 mg, 1
0%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.07-1.81 (10H, m), 2.19-2.2
2 (6H, m), 2.27-2.28 (3H, m), 2.59-2.60 (3H, m),
3.15-3.20 (1H, m), 3.45-3.51 (1H, m), 3.67-3.6
9 (1H, m), 3.73 (3H, s), 4.65-4.72 (1H, m), 5.32 (
2H, s), 5.42-5.44 (2H, brm), 8.19 (1H, s).
ESI-MS m / z: 482 (M + H) ^<+> .
(Example 185)
N-allyl-4-amino-N-cyclohexyl-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2, 3, 5
-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title compound (3 mg, 5
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.07-2.06 (10H, m), 2.24 (3H,
s), 2.27 (3H, d, J = 6.8 Hz), 3.11-3.19 (1H, m), 3.
44-3.51 (1H, m), 3.77-3.77 (3H, bsm), 3.90-4.0
4 (2H, m), 4.41 (1H, brs), 4.53 (1H, dd, J = 10.7, 3
. 9 Hz), 4.74-4.75 (1H, m), 5.08-5.18 (2H, m), 5.
28 (2H, s), 5.48-5.49 (2H, m), 5.80 (1H, brs), 8.
25 (1H, s).
ESI-MS m / z: 508 (M + H) ⁺ .
(Example 186)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- [2- (2-thienyl) ethyl] -7,8-dihydro-2H-6-thia-1,2,3
, 5-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (40 mg) and 2- (2-thienyl) ethanamine (0.024 ml) were used in the same manner as in Example 12 to prepare the title compound (10 mg,
20%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.27 (3H, s), 2.9
1-2.94 (2H, m), 3.22 (1H, dd, J = 16.7, 4.8 Hz), 3.
40 (1H, dd, J = 13.3, 6.2 Hz), 3.52 (1H, dd, J = 13.3)
, 6.2 Hz), 3.70 (1H, dd, J = 16.7, 6.2 Hz), 3.75 (3H
, S), 4.26-4.28 (1H, m), 5.31 (1H, brs), 5.46 (2H
, D, J = 3.4 Hz), 6.62 (1H, d, J = 2.4 Hz), 6.71 (1H, b
rs), 6.86 (1H, dd, J = 5.1, 3.4 Hz), 7.09 (1H, dd, J
= 5.1, 1.2 Hz), 8.20 (1 H, s).
ESI-MS m / z: 496 (M + H) ^<+> .
(Example 187)
4-Amino-N- (1,3-benzodioxol-5-ylmethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H -6
Thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 1- (1,3-benzodioxol-5-yl) methanamine (0.038 ml) were used in the same manner as in Example 12. The title compound (20 mg, 30%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.16 (3H, s), 2.20 (3H, s), 3
. 10-3.25 (2H, m), 3.70 (3H, s), 4.18-4.20 (2H, m
), 4.59 (1H, dd, J = 8.8, 4.4 Hz), 5.31 (2H, s), 5.9
7 (2H, s), 6.69-6.71 (1H, m), 6.79 (1H, d, J = 1.7H)
z), 6.82 (1H, d, J = 7.8 Hz), 6.93 (2H, s), 8.07 (1H
, S), 8.75 (1H, t, J = 5.8 Hz).
ESI-MS m / z: 520 (M + H) ⁺ .
(Example 188)
4-Amino-N- (5-methylfuran-2-ylmethyl) -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,
2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 1- (5-methyl-2-furyl) methanamine (29 mg) were used in the same manner as in Example 12 to prepare
g, 32%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.16 (3H, s), 2.20 (3H, s), 2
. 21 (3H, s), 3.14-3.22 (2H, m), 3.70 (3H, s), 4.2
0-4.23 (2H, m), 4.56 (1H, dd, J = 9.1, 4.4 Hz), 5.3
0 (2H, s), 5.97-5.97 (1H, m), 6.09 (1H, d, J = 2.9H)
z), 6.93 (2H, s), 8.07 (1H, s), 8.74 (1H, t, J = 5.5).
Hz)
ESI-MS m / z: 480 (M + H) ⁺ .
(Example 189)
4-Amino-N- (2-furylmethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2 , 3,5-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (20 mg, 33%) was prepared in the same manner as in Example 12 using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 1- (2-furyl) methanamine (25 mg).
Was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.16 (3H, s), 2.20 (3H, s), 3
. 10-3.18 (2H, m), 3.70 (3H, s), 4.27-4.29 (2H, m
), 4.57 (1H, dd, J = 9.1, 4.4 Hz), 5.30 (2H, s), 6.2
3 (1H, dd, J = 3.2, 0.7 Hz), 6.38 (1H, dd, J = 3.2, 2..
0 Hz), 6.94 (2H, s), 7.57-7.57 (1H, m), 8.07 (1H,
s), 8.79 (1H, t, J = 5.5 Hz)
ESI-MS m / z: 466 (M + H) ^<+> .
(Example 190)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (2-Thienylmethyl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (20 mg, 32%
) Was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.16 (3H, s), 2.20 (3H, s), 3
. 11-3.18 (2H, m), 3.70 (3H, s), 4.44-4.46 (2H, m
), 4.57 (1H, dd, J = 8.9, 4.5 Hz), 5.31 (2H, s), 6.9
4-6.95 (4H, m), 7.38 (1H, dd, J = 4.7, 1.7 Hz), 8.0
7 (1H, s), 8.94 (1H, t, J = 5.5 Hz)
ESI-MS m / z: 482 (M + H) ^<+> .
(Example 191)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (1,3-thiazol-2-yl) -7,8-dihydro-2H-6-thia-1,2,
3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title of the title compound (20 mg, 33%
) Was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.19 (3H, s), 2.22 (3H, s), 3
. 28-3.36 (2H, m), 3.72 (3H, s), 4.79 (1H, t, J = 5.
6 Hz), 5.34 (2H, s), 6.97 (2H, s), 7.23 (1H, d, J = 3)
. 4 Hz), 7.48 (1 H, d, J = 3.4 Hz), 8.10 (1 H, s)
ESI-MS m / z: 469 (M + H) ⁺ .
(Example 192)
4-Amino-N- (4,5-dihydro-1,3-thiazol-2-yl) -2-[(4-
Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-
6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 4,5-dihydro-1,3-thiazol-2-amine (36 mg) were used in the same manner as in Example 12 to prepare the title compound ( 16 mg, 26%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.18 (3H, s), 2.22 (3H, s), 3
. 08 (1H, dd, J = 16.8, 9.4 Hz), 3.22-3.27 (3H, m),
3.62 (2H, t, J = 8.1 Hz), 3.71 (3H, s), 4.68 (1H, dd)
, J = 9.4, 4.4 Hz), 5.31 (2H, s), 6.90 (2H, s), 8.09
(1H, s)
ESI-MS m / z: 471 (M + H) ⁺ .
(Example 193)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-1,3,4-thiadiazol-2-yl-7,8-dihydro-2H-6-thia-1,
2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 1,3,4-thiadiazole-
The title compound (25 mg) was prepared in the same manner as in Example 12 using 2-amine (26 mg).
, 41%) as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.18 (3H, s), 2.22 (3H, s), 3
. 28-3.31 (2H, m), 3.72 (3H, s), 4.81 (1H, t, J = 5.
6 Hz), 5.34 (2H, s), 6.99 (2H, s), 8.10 (1H, s), 9.
16 (1H, s)
ESI-MS m / z: 470 (M + H) ^<+> .
(Example 194)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (5-methyl-1,3-thiazol-2-yl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title compound (20
mg, 32%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.18 (3H, s), 2.22 (3H, s), 2
. 33 (3H, s), 3.24 (2H, dd, J = 16.8, 7.0 Hz), 3.72 (
3H, s), 4.76 (1H, dd, J = 7.0, 4.7 Hz), 5.33 (2H, s)
, 6.99 (2H, s), 7.15 (1H, s), 8.10 (1H, s)
ESI-MS m / z: 483 (M + H) ^<+> .
(Example 195)
4-Amino-N-1,3-benzothiazol-2-yl-2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2
, 3,5-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (20 mg, 33%) was prepared in the same manner as in Example 12 using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and benzothiazol-2-amine (24 mg).
Was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.19 (3H, s), 2.23 (3H, s), 3
. 35-3.38 (2H, m), 3.72 (3H, s), 4.84 (1H, t, J = 5.
5Hz), 5.35 (2H, s), 6.96 (2H, s), 7.30 (1H, t, J = 7
. 6 Hz), 7.43 (1H, t, J = 7.6 Hz), 7.75 (1H, d, J = 7.6)
Hz), 7.94 (1H, d, J = 7.6 Hz), 8.10 (1H, s), 8.28 (1
H, s).
ESI-MS m / z: 519 (M + H) ^<+> .
(Example 196)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-pyridin-2-yl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 2-aminopyridine (24 mg
) To give the title compound (15 mg, 25%) as a solid in the same manner as in Example 12.
¹ H-NMR (CDCl ₃ ) δ: 2.21 (3H, s), 2.27 (3H, s), 3.3
5 (1H, dd, J = 16.7, 4.4 Hz), 3.69-3.73 (4H, m), 4.
45-4.48 (1H, m), 5.45 (4H, s), 7.05 (1H, dd, J = 7.
4,4.9 Hz), 7.68 (1H, t, J = 8.0 Hz), 8.11 (1H, d, J =
8.0 Hz), 8.16 (1 H, s), 8.28 (1 H, d, J = 3.9 Hz), 9.2
3 (1H, s).
ESI-MS m / z: 463 (M + H) ^<+> .
(Example 197)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-phenyl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (15 mg, 25%) was obtained as a solid in the same manner as in Example 12 using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and aniline (0.025 ml).
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.28 (3H, s), 3.3
5 (1H, dd, J = 16.7, 4.2 Hz), 3.62 (1H, dd, J = 16.7,
8.8 Hz), 3.76 (3 H, s), 4.58 (1 H, dd, J = 8.8, 4.2 Hz)
), 5.43 (2H, d, J = 4.2 Hz), 7.12 (1H, t, J = 7.4 Hz),
7.32 (1H, t, J = 7.4 Hz), 7.53-7.55 (2H, m), 8.12 (
1H, s)
ESI-MS m / z: 462 (M + H) ^<+> .
(Example 198)
4-Amino-N-isoxazol-3-yl-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2 , 3, 5
-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title compound (10 mg
, 17%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.21 (3H, s), 2.28 (3H, s), 3.3
4 (1H, dd, J = 16.2, 4.6 Hz), 3.74-3.78 (4H, m), 4.
47 (1H, t, J = 5.4 Hz), 5.27 (2H, s), 5.45 (2H, d, J =
4.6 Hz), 6.99 (1H, s), 8.17 (1H, s), 8.27 (1H, d, J
= 1.7Hz), 9.60 (1H, s)
ESI-MS m / z: 453 (M + H) ^<+> .
(Example 199)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-pyridin-3-yl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 3-aminopyridine (24 mg
) And the title compound (10 mg, 17%) was obtained as a solid in the same manner as in Example 12.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.28 (3H, s), 3.3
7-3.38 (1H, m), 3.53 (1H, dd, J = 16.5, 8.9 Hz), 3.
77 (3H, s), 4.62 (1H, dd, J = 8.9, 4.2 Hz), 5.44 (2H
, S), 7.29-7.32 (1H, m), 8.12 (1H, s), 8.24 (1H, d)
, J = 8.3 Hz), 8.29 (1H, d, J = 4.9 Hz), 8.56 (1H, s).
ESI-MS m / z: 463 (M + H) ^<+> .
(Example 200)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-pyridin-4-yl-7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 4-aminopyridine (24 mg
) To give the title compound (15 mg, 25%) as a solid in the same manner as in Example 12.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.29 (3H, d, J = 5.
6 Hz), 3.34 (1 H, dd, J = 16.7, 4.2 Hz), 3.53 (1 H, dd
, J = 16.7, 8.8 Hz), 3.77 (3H, s), 4.59 (1H, dd, J = 8
. 8, 4.2 Hz), 5.44 (2H, d, J = 4.2 Hz), 7.56 (2H, dd,
J = 4.9, 1.5 Hz), 8.12 (1H, s), 8.43 (2H, dd, J = 4.9)
, 1.5 Hz).
ESI-MS m / z: 463 (M + H) ^<+> .
(Example 201)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (5-methylisoxazol-3-yl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Using the title compound (8
mg, 13%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.38-2.41 (9H, m), 3.13 (2H, q
, J = 7.1 Hz), 4.01 (3H, s), 4.70 (1H, s), 5.63 (2H,
s), 6.61 (1H, s), 8.48 (1H, s).
ESI-MS m / z: 467 (M + H) ⁺ .
(Example 202)
Ethyl 2-[({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-yl} carbonyl) amino] -4-methyl-1,3-thiazole -5
Carboxylate

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Example 1 Using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 2-amino-4-methylthiazole-5-carboxylic acid ethyl ester (48 mg)
In a similar manner to 2, the title compound (20 mg, 32%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.33 (3H, t, J = 7.1 Hz), 2.28 (3
H, s), 2.29 (3H, s), 2.62 (3H, s), 3.38 (1H, dd, J =
16.7, 4.4 Hz), 3.59 (1H, dd, J = 16.7, 7.4 Hz), 3.8
2 (3H, s), 4.29 (2H, q, J = 7.1 Hz), 4.65 (1H, dd, J =
7.4, 4.4 Hz), 5.50 (2H, d, J = 8.1 Hz), 8.25 (1H, s)
.
ESI-MS m / z: 555 (M + H) ⁺ .
(Example 203)
Ethyl 2-[({4-amino-2-[(4-methoxy-3,5-dimethylpyridine-2
-Yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-yl} carbonyl) amino] -1,3-thiazole-5-carboxy rate

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (20 mg, 29 mg, 29) %) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.39 (3H, t, J = 7.1 Hz), 2.25 (3
H, s), 2.27 (3H, s), 3.36-3.41 (1H, m), 3.55 (1H,
dd, J = 16.8, 7.5 Hz), 3.77 (3H, s), 4.39 (2H, q, J =
7.5 Hz), 4.63 (1 H, dd, J = 7.5, 4.4 Hz), 5.45 (2 H, s
), 7.82 (1H, s), 8.16 (1H, s).
ESI-MS m / z: 541 (M + H) ^<+> .
(Example 204)
N- (5-acetyl-4-methyl-1,3-thiazol-2-yl) -4-amino-2-
[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 1- (2-amino-4-methylthiazol-5-yl) ethanone (40 mg) were used in the same manner as in Example 12,
The title compound (20 mg, 30%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.30 (6H, s), 2.49 (3H, s), 2.6
4 (3H, s), 3.37-3.40 (1H, m), 3.53 (1H, dd, J = 16.
7, 7.4 Hz), 3.85 (3H, s), 4.68 (1H, dd, J = 7.4, 4.4)
Hz), 5.51 (2H, d, J = 8.6 Hz), 8.26 (1H, s).
ESI-MS m / z: 525 (M + H) ^<+> .
(Example 205)
Ethyl {2-[({4-Amino-2-[(4-methoxy-3,5-dimethylpyridine-
2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-yl} carbonyl) amino] -1,3-thiazole-4- Yle} acetate

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and (2-aminothiazole-4-
I) Acetic acid ethyl ester (48 mg) was used in the same manner as in Example 12 to obtain the title compound (20 mg, 28%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.27 (3H, t, J = 7.1 Hz), 2.30 (3
H, s), 2.32 (3H, s), 3.37 (1H, dd, J = 16.7, 4.5 Hz)
, 3.55 (1H, dd, J = 16.7, 7.7 Hz), 3.69 (2H, s), 3.8
8 (3H, s), 4.18 (2H, q, J = 7.2 Hz), 4.67 (1H, dd, J =
7.7, 4.5 Hz), 5.54 (2H, d, J = 6.6 Hz), 6.82 (1H, s)
, 8.32 (1H, s).
ESI-MS m / z: 555 (M + H) ⁺ .
(Example 206)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- (5-nitro-1,3-thiazol-2-yl) -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 The title compound (20 mg, 30 mg, 30)
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.27 (3H, s), 2.28 (3H, s), 3.3
7 (1H, dd, J = 16.7, 4.5 Hz), 3.52 (1H, dd, J = 16.7,
7.1 Hz), 3.81 (3H, s), 4.68 (1 H, dd, J = 7.1, 4.5 Hz)
), 5.47 (2H, s), 8.17 (1H, s), 8.32 (1H, s).
ESI-MS m / z: 514 (M + H) ⁺
.
(Example 207)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- [4- (2-morpholin-4-yl-2-oxoethyl) -1,3-thiazole-2
-Yl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Example 1 using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 2- (2-amino-thiazol-4-yl) -1-morpholin-4-yl-ethanone (59 mg)
In the same manner as in 2, the title compound (30 mg, 39%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.27 (3H, s), 3.3
8-3.39 (1H, m), 3.56-3.62 (9H, m), 3.77 (3H, s),
4.65 (1H, dd, J = 7.8, 4.4 Hz), 5.43 (2H, d, J = 2.0H)
z), 6.77 (1H, s), 8.13 (1H, s).
ESI-MS m / z: 596 (M + H) ⁺ .
(Example 208)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- [5- (morpholin-4-ylmethyl) -1,3-thiazol-2-yl] -7,8
-Dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 5- (morpholin-4-yl)
The title compound (20 mg, 27%) was obtained as a solid in the same manner as in Example 12 using -1,3-thiazol-2-amine (52 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.28 (3H, s), 2.4
8 (4H, s), 3.38 (1H, d, J = 3.9 Hz), 3.53 (1H, dd, J =
16.5, 7.7 Hz), 3.70 (4H, t, J = 4.5 Hz), 3.77 (3H, s
), 4.65 (1H, dd, J = 7.7, 4.5 Hz), 5.44 (2H, d, J = 2.
7 Hz), 7.22 (1H, s), 8.14 (1H, s).
ESI-MS m / z: 568 (M + H) ⁺ .
(Example 209)
4-Amino-N- (3-carbamoyl-4-methyl-2-thienyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H- 6-
Thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 2-amino-4-methyl-thiophene-3-carboxamide (40 mg) were used in the same manner as in Example 12 to prepare the title compound (10 mg, 15%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.25 (3H, s), 2.4
4 (3H, s), 3.35-3.40 (1H, m), 3.67 (1H, dd, J = 16.
6, 6.3 Hz), 3.77 (3H, s), 4.67 (1H, dd, J = 6.3, 4.6)
Hz), 5.42 (2H, d, J = 3.4 Hz), 6.53 (1H, d, J = 1.2 Hz)
), 7.49 (2H, s), 8.14 (1H, brs).
ESI-MS m / z: 525 (M + H) ^<+> .
(Example 210)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N-1H-pyrazol-5-yl-7,8-dihydro-2H-6-thia-1,2,3,5
-Tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 5-aminopyrazole (22 m
In the same manner as in Example 12, the title compound (8 mg, 14%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.25 (3H, s), 3.4
0-3.45 (2H, m), 3.76 (3H, s), 5.44 (2H, s), 5.55 (
1H, t, J = 5.4 Hz), 5.98 (1H, d, J = 3.2 Hz), 7.93 (1H
, D, J = 2.9 Hz), 8.16 (1H, s).
ESI-MS m / z: 452 (M + H) ^<+> .
(Example 211)
4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl]-
N- {5-[(4-methylpiperazin-1-yl) methyl] -1,3-thiazole-2-
Yl} -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 Performed with tetraazaacenaphthylene-7-carboxylic acid (50 mg) and 5-((4-methyl-piperazin-1-yl) methyl) -1,3-thiazol-2-amine (55 mg) In the same manner as in Example 12, the title compound (20 mg, 28%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.25 (4H, brs), 2.28 (6H, s), 2
. 48 (8H, brs), 3.37 (1H, dd, J = 16.8, 4.4 Hz), 3.5
4 (1H, dd, J = 16.8, 8.1 Hz), 3.66 (2H, s), 3.77 (3H
, S), 4.65 (1H, dd, J = 8.1, 4.4 Hz), 5.44 (2H, d, J =
2.9 Hz), 7.22 (1H, s), 8.15 (1H, s).
ESI-MS m / z: 581 (M + H) ⁺ .
(Example 212)
4-Amino-N- [5- (hydroxymethyl) -1,3-thiazol-2-yl] -2-
[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5-tetraazaacenaphthylene-7-carboxamide

4-amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -7,8-dihydro-2H-6-thia-1,2,3,5- of Example 8 In the same manner as in Example 12, using tetraazaacenaphthylene-7-carboxylic acid (50 mg) and (2-amino-1,3-thiazol-5-yl) -methanol (34 mg), The compound (15 mg, 23%) was obtained as a solid.
¹ H-NMR (DMSO-d ₆ ) δ: 2.18 (3H, s), 2.21 (3H, s), 3
. 27-3.29 (2H, m), 3.72 (3H, s), 4.57 (2H, d, J = 5.
1 Hz), 4.78-4.79 (1H, m), 5.34 (2H, s), 5.38 (1H,
t, J = 5.6 Hz), 6.98 (2H, s), 7.31 (1H, s), 8.10 (1H
, S).
ESI-MS m / z: 499 (M + H) ^<+> .
(Example 213)
1) 4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3
, 5-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,
3,5-tetraazabenzo [cd] azulen-8-yl trifluoromethanesulfonate

4- [bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,9-dihydro-6-thia- under cooling in an ice bath 1,2,3,5-tetraazabenzo [cd] azulen-8-one (300 mg) was dissolved in dehydrated dichloromethane (5 ml), triethylamine (146 μl) was added, and then trifluoromethane sulfonate anhydride (106 μl). And stirred at 0 ° C. for 3 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order and dried over sodium sulfate. The residue obtained by evaporating the solvent was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain the title compound as a solid (255 mg, 69%).
ESI-MS m / z: 703 (M + H) ^<+> .
2) Ethyl 4- [bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulene-8-carboxylate

4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-8-yl trifluoromethanesulfonate (25 mg) was dissolved in ethanol (2 ml), triethylamine (6 μl), bis (
Triphenylphosphine) palladium (II) dichloride (2.5 mg) was added at room temperature, and the mixture was stirred at 40 ° C. for 3 hours in a carbon monoxide atmosphere. The residue obtained by concentrating the reaction solution was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain the title compound as an oily substance (14 mg, 62%).
¹ H-NMR (CDCl ₃ ) δ: 1.35 (3H, t, J = 7.19 Hz), 1.44 (
18H, s), 2.22 (3H, s), 2.30 (3H, s), 3.75 (3H, s),
4.18 (2H, s), 4.31 (2H, q, J = 7.15 Hz), 5.73 (2H, s
), 8.02 (1H, s), 8.15 (1H, s).
ESI-MS m / z: 627 (M + H) ⁺ .
3) 4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5)
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulene-8-carboxylic acid

Under cooling in an ice bath, ethyl 4- [bis (tert-butoxycarbonyl) amino] -2- [
(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-
6-thia-1,2,3,5-tetraazabenzo [cd] azulene-8-carboxylate (0.92 g) was dissolved in methanol (10 ml), and 1N aqueous sodium hydroxide solution (1
0 ml) was added, and the mixture was stirred for 16 hours while gradually returning to room temperature. The reaction mixture was neutralized with 0.5N aqueous hydrochloric acid, and the solvent was concentrated. The resulting residue was diluted with chloroform, washed with a 10% aqueous citric acid solution, and the organic layer was dried over sodium sulfate. . The residue obtained by distilling off the solvent was recrystallized from hexane and ethyl acetate to obtain the title compound as a solid (0.68 g, 91%).
¹ H-NMR (CD ₃ OD) δ: 1.54 (9H, s), 2.25 (3H, s), 2.3
2 (3H, s), 3.81 (3H, s), 4.18 (2H, s), 5.78 (2H, s)
, 7.81 (1H, s), 8.07 (1H, s).
ESI-MS m / z: 499 (M + H) ^<+> .
4) 4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [ cd] azulene-8-carboxylic acid

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (30 mg) was synthesized in the same manner as in Example 2 to obtain the title compound as a solid (15 mg, 63%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.17 (3H, s), 2.26 (3H, s), 3
. 73 (3H, s), 4.09 (2H, s), 5.50 (2H, s), 7.05 (2H,
brs), 7.61 (1H, s), 8.05 (1H, s).
ESI-MS m / z: 399 (M + H) ^<+> .
(Example 214)
1) tert-butyl {8- (hydroxymethyl) -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1 under ice bath cooling
, 2,3,5-tetraazabenzo [cd] azulene-8-carboxylic acid (
50 mg) was dissolved in tetrahydrofuran (1 ml) and N-methylmorpholine (13 μm) was dissolved.
l), ethyl chloroformate (12 μl) was added and stirred for 2 hours. Subsequently, sodium borohydride (12 mg) and methanol (1 ml) were added to the reaction solution, and the mixture was stirred for 3 hours while gradually returning to room temperature. A 10% aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine in that order, and dried over anhydrous sodium sulfate. The residue obtained by distilling off the solvent was purified by silica gel column chromatography (chloroform-methanol) to give the title compound as an oily substance (35 m
g, 72%).
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.22 (3H, s), 2.3
1 (3H, s), 3.74 (3H, s), 3.75 (2H, s), 4.32-4.35 (
2H, m), 5.64 (2H, s), 6.85 (1H, t, J = 1.38 Hz), 7.4
3 (1H, s), 8.17 (1H, s).
ESI-MS m / z: 485 (M + H) ^<+> .
2) {4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [Cd] azulen-8-yl} methanol

tert-butyl {8- (hydroxymethyl) -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5 −
Synthesis was performed in the same manner as in Example 2 using tetraazabenzo [cd] azulen-4-yl} carbamate (35 mg) to obtain the title compound as a solid (15 mg, 54%).
¹ H-NMR (CDCl ₃ ) δ: 2.22 (3H, s), 2.27 (3H, s), 3.7
1 (2H, s), 3.74 (3H, s), 4.31 (2H, d, J = 1.38 Hz), 5
. 19 (2H, brs), 5.51 (2H, s), 6.78-6.79 (1H, m), 8
. 19 (1H, s).
ESI-MS m / z: 385 (M + H) ^<+> .
(Example 215)
1) tert-butyl {8- [butyl (methyl) carbamoyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1
, 2,3,5-tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Synthesis was performed in the same manner as in Example 9, using tetraazabenzo [cd] azulene-8-carboxyl acid (50 mg) and n-methyl-n-butylamine (23 μl).
The title compound was obtained as a solid (54 mg, 95%).
ESI-MS m / z: 568 (M + H) ⁺ .
2) 4-Amino-N-butyl-2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -N-methyl-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-8-carboxamide

tert-butyl {8- [butyl (methyl) carbamoyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,
2,3,5-tetraazabenzo [cd] azulen-4-yl} carbamate (54 mg)
Was used in the same manner as in Example 2 to obtain the title compound as a solid (22 mg, 50%).
¹ H-NMR (CDCl ₃ ) δ: 0.89-0.96 (3H, m), 1.26-1.36
(2H, m), 1.54-1.61 (2H, m), 2.23 (3H, s), 2.30 (3
H, s), 3.06 (3H, brs), 3.47 (2H, t, J = 7.57 Hz), 3.
75 (3H, s), 3.94 (2H, s), 5.19 (2H, s), 5.54 (2H, s)
), 6.89 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 468 (M + H) ^<+> .
(Example 216)
1) tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8- [methyl (phenyl) carbamoyl] -2,7-dihydro-6-thia-
1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and N-methylaniline (21 μl) were synthesized in the same manner as in Example 9 to give the title compound as a solid (63 mg, 59%) Got as.
¹ H-NMR (CDCl ₃ ) δ: 1.51 (9H, s), 2.21 (3H, s), 2.2
8 (3H, s), 3.41 (3H, s), 3.74 (3H, s), 3.79 (2H, s)
, 5.59 (2H, s), 7.03 (1H, s), 7.16-7.24 (3H, m), 7
. 32-7.39 (3H, m), 8.15 (1H, s).
ESI-MS m / z: 588 (M + H) ^<+> .
2) 4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -N-methyl-N-phenyl-2,7-dihydro-6-thia-1,2, 3,5-tetraazabenzo [cd] azulene-8-carboxamide

tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl)
Methyl] -8- [methyl (phenyl) carbamoyl] -2,7-dihydro-6-thia-1
, 2,3,5-Tetraazabenzo [cd] azulen-4-yl} carbamate (63 mg
) Was used in the same manner as in Example 2 to obtain the title compound as a solid (23 mg, 44%).
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.25 (3H, s), 3.4
1 (3H, s), 3.75 (3H, s), 3.77 (2H, s), 5.15 (2H, br
s), 5.48 (2H, s), 6.97 (1H, s), 7.16-7.24 (3H, m)
, 7.34 (2H, t, J = 7.79 Hz), 8.19 (1H, s).
ESI-MS m / z: 488 (M + H) ^<+> .
(Example 217)
1) tert-butyl {8- (dimethylcarbamoyl) -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and dimethylamine hydrochloride (16 mg) were synthesized in the same manner as in Example 9 to give the title compound as a solid (53 mg, quantitative) Got as.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.22 (3H, s), 2.3
4 (3H, s), 3.10 (6H, brs), 3.75 (3H, s), 3.97 (2H,
s), 5.67 (2H, s), 6.97 (1H, s), 7.46 (1H, s), 8.17
(1H, s).
ESI-MS m / z: 526 (M + H) ^<+> .
2) 4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -N, N-dimethyl-2,7-dihydro-6-thia-1,2,3 5-tetraazabenzo [cd] azulene-8-carboxamide

tert-butyl {8- (dimethylcarbamoyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
Synthesis was performed in the same manner as in Example 2 using 5-tetraazabenzo [cd] azulen-4-yl} carbamate (53 mg) to obtain the title compound as a solid (17 mg, 40%).
¹ H-NMR (CDCl ₃ ) δ: 2.23 (3H, s), 2.31 (3H, s), 3.1
0 (6H, brs), 3.75 (3H, s), 3.95 (2H, s), 5.19 (2H,
s), 5.54 (2H, s), 6.92 (1H, s), 8.19 (1H, s).
ESI-MS m / z: 426 (M + H) ^<+> .
(Example 218)
1) tert-butyl {8-[(3,3-difluoropyrrolidin-1-yl) carbonyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7
-Dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and 3,3-difluoropyrrolidine hydrochloride (29 mg) were synthesized in the same manner as in Example 9 to give the title compound as a solid (60 mg , Quantitative).
¹ H-NMR (CDCl ₃ ) δ: 1.54-1.57 (9H, m), 2.23 (3H, s
), 2.35 (3H, s), 2.37-2.44 (2H, m), 3.76 (3H, s),
3.87 (2H, t, J = 6.88 Hz), 3.94 (2H, t, J = 12.61 Hz)
, 4.02 (2H, s), 5.67 (2H, s), 7.10 (1H, s), 7.46 (1
H, s), 8.18 (1H, s).
ESI-MS m / z: 588 (M + H) ^<+> .
2) 8-[(3,3-Difluoropyrrolidin-1-yl) carbonyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6- Thia-1,2,3,5-tetraazabenzo [cd] azulen-4-amine

tert-butyl {8-[(3,3-difluoropyrrolidin-1-yl) carbonyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-
Dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl}
The title compound was synthesized in the same manner as in Example 2 using carbamate (60 mg).
mg, 46%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.17 (3H, s), 2.25 (3H, s), 2
. 38-2.47 (2H, m), 3.31-3.34 (2H, m), 3.72 (4H, s
), 3.78-3.88 (2H, m), 3.81 (2H, s), 5.47 (2H, s),
7.01 (1H, s), 7.03 (2H, brs), 8.06 (1H, s).
ESI-MS m / z: 488 (M + H) ^<+> .
(Example 219)
1) tert-butyl {8- (butylcarbamoyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and n-butylamine (20 μl) were synthesized in the same manner as in Example 9 to give the title compound as a solid (53 mg, 95%) Obtained.
¹ H-NMR (CDCl ₃ ) δ: 0.95 (3H, t, J = 7.34 Hz), 1.35
1.44 (3H, m), 1.50-1.56 (17H, m), 2.22 (3H, s), 2
. 33 (3H, s), 3.37 (3H, dd, J = 12.61, 7.11 Hz), 3.7
5 (3H, s), 4.14 (2H, s), 5.67 (2H, s), 5.96 (2H, br)
s), 7.29 (1H, s), 7.45 (1H, s), 8.18 (1H, s).
ESI-MS m / z: 554 (M + H) ⁺ .
2) 4-Amino-N-butyl-2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [c
d] Azulene-8-carboxamide

tert-butyl {8- (butylcarbamoyl) -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Using tetraazabenzo [cd] azulen-4-yl} carbamate (53 mg)
Synthesis was performed in the same manner as in Example 2 to obtain the title compound as a solid (27 mg, 62%).
¹ H-NMR (DMSO-D ₆ ) δ: 0.88 (3H, t, J = 7.34 Hz), 1.2
5-1.34 (2H, m), 1.42-1.49 (2H, m), 2.17 (3H, s),
2.24 (3H, s), 3.17 (2H, q, J = 6.42 Hz), 3.72 (3H, s
), 4.06 (2H, s), 5.47 (2H, s), 7.02 (2H, brs), 7.3
9 (1H, s), 8.07 (1H, s), 8.40 (1H, t, J = 5.50 Hz).
ESI-MS m / z: 454 (M + H) ^<+> .
(Example 220)
1) tert-butyl {8- (anilinocarbonyl) -2-[(4-methoxy-3,5
-Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and aniline (18 μl) were synthesized in the same manner as in Example 9 to give the title compound as a solid (5
6 mg, 97%).
¹ H-NMR (CDCl ₃ ) δ: 1.57 (9H, s), 2.23 (3H, s), 2.3
4 (3H, s), 3.76 (3H, s), 4.19 (2H, s), 5.69 (2H, s)
7.16 (1H, t, J = 7.34 Hz), 7.36 (2H, t, J = 7.79 Hz)
, 7.49 (1H, s), 7.56 (2H, d, J = 7.79 Hz), 7.78 (1H,
s), 8.18 (1H, s).
ESI-MS m / z: 574 (M + H) ⁺ .
2) 4-Amino-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -N-phenyl-2,7-dihydro-6-thia-1,2,3,5- Tetraazabenzo [
cd] azulene-8-carboxamide

tert-butyl {8- (anilinocarbonyl) -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Using tetraazabenzo [cd] azulen-4-yl} carbamate (56 mg)
Synthesis was performed in the same manner as in Example 2 to obtain the title compound as a solid (25 mg, 54%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.18 (3H, s), 2.26 (3H, s), 3
. 73 (3H, s), 4.15 (2H, s), 5.51 (2H, s), 7.06-7.1
1 (3H, m), 7.33 (2H, t, J = 7.79 Hz), 7.61 (1H, s), 7
. 71 (2H, d, J = 7.79 Hz), 8.08 (1H, s), 10.24 (1H, s
).
ESI-MS m / z: 474 (M + H) ^<+> .
(Example 221)
1) tert-butyl (8-{[2- (dimethylamino) -2-oxoethyl] carbamoyl} -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2
, 7-Dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulene-4-
Il) Carbamate

4-[(tert-Butoxycarbonyl) amino] -2-[(4-methoxy-3,5-
Dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3,5
-Synthesis was performed in the same manner as in Example 9 using tetraazabenzo [cd] azulene-8-carboxylic acid (50 mg) and glycine dimethylamide acetate (81 mg).
The title compound was obtained as a solid (22 mg, 38%).
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 2.23 (3H, s), 2.3
3 (3H, s), 3.01 (6H, s), 3.76 (3H, s), 4.12-4.14 (
4H, m), 5.68 (2H, s), 7.19 (1H, s), 7.49 (1H, s), 8
. 19 (1H, s).
ESI-MS m / z: 583 (M + H) ^<+> .
2) 4-Amino-N- [2- (dimethylamino) -2-oxoethyl] -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6 -Thia-1,2,3,5-tetraazabenzo [cd] azulene-8-carboxamide

tert-butyl (8-{[2- (dimethylamino) -2-oxoethyl] carbamoyl} -2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -2,
The title compound was synthesized in the same manner as in Example 2 using 7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl) carbamate (20 mg). Obtained as a solid (10 mg, 60%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.17 (3H, s), 2.25 (3H, s), 2
. 83 (3H, s), 2.99 (3H, s), 3.29 (2H, s), 4.01 (2H,
d, J = 5.96 Hz), 4.08 (2H, s), 5.49 (3H, s), 7.01 (2
H, brs), 7.48 (1H, s), 8.07 (1H, s), 8.55 (1H, t, J
= 5.96 Hz).
ESI-MS m / z: 483 (M + H) ^<+> .
(Example 222)
1) Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -8-pyrimidin-5-yl-2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-8-yl trifluoromethanesulfonate (50 mg) dissolved in 1,4-dioxane (4 ml), pyrimidine-5-boronic acid (13 mg), 2N aqueous sodium carbonate solution (2 ml) and bis (triphenylphosphine) palladium (II) dichloride (5 mg) were added, and the mixture was stirred at 40 ° C. for 2 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with water and then saturated brine and dried over anhydrous sodium sulfate. The residue obtained by evaporating the solvent was purified by silica gel column chromatography (chloroform-methanol) to obtain the title compound as an oily substance (45 mg).
¹ H-NMR (CDCl ₃ ) δ: 1.45 (9H, s), 1.56 (9H, s), 2.2
2 (3H, s), 2.32 (3H, s), 3.75 (3H, s), 4.21 (2H, s)
, 5.73 (2H, s), 7.26 (1H, s), 8.15 (1H, s), 8.90 (2
H, s), 9.21 (1H, s).
ESI-MS m / z: 633 (M + H) ^<+> .
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-pyrimidin-5-yl-2,7-dihydro-6-thia-1,2,3,5- Tetraazabenzo [
cd] azulen-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-pyrimidin-5-yl-2,7-dihydro-6-thia-1,2, 3,
5-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (45 mg)
Was used in the same manner as in Example 2 to obtain the title compound as a solid (8 mg, 26%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.18 (3H, s), 2.25 (3H, s), 3
. 73 (3H, s), 4.32 (2H, s), 5.48 (2H, s), 7.01 (2H,
brs), 7.28 (1H, s), 8.08 (1H, s), 9.11 (2H, s), 9.
14 (1H, s).
ESI-MS m / z: 433 (M + H) ^<+> .
(Example 223)
1) Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -8-pyridin-3-yl-2,7-dihydro-6-thia-1,2,3
5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-tetraazabenzo [cd] azulen-8-yl trifluoromethanesulfonate (50 mg) and pyridine-3-boronic acid neopentyl glycol ester (21 mg) were synthesized in the same manner as in Example 222. The title compound as a solid (48
mg, quantitative).
¹ H-NMR (CDCl ₃ ) δ: 1.45 (18H, s), 2.22 (3H, s), 2.
31 (3H, s), 3.75 (3H, s), 4.21 (2H, s), 5.72 (2H, s
), 7.21 (1H, s), 7.65-7.81 (2H, m), 8.16 (1H, s),
8.60 (1H, dd, J = 0.58, 1.38 Hz), 8.79 (1H, d, J = 1.
83 Hz).
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-pyridin-3-yl-2,7-dihydro-6-thia-1,2,3,5- Tetraazabenzo [c
d] Azulene-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-pyridin-3-yl-2,7-dihydro-6-thia-1,2, 3, 5
-Tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (49 mg) was synthesized in the same manner as in Example 2 to obtain the title compound as a solid (12 mg, 36%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.18 (3H, s), 2.25 (3H, s), 3
. 73 (3H, s), 4.29 (2H, s), 5.47 (2H, s), 6.98 (2H,
brs), 7.13 (1H, s), 7.43 (1H, dd, J = 8.02, 4.81 Hz)
), 8.04-8.08 (2H, m), 8.54 (1H, dd, J = 4.81, 1.60)
Hz), 8.86 (1H, d, J = 2.29 Hz).
ESI-MS m / z: 432 (M + H) ^<+> .
(Example 224)
1) Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridine-2-
Yl) methyl] -8-phenyl-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [cd] azulen-4-yl} imide dicarbonate

4- [Bis (tert-butoxycarbonyl) amino] -2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methyl] -2,7-dihydro-6-thia-1,2,3
, 5-Tetraazabenzo [cd] azulen-8-yl trifluoromethanesulfonate (50 mg) and phenylboronic acid (13 mg) were synthesized in the same manner as in Example 222 to give the title compound as a solid ( 32 mg, 71%).
¹ H-NMR (CDCl ₃ ) δ: 1.45 (18H, s), 2.22 (3H, s), 2.
30 (3H, s), 3.74 (3H, s), 4.22 (2H, s), 5.71 (2H, s)
), 7.17 (1H, s), 7.35-7.52 (5H, m), 8.17 (1H, s).
ESI-MS m / z: 631 (M + H) ⁺ .
2) 2-[(4-Methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-phenyl-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo [ cd] azulen-4-amine

Di-tert-butyl {2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methyl] -8-phenyl-2,7-dihydro-6-thia-1,2,3,5- Synthesis was carried out in the same manner as in Example 2 using tetraazabenzo [cd] azulen-4-yl} imide dicarbonate (32 mg) to obtain the title compound as a solid (12 mg, 55%).
¹ H-NMR (DMSO-D ₆ ) δ: 2.18 (3H, s), 2.25 (3H, s), 3
. 73 (3H, s), 4.26 (2H, s), 5.46 (2H, s), 6.96 (2H,
brs), 7.00 (1H, s), 7.34-7.37 (1H, m), 7.40-7.4.
4 (2H, m), 7.62-7.65 (2H, m), 8.08 (1H, s).
ESI-MS m / z: 431 (M + H) ⁺ .
(Reference Example 1)
1) 4-ethyl-2,3,5-trimethylpyridine 1-oxide

4-Bromo-2,3,5-trimethylpyridine 1-oxide (5.76 g), tetrahydrofuran (60 mL), 15% triethylaluminum / toluene solution (40 mL)
And a mixture of tetrakis (triphenylphosphine) palladium (0) (1.54 g) was heated to reflux for 6 hours. After allowing to cool to room temperature, toluene (60 mL), methanol (12 mL) and then saturated aqueous ammonium chloride (18 mL) were added to the reaction mixture, and the mixture was heated to reflux for 1 hr. The mixture was allowed to cool to room temperature, insoluble matters were filtered off, and the filtrate was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain the title compound (3.84 g, 87%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.10 (3H, t, J = 7.6 Hz), 2.22 (3
H, s), 2.27 (3H, s), 2.52 (3H, s), 2.62 (2H, q, J = 7)
. 6 Hz), 8.01 (1H, s).
ESI-MS m / z: 166 (M + H) ^<+> .
2) (4-Ethyl-3,5-dimethylpyridin-2-yl) methyl acetate

The above mixture consisting of 4-ethyl-2,3,5-trimethylpyridine 1-oxide (3.84 g) and acetic anhydride (50 mL) was heated to reflux for 30 minutes. After allowing to cool to room temperature, the reaction mixture was concentrated under reduced pressure, dissolved in chloroform and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate-hexane) to give the title compound (3.64 g, 76%) as an oil. Obtained.
¹ H-NMR (CDCl ₃ ) δ: 1.12 (3H, t, J = 7.6 Hz), 2.12 (3
H, s), 2.29 (3H, s), 2.29 (3H, s), 2.68 (2H, q, J = 7)
. 6 Hz), 5.22 (2H, s), 8.21 (1 H, s).
ESI-MS m / z: 208 (M + H) ^<+> .
3) 2-Chloromethyl-4-ethyl-3,5-dimethylpyridine hydrochloride

The above (4-ethyl-3,5-dimethylpyridin-2-yl) methyl acetate (41
5 mg), methanol (5 mL) and potassium carbonate (553 mg)
Stir at 0 ° C. for 30 minutes. After cooling to room temperature, the reaction solution was concentrated under reduced pressure, dissolved in chloroform and washed with water. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The obtained residue was dissolved in chloroform, thionyl chloride (1 mL) was added under ice cooling, and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure, and decanted with toluene to obtain the title compound (299 mg, 68%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 1.23 (3H, t, J = 7.7 Hz), 2.50 (3
H, s), 2.55 (3H, s), 2.90 (2H, q, J = 7.7 Hz), 5.16 (
2H, s), 8.34 (1H, s).
ESI-MS m / z: 184 (M + H) ⁺ .
(Reference Example 2)
1) 3-Chloro-2,5-dimethylpyridine 1-oxide

3-Chloro-2,5-dimethylpyridine (1.10 g) in dichloromethane (30 mL)
M-Chloroperbenzoic acid (1.61 g) was added with stirring under ice cooling, and the mixture was stirred overnight at room temperature. The reaction solution was washed with 1N sodium hydroxide, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (1.21 g, 99%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.27 (3H, s), 2.59 (3H, s), 7.1
3 (1H, s), 8.07 (1H, s).
ESI-MS m / z: 158 (M + H) ⁺ .
2) 3-Chloro-2,5-dimethyl-4-nitropyridine 1-oxide

The 3-chloro-2,5-dimethylpyridine 1-oxide (1.20 g) was concentrated sulfuric acid (
6 mL), and a mixed solution of fuming nitric acid (9.5 mL) and fuming sulfuric acid (5.5 mL) was added dropwise over 25 minutes while stirring on ice. The mixture was stirred for 30 minutes and then stirred at 90 ° C. for 2 hours. The reaction solution was allowed to cool and then poured into ice water, and neutralized by adding ammonium carbonate with stirring at room temperature. Insolubles were filtered off and extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform-methanol) to obtain the title compound (1.11 g, 72%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.29 (3H, s), 2.63 (3H, s), 8.1
3 (1H, s).
ESI-MS m / z: 203 (M + H) ^<+> .
3) 3,4-Dichloro-2,5-dimethylpyridine 1-oxide

3-Chloro-2,5-dimethyl-4-nitropyridine 1-oxide (405 mg)
) Was dissolved in dichloromethane (5 mL), and phosphorus oxychloride (915 μL) was added with ice-cooling and stirring. After stirring overnight at room temperature, the reaction mixture was poured into ice water and neutralized with 5N sodium hydroxide and saturated aqueous sodium hydrogen carbonate with stirring under ice cooling. Extraction was performed with chloroform, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (387 mg, quantitative) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.34 (3H, s), 2.66 (3H, s), 8.1
2 (1H, s).
ESI-MS m / z: 192 (M + H) ⁺ .
4) (3,4-Dichloro-5-methylpyridin-2-yl) methyl acetate

The title compound (156 mg, 33%) was obtained as an oil in the same manner as in Reference Example 1-2) using the above 3,4-dichloro-2,5-dimethylpyridine 1-oxide (384 mg).
¹ H-NMR (CDCl ₃ ) δ: 2.16 (3H, s), 2.40 (3H, s), 5.3
2 (2H, s), 8.33 (1 H, s).
ESI-MS m / z: 234 (M + H) ^<+> .
5) 2-Chloromethyl-3,4-dichloro-5-methylpyridine hydrochloride

(3,4-Dichloro-5-methylpyridin-2-yl) methyl acetate (15
In the same manner as in Reference Example 1-3), the title compound (141 mg, 89%) was obtained as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.60 (3H, s), 5.13 (2H, s), 8.5
6 (1H, s).
ESI-MS m / z: 210 (M + H) ^<+> .
(Reference Example 3)
1) 3-Chloro-4-methoxy-2,5-dimethylpyridine 1-oxide

3-Chloro-2,5-dimethyl-4-nitropyridine 1-oxide (700 mg) obtained in Reference Example 2-2) was added to a 0.59 M sodium methoxide / methanol solution, and the mixture was stirred at room temperature for 18 hours under an argon atmosphere. Stir. The reaction mixture was concentrated under reduced pressure, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure to obtain the title compound (625 mg, 96%) as a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.24 (3H, s), 2.62 (3H, s), 3.8
7 (3H, s), 8.07 (1H, s).
ESI-MS m / z: 188 (M + H) ⁺ .
2) (3-Chloro-4-methoxy-5-methylpyridin-2-yl) methyl acetate

3-Chloro-4-methoxy-2,5-dimethylpyridine 1-oxide (620 m
g) The title compound (460 mg, 61%) was obtained as an oil in the same manner as in Reference Example 1-2).
¹ H-NMR (CDCl ₃ ) δ: 2.16 (3H, s), 2.29 (3H, s), 3.9
2 (3H, s), 5.30 (2H, s), 8.29 (1H, s).
ESI-MS m / z: 230 (M + H) ^<+> .
3) 2-Chloromethyl-3-chloro-4-methoxy-5-methylpyridine hydrochloride

In the same manner as in Reference Example 1-3) using the above (3-chloro-4-methoxy-5-methylpyridin-2-yl) methyl acetate (450 mg), the title compound (118 mg, 79
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.45 (3H, s), 4.29 (3H, s), 5.1
5 (2H, s), 8.43 (1H, s).
ESI-MS m / z: 206 (M + H) ^<+> .
(Reference Example 4)
1) 5-chloro-2,3-dimethylpyridine 1-oxide

The title compound (1.92 g, quantitative) was obtained as a solid in the same manner as in Reference Example 2-1) using 5-chloro-2,3-dimethylpyridine (1.72 g).
¹ H-NMR (CDCl ₃ ) δ: 2.34 (3H, s), 2.46 (3H, s), 7.0
8 (1H, s), 8.20 (1H, s).
ESI-MS m / z: 158 (M + H) ⁺ .
2) 5-Chloro-2,3-dimethyl-4-nitropyridine 1-oxide

Using the 5-chloro-2,3-dimethylpyridine 1-oxide (1.90 g), the title compound (1.94 g, 79%) was obtained as a solid in the same manner as in Reference Example 2-2).
¹ H-NMR (CDCl ₃ ) δ: 2.33 (3H, s), 2.51 (3H, s), 8.2
9 (1H, s).
ESI-MS m / z: 203 (M + H) ^<+> .
3) 5-Chloro-4-methoxy-2,3-dimethylpyridine 1-oxide

5-Chloro-2,3-dimethyl-4-nitropyridine 1-oxide (455 mg)
) To give the title compound (405 mg, 96%) as a solid in the same manner as in Reference Example 3-1).
¹ H-NMR (CDCl ₃ ) δ: 2.28 (3H, s), 2.48 (3H, s), 3.8
6 (3H, s), 8.24 (1 H, s).
ESI-MS m / z: 188 (M + H) ⁺ .
4) (5-Chloro-4-methoxy-3-methylpyridin-2-yl) methyl acetate

5-chloro-4-methoxy-2,3-dimethylpyridine 1-oxide (400 m
g) The title compound (346 mg, 71%) was obtained as an oil in the same manner as in Reference Example 1-2).
¹ H-NMR (CDCl ₃ ) δ: 2.13 (3H, s), 2.29 (3H, s), 3.9
2 (3H, s), 5.19 (2H, s), 8.39 (1H, s).
ESI-MS m / z: 230 (M + H) ^<+> .
5) 2-Chloromethyl-5-chloro-4-methoxy-3-methylpyridine hydrochloride

In the same manner as in Reference Example 1-3) using the above (5-chloro-4-methoxy-3-methylpyridin-2-yl) methyl acetate (340 mg), the title compound (326 mg, 91
%) As a solid.
¹ H-NMR (CDCl ₃ ) δ: 2.47 (3H, s), 4.32 (3H, s), 5.0
9 (2H, s), 8.54 (1H, s).
ESI-MS m / z: 206 (M + H) ^<+> .
(Test Example 1 Anti-cell test)
Two types of cells (human breast cancer-derived cell line SK-BR-3, human lung cancer-derived cell line NCI-H4
60) was used to carry out the anti-cell test.

Each cell was suspended in a medium and seeded in a 96-well multiwell plate at 500 cells / 150 μL / well. The test compound was dissolved in DMSO and diluted with a medium to prepare a sample solution (DMSO concentration of 0.5% or less). On the day after seeding, 50 μL of DMSO-containing medium (hereinafter referred to as DMSO diluted solution, DMSO concentration of 0.5% or less) or sample solution to which no test compound was added was added to the cells. MTT assays were performed immediately after sample solution or DMSO dilution was added to the cells and 72 hours later. The MTT assay was performed as follows.

20 μL of 5 mg / mL MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) solution was added to each well. afterwards,
Plates were incubated for 4 hours at 37 ° C., 5% CO ₂ . After centrifuging the plate at 1200 rpm for 5 minutes, the culture supernatant was removed by suction with a dispenser. DMSO in each well 15
0 μL each was added to dissolve the produced formazan. The color of each well was made uniform by stirring the plate using a plate mixer. The absorbance of each well is OD 5
Measurement was performed using a plate reader under the conditions of 40 nm and reference 660 nm.

The OD value measured immediately after addition of the sample solution is S, the OD value measured 72 hours after addition of the sample solution is T, and the OD value measured 72 hours after addition of the DMSO diluted solution is C. T / C (%) at each concentration was determined, a dose response curve was drawn, and a 50% growth inhibitory concentration (GI ₅₀ value) was calculated.
T / C (%) = (T−S) / (C−S) × 100
The results are shown below.

(Test Example 2 Hsp90 ATPase assay)
Using recombinant yeast Hsp90 protein (hereinafter referred to as rHsp90), Hsp90
ATPase assay was performed. Yeast Hsp90 DNA was cloned from a yeast genomic DNA library according to conventional methods. Cloned yeast Hsp90 DNA
Was incorporated into an E. coli expression plasmid and this plasmid was expressed in E. coli to obtain rHsp90.

The test compound was dissolved to 10 mM using DMSO. 4m of dissolved solution
Diluted with DMSO to a 3-fold dilution from M to 8 concentrations. Each diluted solution was added to assay buffer (100 mM Tris, pH 7.4, 20 mM KCl, 6 mM MgCl _2).
(Concentration of each test compound solution: 400 μM, 133 μM,
44.4 μM, 14.8 μM, 4.94 μM, 1.65 μM, 0.549 μM, 0.18
3 μM. DMSO concentration 10%).

rHsp90 was added to TE buffer (20 mM Tris, pH 7.4, 1 mM EDTA).
) To a concentration of 2.531 mg / mL. The lysed solution is diluted to 125 μg / mL with assay buffer and 40 aliquots are added to each well of a 96 well assay plate.
A μL aliquot was dispensed (final concentration 100 μg / mL).

5 μL of the test compound solution was dispensed into each well, and then the solution in each well was mixed using a plate mixer. 100 mM ATP (Sigma, Catalog No. A-7699
) Was diluted to 1 mM with assay buffer, and 5 μL was dispensed into each well (final concentration 100 μM). The solution in each well was mixed using a plate mixer, and then the assay plate was allowed to stand for 2 hours in an incubator set at 37 ° C.

BIOMOL GREEN Reagent (BIOMOL, catalog number AK-11)
100 μL of 1) was dispensed into each well to stop the reaction. Mix the solution in each well by pipetting (3 times), then add 10% of 34% sodium citrate to each well.
Dispensed one by one. After mixing the solution in each well by pipetting (three times), the assay plate was allowed to stand at room temperature for 10 minutes. The absorbance of each well was measured at V _max 630 nm.

The absorbance of a well to which a test compound and rHsp90 were added was A, the absorbance of a well to which only rHsp90 was added was B, and the absorbance of a well to which neither of the test compound or rHsp90 was added was C. The ratio (T / C value) between the compound addition group and the test compound non-addition group was determined.

T / C = (AC) / (BC)
Furthermore, ATP using GraphPad Prism 4 (Graph Pad)
The concentration at which the activity was inhibited by 50% (IC ₅₀ value) was calculated. The results are shown below.

Claims (20)

Formula (1)


[In Formula (1),
R ¹ is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms,
Represents an ethylene group or a propenylene group,
R ² represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent,
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
Here, the same or different substituents each independently have a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, or a substituent. An alkenyl group having 1 to 8 carbon atoms, an alkynyl group having 1 to 8 carbon atoms which may have a substituent, an alkoxy group having 1 to 8 carbon atoms which may have a substituent, and a substituent. C1-C8 alkoxycarbonyl group which may have, C1-C8 which may have a substituent
An alkanoyloxy group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, an optionally substituted alkylsulfonyloxy group having 1 to 8 carbon atoms, An optionally substituted amino group, a cyano group, an optionally substituted aryl group, an optionally substituted heterocyclic group, an oxo group and = NOR ³¹ (wherein R ³¹ represents a hydrogen atom or an optionally substituted alkyl group having 1 to 8 carbon atoms.), And a plurality of the same or different substituents. In some cases, any two substituents of the same or different substituents, together with the carbon atom to which they are substituted, may have a saturated or unsaturated condensed type that may have a substituent. Or spiro-type 3 members 8-membered ring may be a has been formed. ]
Or a salt or a solvate thereof. The compound according to claim 1, a salt thereof, or a solvate thereof, wherein R ^{1 in} formula (1) is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms. . The compound, its salt, or those solvates of Claim 1 or 2 whose R < ² > of Formula (1) is the heterocyclic group which may have a substituent. R ² is a pyridyl group which may have a substituent of the formula (1), compound according to any one of claims 1 to 3, a salt thereof, or a solvate. The ring A of the formula (1) is a 6-membered or 7-membered ring (wherein the constituent atoms of the ring of the ring A are carbon atoms other than the 6-position sulfur atom). The compound of any one, its salt, or those solvates. R ^{3 in} Formula (1) is a hydrogen atom or 1 to 4 same or different substituents substituted on ring A, wherein the same or different substituents are each independently a hydroxy group, A carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, an optionally substituted alkynyl group having 1 to 8 carbon atoms, and an optionally substituted carbon number An alkoxy group having 1 to 8 carbon atoms, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, and an optionally substituted alkylsulfonyloxy having 1 to 8 carbon atoms A substituent selected from the group consisting of a group, an optionally substituted amino group, a cyano group, an optionally substituted heterocyclic group and an oxo group, and the same or different When there are multiple substituents, the same or different Any two of the substituents, together with the carbon atom to which they are substituted, may have a substituent, a saturated or unsaturated condensed or spiro type 3-membered to May form an 8-membered ring,
The compound of any one of Claims 1-5, its salt, or those solvates. Formula (1) is the following formula (1a)


(In the formula ^{(1a), R 1, R} 2 and ^{R 3} are each, according to claim 1 ^R 1, ^{R 2} and ^{R 3}
It is synonymous with. Or a salt thereof or a solvate thereof. Formula (1) is the following formula (1b)


(In the formula ^{(1b), R 1, R} 2 and ^{R 3} are each, according to claim 1 ^R 1, ^{R 2} and ^{R 3}
It is synonymous with. Or a salt thereof or a solvate thereof. Formula (1) is the following formula (1c)


(In the formula ^{(1c), R 1, R} 2 and ^{R 3} are each, according to claim 1 ^R 1, ^{R 2} and ^{R 3}
It is synonymous with. Or a salt thereof or a solvate thereof. Formula (1) is the following formula (1d)


(In the formula ^{(1d), R 1, R} 2 and ^{R 3} are each, according to claim 1 ^R 1, ^{R 2} and ^{R 3}
It is synonymous with. Or a salt thereof or a solvate thereof. Formula (2)


[In Formula (2),
R ¹ is a methylene group which may be substituted with one or two alkyl groups having 1 to 8 carbon atoms,
Represents an ethylene group or a propenylene group,
R ² represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent,
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
Here, the same or different substituents each independently have a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, or a substituent. An alkenyl group having 1 to 8 carbon atoms, an alkynyl group having 1 to 8 carbon atoms which may have a substituent, an alkoxy group having 1 to 8 carbon atoms which may have a substituent, and a substituent. C1-C8 alkoxycarbonyl group which may have, C1-C8 which may have a substituent
An alkanoyloxy group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, an optionally substituted alkylsulfonyloxy group having 1 to 8 carbon atoms, An optionally substituted amino group, a cyano group, an optionally substituted aryl group, an optionally substituted heterocyclic group, an oxo group and = NOR ³¹ (wherein R ³¹ represents a hydrogen atom or an optionally substituted alkyl group having 1 to 8 carbon atoms.), And a plurality of the same or different substituents. In some cases, any two substituents of the same or different substituents, together with the carbon atom to which they are substituted, may have a saturated or unsaturated condensed type that may have a substituent. Or spiro-type 3 members It may form a 8-membered ring,
R ⁴ represents an amino group having a protecting group. ]
Or a salt or a solvate thereof. Formula (3)


[In Formula (3),
Ring A represents a 5-membered to 8-membered ring (wherein the ring A ring has a constituent atom other than the 6-position sulfur atom,
It is a carbon atom. ),
R ³ represents a hydrogen atom or 1 to 4 same or different substituents substituted on ring A;
Here, the same or different substituents each independently have a halogen atom, a hydroxy group, a carboxy group, an optionally substituted alkyl group having 1 to 8 carbon atoms, or a substituent. An alkenyl group having 1 to 8 carbon atoms, an alkynyl group having 1 to 8 carbon atoms which may have a substituent, an alkoxy group having 1 to 8 carbon atoms which may have a substituent, and a substituent. C1-C8 alkoxycarbonyl group which may have, C1-C8 which may have a substituent
An alkanoyloxy group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxy group, an optionally substituted alkylsulfonyloxy group having 1 to 8 carbon atoms, An optionally substituted amino group, a cyano group, an optionally substituted aryl group, an optionally substituted heterocyclic group, an oxo group and ═NOR ³¹ (wherein R ³¹ represents a hydrogen atom or an optionally substituted alkyl group having 1 to 8 carbon atoms.), And a plurality of the same or different substituents. In some cases, any two substituents of the same or different substituents, together with the carbon atom to which they are substituted, may have a saturated or unsaturated condensed type that may have a substituent. Or spiro-type 3 members ~ Ring may be a has been the formation of the members. ]
Or a salt or a solvate thereof. The HSP90 inhibitor containing the compound of any one of Claims 1-10, its salt, or those solvates. An ATPase activity inhibitor of HSP90 containing the compound according to any one of claims 1 to 10, a salt thereof, or a solvate thereof. The binding inhibitor of HSP90 and ATP containing the compound of any one of Claims 1-10, its salt, or those solvates. The pharmaceutical which contains the compound of any one of Claims 1-10, its salt, or those solvates as an active ingredient. The anticancer agent which contains the compound of any one of Claims 1-10, its salt, or those solvates as an active ingredient. A pharmaceutical composition comprising the compound according to any one of claims 1 to 10, a salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier. A method for treating cancer, comprising administering the compound according to any one of claims 1 to 10, a salt thereof, or a solvate thereof. Use of the compound according to any one of claims 1 to 12, a salt thereof or a solvate thereof for the production of a medicament.